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CHAPTER 1
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Chapter 1
GENERAL INTRODUCTION
Cancer refers to lesions associated with the acquired capacity to freely proliferate, dissem-
inate and grow in tissue that is diﬀerent from the tissue of origin. It can originate from almost 
every cell type in the body [1, 2]. The probability of cancer development is strongly related to 
risk factors, which include environmental, behavioral (smoking, diet, physical activity, etc.) or 
genetic factors. Aging is also a risk factor of cancer; considering the generalized increse of life 
expectancy in developed countries, the incidence of cancer is expected to increase [3]. In the 
Figure 1. Schematic representation of molecules and supramolecular structures used as carriers 
in tumor imaging and therapy. A-B) Molecular carriers. A) Example of a targeting peptide: 
schematic structure of the somatostatin analogue octreotide; B) Example of a polymer: schematic 
structure of a tri-block copolymer. Blue dots represent the hydrophilic blocks; red dots represent the 
hydrophobic block. C-D) Supramolecular carriers. C) Schematic representation of a micelle: in blue is 
represented the hydrophilic corona and in red the hydrophobic core; D) Schematic representation of 
a polymersomes. The by-layer is depicted in dark-gray (hydrophilic part) and red (hydrophobic part). 
E) Schematic representation of an inorganic nanoparticle. Inorganic carrying nanoparticles include 
quantum dots, carbon nanotubes etc.
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Introduction
last decades, cancer incidence has indeed been increasing; however, improvements in cancer 
management have signiﬁcantly reduced cancer mortality [2]. Common treatment approaches 
for cancer include surgical resection of lesions and systemic administration of anti-cancer 
drugs.
Surgical resection is often part of cancer treatment and may be the treatment of choice 
and curative for deﬁned, contained and non-metastasized lesions. When surgical resection is 
not possible or does not suﬃce, systemic therapy (such as chemo- or radio- therapy) is (also) 
required [4, 5], as it allows for whole-body distribution and treatment of primary tumor and 
metastases. 
The localization and the determination of tumor stage and dissemination are therefore 
crucial to deﬁne the best approach. Molecules able to speciﬁcally accumulate in tumor tissue 
have greatly improved the detection via molecular imaging and the delivery of drugs for ther-
apeutic purposes [4, 6]. The results obtained in cancer imaging and therapy have strongly en-
couraged novel research leading to a huge proliferation of novel tumor-targeting compounds 
[7].These compounds are designed to show accumulation at the target site, bind to receptor 
structures, or are cleaved in a speciﬁc way by enzymes. Besides molecular probes, supramo-
lecular particles are also being developed, including polymers, polymeric micelles, nanoparti-
cles, liposomes, and micro bubbles. They represent emerging molecular imaging instruments 
because of their high versatility to serve as imaging agents. Examples of molecules used for 
tumor targeting are shown in Figure 1.
Labels most commonly used for imaging include radionuclides, ﬂuorescent molecules, 
paramagnetic ions or combinations thereof. Besides providing a signal for imaging, various 
labels can also be used for therapeutic purposes and/or for theranostic approaches. The use of 
radionuclides attached to speciﬁc targeting compounds, is an approach within nuclear oncol-
ogy that has been gaining increasing interest [8].
However for eﬀective in vivo applications, imaging and therapeutic agents must overcome 
numerous physiological hurdles within the body, including rapid excretion, non-speciﬁc accu-
mulation in non-target tissues, metabolic degradation, clearance and pharmacologic delivery 
barriers [9]. In this thesis, we describe our studies on biological properties of two categories 
of biomolecules, i.e. peptides and nanoparticles, that were either labeled with a radionuclide 
or dual labeled with a radionuclide and an ﬂuorochrome, thereby describing some main bio-
logical barriers these compounds have to overcome, to reach the tumor tissue. 
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Chapter 1
Introduction to radioactivity
All matter consists of atoms, with a positively charged nucleus, surrounded by a cloud of 
negatively charged electrons. Atomic nuclei consist of two particle types with similar mass: 
protons (positively charged) and neutrons (uncharged). The number of protons within an 
atomic nucleus (referred to as atomic number, Z) determines to which element the atom 
belongs. Each element is characterized by a unique number of protons, and the same number 
of electrons. Neutrons in the nuclei “balance” the repulsion among the positively charged 
protons and determine the stability of the atom. The optimal ratio between protons and neu-
trons for stable nuclei changes over the periodic table, but lies between 1 and 1.4 [10] (Figure 
2). The number of neutrons (neutron number, N) in atoms having the same atomic number 
(i.e. same element), does not inﬂuence the chemical properties of an element. Nuclei having 
non-optimal proton/neutron ratios are unstable and will decompose, emitting ionizing elec-
tromagnetic and/or particle radiation in order to reach a stable state (i.e. optimal proton/neu-
Figure 2. Nuclides by type of decay. Every square represents a diﬀerent element as function of its 
number of neutrons and number of protons. Stable nuclides are depicted in black. Nuclides with 
excessive neutrons or protons are unstable leading to ȕ− (light blue) or ȕ+ (pink) decay, respectively. At 
high atomic number (on the top-right of the graph), alpha emission (yellow) or spontaneous ﬁssion 
(green) become common decay modes. The line indicated as N=Z represents the theoretical position 
on the graph of nuclides for which proton number is the same as neutron number. Į: alpha decay; 
ȕ+: beta + decay; EC: electron capture; ȕ-: beta- decay; n: neutron emission; p: proton emission; SF: 
spontaneous ﬁssion. (Image adapted from International Atomic Energy Agency, webpage https://
www-nds.iaea.org/relnsd/vcharthtml/VChartHTML.html with permission from the copyright 
holder).
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Introduction
tron ratio). Depending on the composition of the nucleus, diﬀerent decay modes exist, leading 
to a release of energy and the transition to a lower energy state. The three main decay modes 
of radionuclides used in medicine, distinguished by the type of the emitted radiation/particle 
are: the emission of alpha (Į) particles (Į-decay), beta (ȕ, + or -) particles (ȕ+ and - -decay), or 
gamma (Ȗ) radiation (Ȗ-decay). 
Radionuclides in nuclear medicine
Radioactivity in medicine is mainly used for nuclear imaging and oncological therapy, 
although radiation is used for other medical applications as well [11, 12]. 
The aim of nuclear imaging in oncology is the detection of tumor tissue for diagnosis, 
staging and monitoring after treatment. For this purpose, nuclear agents are administered 
to generate three dimensional (3D) maps of radioactivity distribution, used to assess tumor 
status [11, 12]. Gamma photons are most suitable for imaging purposes as they have deep 
penetration in biological tissues and little release of energy over their path. These two proper-
ties allow for the detection of deep lesions with low/no damage to normal tissue.
Gamma photons can be detected with the aid of two nuclear imaging techniques: Sin-
gle Photon Emission Computed Tomography (SPECT) or Positron Emission Tomography 
(PET). 
In SPECT imaging, single photons emitted from a radioactive source are detected by 
rotating gamma cameras (Figure 3A). Data is collected and processed via a reconstruction 
algorithm to generate 3D images that represent the distribution of radioactivity. SPECT ma-
chines are equipped with an absorbing plate (called “collimator”) with holes (parallel-holes or 
pin-holes) [13, 14] (Figure 3B). Pinhole collimators give higher spatial resolution compared 
to parallel-holes, but require that the collimator is close to the emitting source. This option 
makes SPECT an excellent tool for “small object imaging” such as in preclinical investiga-
tions [15] (Figure 3). 
PET is another nuclear imaging technique, broadly employed at the clinical and preclin-
ical level. It is the most sensitive nuclear imaging method, as no collimators are needed [16]. 
PET relies on the detection of two gamma photons generated after positron (ȕ+) decay. After 
radioactive decay of the nucleus the positron can travel over a short distance in the tissue 
while losing kinetic energy. It then interacts with an electron resulting in mutual annihilation 
and release of energy in the form of two electromagnetic photons of 511 keV each, that travel 
in opposite direction [17]. The detection of these two photons by the PET camera occurs 
simultaneously allowing for the 3D localization of the originating source (Figure 4). 
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Chapter 1
Both SPECT and PET imaging are often combined with another technique such as 
Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). The combination with 
such techniques improves the 3D source localization by providing anatomical reference [18]. 
The studies presented in this thesis are performed using a state-of-the art preclinical SPECT/
CT platform.
Figure 3. Single Photon Emission Computed Tomography (SPECT). A) Schematic representation 
of the SPECT imaging principle. Gamma photons resulting from nuclear disintegrations are 
detected by a detector. The presence of a parallel-hole collimator allows only perpendicular photons 
to pass through and reach the detector. Other photons are absorbed by the collimator. B) Schematic 
representation of pinhole (left) and paralle-hole (right) collimation in SPECT imaging.
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Introduction
Ionizing radiation emitted by radionuclides can also be used for therapeutic purposes. 
Radiation is used to cause damage in cancer cells resulting in cancer cell death or reduced 
proliferative capacity. To be eﬀective in inducing (fatal) biological damage the radiation dose 
delivered to the tumor must be suﬃciently high. For this purpose, emitted ionizing radia-
tion should have limited tissue penetration and release energy over a short path. Currently 
radionuclides emitting ȕ- particles are the most used for therapy; however also Į particle and 
Auger electron-emitting radionuclides have shown to be suitable for therapeutic applications 
[11, 19]. 
Considering the properties needed for imaging or therapy, radionuclides can be classiﬁed 
as imaging radionuclides or therapeutic radionuclides (Table 1). A radionuclide can decay via 
more than one decay mode. In some cases one radionuclide can be suitable for both imaging 
and therapy, and can be classiﬁed as a true “theranostic” radionuclide (therapy + diagnosis). 
An attractive example is represented by 177Lu, a radionuclide used for therapy decaying via ȕ- 
emission. During therapy, however it is also suitable for SPECT imaging because of its emis-
sion of gamma radiations. In Table 1 several used radionuclides in nuclear medicine are listed.
Figure 4. Schematic representation Positron Emission Tomography (PET) imaging principle. 
A positron (ȕ+) is emitted after the radioactive disintegration of one proton into a neutron; after 
disintegration, the positron travels shortly before interacting with an electron. The interaction results 
in the annihilation of the positron and electron, and the release of energy by two electromagnetic 
radiation of 511 keV traveling oppositely. The detectors of a PET machine areable to detect the two 
emitted photons contemporaneously and form a three-dimensional image localizing the emitting 
source.
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Chapter 1
Carriers: molecules to bring radioactivity in target 
tissues
To be eﬃcient in exerting diagnostic or therapeutic functions, radioactivity needs to reach 
and accumulate in tumor tissue at a suﬃciently high level. Radionuclides can be injected as 
free agent, although most often they are incorporated in a bigger structure, a carrier, to im-
prove the accumulation in tumor tissue. Such carriers comprise molecules of diﬀerent chem-
ical/physical properties and biological behaviors (Figure 1) [6, 20]. An extensive description 
of various carriers available or used for the delivery of radioactivity for tumor diagnosis and 
therapy has been published by Psimadas et al. [21] and by Gudkov et al. [22].
Table 1. List of radionuclides applied in nuclear medicine
Data present the physical half-life, the main nuclear emission pathway and the main application in 
nuclear medicine. T½ (h): physical half-life in hours; Į: alpha-decay; ȕ+: beta+-decay; ȕ-: beta--decay; 
Ȗ: gamma-decay; IC: internal conversion; EC: electron capture; PET: positron emission tomography; 
SPECT: single photon emission tomography.
Radionuclide T½ (h) Decay Mode Main use in nuclear medicine
99mTc 6.02 IC, Ȗ Imaging (SPECT)
111In 67.9 EC, Ȗ Imaging (SPECT)
Therapy
67Ga 78.26 EC, Auger, Ȗ Imaging (SPECT)
123I 13.2 EC, Ȗ Imaging (SPECT)
18F 1.83 ȕ+, EC Imaging (PET)
68Ga 1.13 ȕ+, EC Imaging (PET)
64Cu 12.7 ȕ+, ȕ-, EC Imaging (PET)
Therapy 
86Y 14.7 ȕ+, EC Imaging (PET)
124I 99.6 ȕ+, Ȗ Imaging (PET)
90Y 64.1 ȕ- Therapy
177Lu 161 ȕ-, Ȗ Therapy 
Therapy + Imaging
67Cu 61.9 ȕ- Therapy
213Bi 0.76 Į, ȕ- Therapy
225Ac 240 Į Therapy
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Introduction
Once introduced into a biological system, carriers have to face several challenges. In or-
der to accumulate in target tissue, carriers have to evade host clearance pathways, including 
the immune system and other physiological and pharmacological barriers. Moreover, next to 
suﬃcient accumulation in the target tissue, carriers should show tolerable accumulation in 
oﬀ-target tissues. 
Accumulation of a carrier in the tumor is inﬂuenced by both carrier’s properties and tumor 
properties. 
The retention of carriers in oﬀ target tissue often concerns the main clearance organ for a 
speciﬁc carrier (e.g. liver, spleen, or kidneys). When accumulation in these organs is elevated 
it can become critical because of possible toxic eﬀects to these organs. 
Focusing on the two types of radiolabeled carriers as investigated in this project, i.e. pep-
tides and polymer based nanoparticles, the possible ways of carrier accumulation and clear-
ance routes are discussed, since they may inﬂuence biodistribution outcomes. 
Radiolabelled peptides
Peptides are molecules consisting of amino-acids (<100) linked via peptide bonds. 
Stabilized peptides were preferred over the endogenous peptides for the delivery of ra-
dioactive agents to tumors expressing speciﬁc receptors because of the longer in vivo stability 
[23, 24].
For nuclear imaging, as well as radionuclide therapy, the incorporation of a radionuclide is 
a crucial aspect. Chelating structures (“chelators”) are often used to modify peptides, allowing 
for stable incorporation of many clinically relevant radionuclides. In some cases, chelators 
have been shown to be more suitable for use in humans compared to other approaches (e.g. 
iodination) [25]. Moreover, coupling of chelators is in general well tolerated by peptides, i.e. 
the receptor binding capacity is preserved [26-28].
Active targeting: the prototype of receptor-mediated tumor targeting by 
somatostatin analogues
Receptors are protein-based structures allowing for e.g. cellular communication with the 
outer environment. Some tumors are known to overexpress one or more membrane recep-
tors. Speciﬁc targeting carriers binding to the overexpressed receptor can be used to deliver 
radioactivity for imaging and/or therapy, indicated as “active targeting” [29]. A convincing 
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example of the potential of such active targeting is represented by the currently widely used 
approach for imaging and therapy of neuroendocrine tumors (NET) [30]. NETs represent a 
rare neoplasm that are known to highly overexpress somatostatin receptors (SSTR) [31]. In 
(patho)physiological conditions SSTR binds endogenous somatostatin, which has an inhibi-
tory eﬀect on tumor cell growth and hormone secretion [32]. 
Small stable somatostatin peptide analogues that are able to bind SSTR with high aﬃnity 
have been developed. Compared to endogenous peptide such somatostatin analogues also 
have longer stability in vivo and therefore higher pharmacologic eﬃcacy. In clinical studies, 
somatostatin analogues have been introduced as a palliative treatment for NETs, providing 
symptom alleviation and in some cases interruption of tumor growth [33, 34]. 
The radiolabeling of somatostatin analogues with speciﬁc imaging radionuclides, has en-
abled detection of tumor lesions via nuclear imaging techniques for non-invasive diagnosis, 
staging and follow up of NETs (Figure 5) [35]. 
As a next step, the capacity of somatostatin analogues to reach SSTR was used to deliver 
therapeutic radionuclides to NETs, an approach that is known as peptide receptor radionu-
Figure 5. Schematic representation of a targeting carrier and active targeting. A) Schematic 
representation of a radiolabeled peptide. The targeting carrier is derivatized with a chelator for 
radionuclide binding and sometimes also a linker; B) Targeting peptides binding receptors that are 
(over)expressed on the membrane of tumor cells.
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Introduction
clide therapy (PRRT). Clinical studies on PRRT treatment proved the eﬃcacy and the safety 
of this approach for NETs; minor and partial tumor responses in up to 35% of cases and 
tumor stabilization in the 60% of cases was observed [36, 37].
A high tumor dose and favorable ratio between the dose to the tumor and the dose to 
healthy (dose limiting) tissues are the major aims during PRRT. The amount of radioactivity 
delivered to the tumor determines the therapeutic response; while the high dose ratio be-
tween tumor and healthy tissues is needed to reduce oﬀ target toxicity. Speciﬁc activity and 
treatment schemes have shown to inﬂuence these two parameters, as shown in Chapter 2.2.
Speciﬁc activity of a radiolabeled peptide can be deﬁned as the amount of radioactivity 
coupled to a peptide (MBq/nmol). This ratio can aﬀect the tumor dose, as high speciﬁc activ-
ities will lead to lower saturation levels of the receptors. In conditions of high speciﬁc activity, 
the level of radiolabeled peptide molecules binding SSTR is higher and the dose to the tumor 
will increase [38]. 
As shown in Chapter 2.2 variations of fractionation schemes of therapeutic doses in ra-
dionuclide therapy can inﬂuence the therapeutic outcome as well. In this preclinical study we 
obtained signiﬁcantly increased tumor to organ ratios in groups treated with the same dose of 
177Lu-DOTA,Tyr3-octreotate administered at diﬀerent time points.
Main clearance pathway in NET radionuclide therapy 
Despite PRRT with radiolabeled somatostatin analogues is eﬀective and well tolerated 
in patients [35] systemic application of radiolabeled peptides exposes the body to radiation. 
Mild nonspeciﬁc side eﬀect (abdominal pain and fatigue) are often observed after administra-
tion of therapeutic doses of radiolabeled somatostatin analogues [35, 39]. Next to that speciﬁc 
organs like kidney and bone marrow can experience toxicity as well [39]. 
Kidneys are the main organs involved in clearance of most chelated radiopeptides and 
can be aﬀected by radiation damage. Radiolabeled somatostatin analogues reach the kidneys 
via the renal artery; the peptides are ﬁltered at the level of the glomerulus and most of them 
are then excreted via the urine [26, 40, 41]. A relatively small but signiﬁcant amount of so-
matostatin analogues however is reabsorbed in the kidney in the proximal tubules via both 
SSTR-mediated [42] and “not-SSTR-mediated” mechanisms [40]. These mechanisms deter-
mine reabsorption and retention of the radioactivity in the kidneys over time . 
 As a result of re-uptake and retention of radioactivity, the kidney can develop acute 
or late toxicity during or after treatment with radiolabeled somatostatin analogues [43-45]. 
Positively charged molecules can interfere with the mechanism of peptide-reabsorption. 
The application of positively charged amino-acids has been shown to provide renal protection 
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in treated patients by reducing the reabsorption of radiolabeled somatostatin analogues [46, 
47]. 
Somatostatin analogues for multimodal image-guided surgery
Despite the enormous improvement in the systemic treatment of cancer, the most success-
ful results in tumor management are still obtained by surgical resection of operable lesions 
[48]. Improvements in resection outcomes have been reached by the use of nuclear imaging 
techniques that allow for tumor localization prior to surgery and the set-up of a surgical plan 
[48, 49].
In principle, the same radiation used for nuclear imaging can be used to provide surgical 
guidance during surgery as well and improve resection outcomes [48-51]. The radioactive sig-
nal, identiﬁed via a portable gamma-detector can guide the surgeon towards the lesions, even 
when it is localized deep in the tissue. Radio-guidance has brought a signiﬁcant improvement 
in surgery of tumor because of the real-time feedback during resection [50-52]. The approach 
however has drawbacks as well and could proﬁt from additional optical signal feedback during 
surgery.
Optical image-guided surgery makes use of optical probes to provide real-time visual 
feedback during surgery. The application in diﬀerent procedures in human patients has pro-
vided extremely encouraging results [53, 54]. On the other hand optical signals suﬀer from 
poor penetration in biological tissue, restricting the application of optical probes to superﬁcial 
lesions only [55]. 
Optical-and-nuclear dual-modality imaging probes have raised interest in the ﬁeld of im-
age-guided surgery because of the complementary characteristics [56, 57]. While radioactive 
signals can be detected from deeply lying lesions, the optical signal is very eﬀective in giving 
the needed real-time visual feedback in close proximity to the lesion [48, 56, 58-60]. 
The simultaneous use of the two imaging modalities could be accomplished by two main 
approaches [58, 61]: by using one single agent carrying both a nuclear and a ﬂuorescent moi-
ety, or by the co-injection of two agents (one conjugated with a radiotracer, and the other con-
jugated with a ﬂuorescent probe). One single carrier with multiple labels was found preferable 
over the two mono-functionalized ones because of the more reliable and coherent feedback 
(i.e. overlapping of nuclear and optical signal) [60, 62]. 
The ﬁrst application of agents carrying optical-and-nuclear labels for image-guided sur-
gery was in sentinel lymph node detection and resection in breast [60] and prostate cancer 
[58, 59]. In these cases, the carrying molecules were dual-labeled colloids able to diﬀuse pas-
sively through the lymphatic system [41].
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 Figure 6. Schematic representation of three image guided surgery options. A) Diagram of nuclear-
signal based guided surgery pros and cons. Detection can be performed prior to resection via nuclear 
imaging approaches (e.g. SPECT) for preoperative imaging. During the surgery, superﬁcial or deep 
lesions can be detected by a dedicated gamma detector that guides the surgeon towards the lesion. The 
method lacks real-time optical feedback and is prone to result in incomplete resection; B) Diagram 
of optical-imaging based guided surgery pros and cons. The surgeon can read the optical signal at the 
operative theater and get a real-time optical feedback of superﬁcial lesions. The optical signal allows 
for complete and precise resection; C) Diagram of multimodality (nuclear-signal and optical-imaging) 
imaging based guided surgery. It combines the beneﬁts of nuclear signal and optical imaging guided 
surgery, providing the possibility of pre-operative nuclear imaging, detection of deep lesions, real-time 
optical feedback for localization and complete resection of tumor. 
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Further steps in multimodality guided surgery were made by modifying targeting peptides 
with a multimodal moiety and use them to mark tumor lesions. For some peptides commonly 
used for tumor targeting, the attachment of a multimodal moiety did not substantially alter 
the aﬃnity for the receptor. Multimodality peptides applied in vivo in preclinical studies 
showed considerable levels of accumulation in the tumor and allowed for tumor detection via 
both nuclear and optical imaging. Results with targeting peptides carrying multimodal agents 
were extremely positive [48, 56], and gave high expectation for further improvement in im-
age-guided surgery, and potential to translate the method to the clinic (Figure 6). In Chapter 
2.1, the study on the potential of this dual-imaging approach using somatostatin analogs as 
targeting vector are described; hereby focusing on the eﬀects of the dual-labeling procedure 
on receptor binding aﬃnity and in vivo tumor accumulation capability of the modiﬁed tracers.
Radiolabeled nanoparticles
Nanoparticles have a size between ﬁve to several hundreds of nanometers. They can inter-
act with cancer tissue, biomolecules and subcellular structures [63]. Many nanoparticles are 
available for medical application; they can diﬀer in terms of size, shape, chemical composition 
etc. An interesting aspect of nanoparticles is their versatility as biological carrier, which in-
cludes the possibility to carry radionuclides. 
For some nanoparticles radiolabeling is often obtained via attachment of a chelator on the 
outer structure that can be subjected to a radiolabeling step [64, 65]; other nanoparticles can 
incorporate radionuclides (or small radioactive complexes) and stably retain them [66]. 
Despite the large number of nanoparticles available, when applied in vivo, they follow 
similar pathways with regard to tumor accumulation and clearance pathways [67]. 
Tumor accumulation of nanoparticles occurs mostly via the Enhanced Permeability and 
Retention (EPR) eﬀect, also referred to as “passive targeting” [29]. In contrast to active tar-
geting, that involves binding/interaction of a probe with a speciﬁc target , the EPR eﬀect 
is based on passive extravasation of particles though leaky blood vessels as is often the case 
with tumor vasculature [68]. Accumulation in tumors, therefore, is not restricted to one (or 
few) tumor type(s) expressing a speciﬁc target, but nanoparticles can potentially target every 
solid tumor via the EPR eﬀect. It is possible to attach speciﬁc ligands for tumor targeting to 
nanoparticles adding the mechanism of speciﬁc target -ligand interaction (so called “targeted 
nanoparticles”) to the biodistribution properties of nanoparticles [29]
Many nanoparticles share the same clearance pathway. Clearance generally occurs via liver 
and/or spleen, as the size of nanoparticles often exceeds the renal ﬁltration limit (being <5 
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nm)[41]. Clearance via liver or spleen can result in accumulation of particles in these two 
organs, whereas further clearance steps can involve other tissues as well (e.g. intestines via 
hepatobiliary excretion). Often long lasting retention of nanoparticles is seen in the liver and 
spleen; they might become dose limiting organs in case particle uptake is high.
In this thesis, we describe the investigation of two diﬀerent types of polymeric nanoparti-
cles that show potential as carrier and for delivery of radioactivity to tumors. We tested these 
nanoparticles in their molecular form, i.e. unimers, or in their supramolecular form as micelles.
Block copolymers and Pluronic unimers. Polymers are nanosized macromolecules con-
sisting of repeated parts. When the same part is repeated, the polymer is called a “homo-poly-
mer”; when diﬀerent parts are repeated the polymer is called “copolymer”. When chemically 
similar repeated units are organized in blocks and linked together by a covalent bond, the 
polymer is named a “block copolymer”. Pluronics are a class of amphiphilic linear tri-block 
copolymers consisting of a hydrophilic part of poly(ethylene oxide) (PEO) and a hydrophobic 
part of poly(propylene oxide) (PPO), arranged in a A-B-A tri-block structure: PEO-PPO-
PEO [69]. They have an extremely versatile structure, are easy to modify by the attachment of 
Figure 7. Schematic representation of a Pluronic P94 block copolymer. A) Structure of Pluronic 
P94; B) Example of the radiolabeled DTPA-P94. PPO: poly(propylene oxide (hydrophobic part); 
PEO: poly(ethylene oxide)(hydrophilic part).
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diﬀerent moieties and present excellent properties for in vivo application such as the high lon-
gevity in vivo and low level of toxicity [64]. Some formulations of Pluronics block copolymer 
have been approved by the Food and Drug Administration (FDA); they are used in cosmetics, 
in food and in the clinic as a adjuvant for injection [70]. Pluronics have also shown potential 
in anti-multi-drug-resistance in tumors and as platform for the delivery of drugs to tumor 
lesions [71, 72]. Because of their nanosized dimension (4-10 nm)[64], Pluronics as unimers 
can accumulate in tumor tissues as a result of the EPR eﬀect [29, 73] (Figure 7). Application 
of Pluronic P94 block-copolymer in vivo as carrier for the delivery of agents (i.e. radioactivity) 
is described in Chapter 3.1.
Block-copolymer-based supramolecular aggregates. In aqueous solution, at speciﬁc 
concentrations and temperatures, block copolymers can stably aggregate into supramolecular 
structures deﬁned as “polymeric supramolecular aggregates”. Because of this property poly-
meric aggregates, at room temperature and in polar solvents, are thermodynamically more 
stable than the copolymer and tend to remain aggregated. 
Figure 8. Schematic representation of PS-b-PEO block copolymer and diagram of PS-b-PEO 
based supramolecular aggregate formation. 1- PS-b-PEO block copolymer in a chloroform 
solution is added to a watery solution; 2- chloroform is evaporated; 3- During the evaporation of 
chloroform PS-b-PEO copolymer aggregates in supramolecular aggregates. PS: Poly(styrene); PEO: 
poly(ethylene-oxide)
513958-L-sub01-bw-Santini
Processed on: 22-9-2017 PDF page: 25
25
Introduction
Application in vivo demonstrated that supramolecular structures of PS-b-PEO copoly-
mers have long lasting stability in the circulation and the ability to accumulate in the tumor 
via the EPR eﬀect, suggesting potential as a delivery system to tumors. In this respect, PS-b-
PEO polymeric aggregates have shown high versatility for labeling with diﬀerent agents [74]. 
The capacity to generate nanoparticles with good kinetic and thermodynamic stability, 
that are tunable in size and easy to load with diﬀerent agents, is a crucial aim for in vivo ap-
plications [75, 76]. Lately, poly(styrene)-poly(ethylene-oxide) block copolymers (PS-b-PEO) 
have shown interesting properties such as spontaneous aggregation in supramolecular struc-
ture (e.g. micelles, polymerosomes) tunable morphology (i.e. size and shape) and potential for 
easy loading [66, 74]. Poly(styrene) cores (PS) present a “glassy” structure, meaning that once 
Figure 9. Schematic representation of passive targeting: the Enhanced Permeability and Retention 
(EPR) eﬀect. Tumor vessels present bigger fenestration compared to healthy vasculature. Tumor 
vessels are thus more permeable to solutes in the blood stream. Particles from 5 nm up to 500 have 
shown to be able to extravasate at the tumor level and accumulate there.
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aggregates are formed the block copolymer cannot freely dissociate anymore [66, 74, 77] , 
thus conferring extensive stability in diﬀerent conditions, including physiological conditions 
in vivo. 
The loading of PS-b-PEO aggregates with diﬀerent agents occurs during the synthesis of 
supramolecular structures, without the need of chemical modiﬁcations. Formation of supra-
molecular structures enables stable incorporation of hydrophobic complexes (e.g. 111In-tropo-
lone [66] or ﬂuorophore [74]). This principle can be applied not only for the incorporation 
of imaging agents, but also therapeutic agents, making the PS-b-PEO aggregates suitable for 
theranostic applications (Figure 8). The ﬁrst application of radiolabeled PS-b-PEO supramo-
lecular aggregates is shown in Chapter 3.2. The role of the size in the distribution of these 
radiolabeled PS-b-PEO supramolecular aggregates is described in Chapter 3.3.
Passive targeting: selective tumor accumulation of nanoparticles via the EPR 
effect
The EPR eﬀect is a passive phenomenon occurring in rapidly growing, solid tumors. In such 
tumors the demand of oxygen and nutrient grow accordingly and this cannot be covered by sim-
ple diﬀusion [68]. Although tumor cells can become quite resistant to starvation and hypoxia, 
soon in the progress of cancer, the formation of new vasculature that improves the delivery of 
nutrients can be observed [78]. This phenomenon is known as tumor angiogenesis [79]. Due to 
a persistent stimulatory signal from tumor cells, the newly formed vasculature is continuously 
remodeled and remains in a substantially underdeveloped state [79]. Compared to normal ma-
ture vessels, the underdeveloped tumor vasculature has bigger fenestrations of 100-600 nm [80], 
no tight junction between endothelial cells [81, 82] and the tumor tissue misses a functional 
lymphatic system [68, 83]. These conditions favor vessel permeability due to the bigger fenestra-
tion, and an improved retention, because of the lack of lymphatic drainage. 
Size is one of the most important parameters for the EPR eﬀect. Particles between 5 
to 200 nm present a higher level of EPR mediated accumulation in tumor tissue compared 
to those of <5 nm, which are rapidly cleared from tissues [84, 85]. A second parameter for 
successful EPR eﬀect, is the biological half-life of particles in the circulation. Particles that 
remain longer in circulation have higher chance to pass through the tumor vasculature and 
extravasate. The extent of accumulation in the tumor due to the EPR eﬀect is also dependent 
on the intra-tumoral pressure.
Despite the diﬃculties encountered to obtain a suﬃcient level of carriers (and payload) 
in the tumor, one big advantage of EPR over targeted accumulation is the potentially broad 
applicability of the method. As a tumor-speciﬁc targeting agent is not required, particles that 
beneﬁt from the EPR eﬀect can be used to deliver agents to any solid tumor with leaky vessels 
(Figure 9). 
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Main clearance organs of nanoparticles: the liver and spleen
The liver is an organ involved in many vital functions. In pharmacology, the interest around 
the liver is mostly on its role as clearance/detoxifying organ; the liver is able to retain, inacti-
vate and regulate excretion of drugs. The liver receives blood supply from the systemic circu-
lation via the portal vein and the hepatic artery. Blood enters via the hepatic tissue, afterwards 
it further subdivides into a network of capillaries with a diameter of 5-10 μm and fenestrae 
of 100-150 nm, called sinusoids [86-88]. The fenestrae of sinusoids allow the passage of most 
of the plasma components in the space of Disse. In general molecules with a size <200 nm 
can pass through the fenestrae and become available for the hepatic cells that can internalize 
them via pinocytosis and receptor mediated endocytosis [89]. Endothelial cells and Kupﬀer 
Figure 10. Liver and structure of liver sinusoid. Above: diagram of the liver. Below: diagram of 
liver sinusoid. The sinusoid capillaries mainly contain sinusoidal endothelial cells (70%) and resident 
liver macrophages known as the Kupﬀer cells (20%). Particles up to ~230 nm of diameter can be 
internalized by the sinusoidal endothelial cells that break the particles down or transfer them to the 
space of Disse. Bigger particles are phagocytized by Kupﬀer cells and are degraded in phagolysosomes 
before being eliminated by exocytosis (Image adapted from http://www.amfe.fr/maladies/description-
du-foie/) 
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cells (resident liver macrophages) represent the most abundant cells in the sinusoids and have 
an important role in the clearance of nanoparticles [90-92]. The sinusoidal endothelial cell 
can internalize the particles up to ~230 nm of diameter, break them down or transfer them 
to the space of Disse [92, 93]. Bigger particles are phagocytized by Kupﬀer cells instead [94], 
degraded in phagolysosomes and eliminated by exocytosis [95]. 
The liver is the organ that generally shows the highest uptake of nanoparticles [73] and is 
the ﬁrst organ responsible for the depletion of carrier from the circulation and for reduction 
of tumor availability. Reducing the liver clearance might therefore be an eﬃcient method to 
increase bio-availability and the targeting potential of nanocarrier (Figure 10).
The spleen is the second organ involved in the clearance of nanoparticles [96]. It is a lym-
phoid organ that is highly vascularized and contributes to the clearance of senescent eryth-
rocytes, cellular debris and opsonized microorganisms from the circulation. It is anatomically 
organized in two distinct areas, the white pulp and red pulp. The white pulp is close to the 
arteries, and is involved in the proliferation of lymphocytes and in adaptive immunity. The red 
pulp is mainly represented by vascular sinusoids with a speciﬁc sieve structure [67, 97]; it is 
also the area where the splenic macrophages are located. When the blood passes through the 
splenic sinusoids of the red pulp, this speciﬁc structure promotes a sieving of the blood and 
the retention of unhealthy cells, pathogens and debris. The presence of macrophages further 
Figure 11. Schematic representation of spleen structure. The blood reaches the red pulp in the 
spleen via the splenic artery that further branches into smaller vessels, with a sinusoidal structure. 
Blood cells pass through the sinusoids in the red pulp. Blood is then sieved by a speciﬁc structure 
that results in removal of unhealthy blood cells, pathogens and debris and particles above 200 nm in 
diameter from the blood.
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favors the elimination of senescent erythrocytes or pathogens from the circulation and helps 
to keep the sieve structure clean [96] (Figure 11). Spherical carriers, above 200 nm in diam-
eter, can be retained for long time in the spleen. Shape of particles also seems to play a sig-
niﬁcant role during the sieving through the spleen and recent studies showed that elongated, 
irregular and stiﬀ structured particles are also highly retained [74]. 
Similarly, to what occurs in the liver, the spleen is also responsible for the depletion of 
nanoparticles from the circulation. A reduction of splenic uptake by speciﬁc changes in the 
structure of carriers might have a positive eﬀect on the level of particles reaching the tumor 
and might signiﬁcantly inﬂuence the delivery of agents for imaging or therapy.
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Thesis outline
This thesis describes the biodistribution and tumor uptake of novel molecular or supramo-
lecular carriers, for imaging, therapy and image-guided surgery. 
The in vivo behavior of targeting, peptide-based carriers is described in Chapter 2. 
In Chapter 2.1 we described that octreotate, a somatostatin analogue, was used to synthe-
tize a multimodally labeled derivative that we tested in vivo in preclinical studies. 
 Radiolabeled somatostatin analogues are being used successfully in the clinic to deliver 
therapeutic (or theranostic) radionuclides to tumor lesions. Radionuclide therapy with radio-
labeled somatostatin analogues might be further improved by tuning parameters such as the 
treatment scheme and/or the administered speciﬁc activity. The eﬀect of variation in these 
parameters on tumor responses is described in Chapter 2.2. 
Nanoparticles represent a very versatile delivery platform for diﬀerent agents, including 
radionuclides. In Chapter 3 we describe the potential of two diﬀerent types of nanoparticles 
for tumor targeting. 
Pluronics P94 are linear amphiphilic block-copolymers that can be applied for tumor 
delivery. Chapter 3.1 describes the eﬀects of diﬀerent injection routes on the distribution of 
Pluronics P94.
In Chapter 3.2 and Chapter 3.3 we describe the synthesis and the in vivo application of 
nanoparticles derived from spontaneously aggregated of PS-b-PEO block copolymer.
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ABSTRACT
In the treatment of neuroendocrine tumors (NET), complete surgical removal of malig-
nancy is generally desirable, as it oﬀers curative results. Pre-operative guidance with radiola-
beled somatostatin analogues, commonly used for NET diagnosis and pre-operative planning, 
is limited by its low resolution, with the risk that tumor margins and small metastases will 
be incompletely resected with subsequent recurrence. A single hybrid probe combining ra-
diotracer and optical dye would enable high-resolution optical guidance, also during surgery. 
In the current study, the hybrid labeled somatostatin analogue Cy5-DTPA-Tyr3-octreotate 
was synthesized and evaluated for its ability to speciﬁcally trace NET cells in vitro and in an 
animal model. The performance of the hybrid tracer was compared to that of octreotate with 
only radiolabel or only optical label. 
Methods: The binding aﬃnity and internalization capacity of Cy5-DTPA-Tyr3-octreotate 
were assessed in vitro. Biodistribution proﬁles and both nuclear and optical in vivo imaging 
of Cy5-111In -DTPA-Tyr3-octreotate were performed in NET-bearing mice and compared to 
the performance of 111In-DTPA-Tyr3-octreotate. 
Results: In vitro studies showed low receptor aﬃnity and internalization rate for Cy5-DT-
PA-Tyr3-octreotate. The KD value was 387.7 ± 97.9 nM for Cy5-DTPA-Tyr3-octreotate, while 
it was 120.5 ± 18.1 nM for DTPA-Tyr3-octreotate. Similarly, receptor-mediated internal-
ization reduced from 33.76 ± 1.22% applied dose (AD) for DTPA-Tyr3-octreotate to 1.32± 
0.02% AD for Cy5-DTPA-Tyr3-octreotate. In contrast, in vivo and ex vivo studies revealed 
similar tumor uptake values of Cy5-111In -DTPA-Tyr3-octreotate and 111In -DTPA-Tyr3-oc-
treotate (6.93 ± 2.08 and 5.16 ± 1.27, respectively). All organs except the kidneys showed 
low background radioactivity, with especially low activities in the liver, and high tumor/tissue 
ratios were achieved—both favorable for the tracer’s toxicity proﬁle. Hybrid imaging in mice 
conﬁrmed that the nuclear and ﬂuorescence signals co-localized. 
Conclusion: The correlation between ﬁndings with the optical and the nuclear probes un-
derlines the potential of combining SPECT-imaging with ﬂuorescence guidance and shows 
the promise of this novel hybrid peptide for pre-operative and intra-operative imaging of 
NET.
Keywords: image-guided surgery, octreotate, neuroendocrine tumors, multimodal imag-
ing
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INTRODUCTION
Neuroendocrine tumors (NET) are rare neoplasms originating from endocrine cells and 
are known to overexpress the somatostatin receptor (sst). Of the ﬁve sst subtypes described, 
subtype 2 (sst2) is the most commonly overexpressed in NET (1). Radiolabeled somatostatin 
peptide analogues, such as octreotide and Tyr3-octreotate, have high aﬃnity for the sst2 re-
ceptor (2). They have been used successfully in diagnosing patients with NET using nuclear 
imaging technologies, such as Single-Photon Emission Computed Tomography (SPECT) or 
Positron Emission Tomography (PET), in combination with computed tomography (CT). 
They have also been used successfully for peptide receptor radionuclide therapy in patients 
with metastasized disease (2,3), although surgical resection of the tumor tissue, if possible, is 
the preferred treatment for NET (4,5).
Eﬃcient tumor detection can considerably improve pre-operative planning and result in 
better patient survival. In current clinical practice, 68Ga and 111In are common radiolabels used 
in the pre-operative evaluation of lesions using PET- or SPECT- based imaging, respectively 
(6). 
The introduction of portable gamma probes enabled real-time radioguidance during sur-
gery (7-9). Nevertheless, radioguidance cannot determine tumor margins nor identify small 
metastases very accurately (4,10). The poor visual discrimination between tumor and healthy 
tissues raises the chance of an incomplete resection, associated with disease progression or 
recurrence (10).
Fluorescence imaging is an alternative technology for intraoperative guidance (11), that 
provides higher resolution and real-time optical detection of the tumor. However, photon 
attenuation limits tissue penetration to less than one centimeter (12); therefore, deep lesions 
cannot be identiﬁes based on ﬂuorescence signal alone (10,13,14).
The simultaneous use of optical and nuclear imaging modalities with their complemen-
tary strengths can improve surgical guidance and consequently resection outcome, as has 
been shown for sentinel node detection and resection (15).Dual-modality (or rather hybrid) 
radiocolloids oﬀer two read-outs during surgery: the nuclear signal can roughly indicate the 
target location pre- and intra- operatively, and the ﬂuorescence signal gives real-time, (sub) 
mm resolution during surgery, allowing accurate identiﬁcation and precise resection. 
Can this concept also be applied to tumor resection? Tumor-speciﬁc tracers, such as the 
peptide analogues mentioned above, are essential (10,12), and two strategies can be followed. 
One strategy involves co-injection of two single-labeled targeting agents, i.e. one agent car-
rying a ﬂuorescent dye and one agent carrying a nuclear label. Alternatively, ﬂuorescent and 
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Figure 1. Structures of (A) Cy5-DTPA-Tyr3-octreotate; (B) DTPA-Tyr3-octreotate; (C) Cy5-Tyr3-
octreotate.
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nuclear labels can both be attached to one targeting moiety, creating an imaging agent with 
two functionalities. The main drawback of the ﬁrst strategy is the potentially diﬀerent biodis-
tribution proﬁle of the two tracers, which could mean a mismatch between nuclear and optical 
signals (10). In contrast, the second strategy will provide automatic co-localization of the two 
signals. Such dual functionalization can be achieved by introducing two separate imaging la-
bels onto each peptide or by introducing a single, hybrid label containing both functionalities 
(16). With the double-labeling approach, many previous studies with peptide-based trac-
ers have demonstrated a substantial reduction in peptide-receptor aﬃnity, including tracers 
based on somatostatin analogues (16,17). However, hybrid-label-modiﬁed tracers maintain 
a considerable level of receptor aﬃnity both in vitro and in vivo (16-18). To the best of our 
knowledge, however, none of the hybrid-labelled somatostatin analogues have been tested for 
targeted imaging in vivo.
In this study we have investigated the tumor targeting potential of a newly synthetized 
somatostatin analogue, the hybrid tracer Cy5-DTPA-Tyr3-octreotate (Fig. 1A), in vitro and 
in vivo. The tracer carries, on a single platform, the chelator diethylene triamine pentaacetic 
acid (DTPA), which chelates radiometals constituting the nuclear beacon, and the ﬂuorescent 
cyanine dye Cy5 (Ȝex=650 nm; Ȝem=670 nm) as optical label. This tracer was compared with the 
more traditional somatostatin analogue DTPA-Tyr3-octreotate (Fig. 1B) and the ﬂuorescently 
labeled Cy5 Tyr3-octreotate (Fig. 1C).
MATERIALS AND METHODS
Synthesis 
Cy5-DTPA hybrid label. Cy5 was synthesized following a previously described procedure 
(19). The hybrid imaging label was synthesized using solid-phase peptide synthesis. After 
Fmoc deprotection (20% piperidine in dimethylformamide (DMF)), Fmoc-Lys(IvDde)-OH 
(2 equivalents (eq.)) was coupled overnight using PyBOP (2eq.), HOBt (2 eq.), DiPEA (4 
eq.) in DMF. After subsequent deprotection of the N-terminus, DTPA (tBu)4 (1.3 eq.) was 
coupled overnight using PyBOP (1.3 eq.), HOBt (1.3 eq.), DiPEA (3 eq.) in DMF . Next, the 
IvDde protecting group was removed with 2% hydrazine hydrate in DMF. Then Cy5 (1.3 eq.) 
was coupled overnight using PyBOP (1.3 eq.), HOBt (1.3 eq.), DiPEA (10 eq.) in DMF. The 
hybrid label was deprotected and cleaved from the resin by treatment with triﬂuoroacetic acid 
(TFA) (92.5%), ethylenediamine (2.5%), TiS (2.5%) and water (2.5%) for 2 h. Subsequently, 
the compound was precipitated in cold methyl-tert-butyl-ether/hexane (1:1), dissolved in 
20% CH3CN in H2O, and lyophilized. The crude intermediate was used for the next reaction 
where a reactive linker was introduced. N-succinimidyl-4-maleimidobutyrate (2 eq.) was re-
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acted with the free thiol of the cysteine in dimethylsulfoxide with DiPEA (4 eq.). 30 mg of 
the crude product was puriﬁed by reversed-phase HPLC using a gradient of 0.1% TFA in 
H2O/CH3CN 95:5 to 0.1% TFA in H2O/CH3CN 5:95 in 40 minutes. Fractions containing 
the right mass were pooled and lyophilized to yield 9.5 mg of a blue ﬂuﬀy solid. MS: [M+H]+ 
calculated 1650.5, found 1651.5.
Synthesis of DTPA-Tyr3-octreotate, Cy5-Tyr3-octreotate, and Cy5-
DTPA-Tyr3-octreotate.
Resin-bound D-Phe-Cys(Acm)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Acm)-Thr(t-
Bu)(1) was synthesized as previously described (20) and further speciﬁed in Supplementary 
Information. Peptidyl resin 1 (25 μmol) was swollen in CH2Cl2. Depending on the peptide 
under synthesis, diﬀerent concentrations of DTPA-tetra (t-Bu ester), Cy5, or Cy5-DTPA hy-
brid label was added to the mixture with diﬀerent concentrations of peptide coupling agents in 
DMF. The mixture was stirred overnight at room temperature. The resin was then washed with 
DMF (3×) and CH2Cl2 (3×) and dried under vacuum. DTPA-Tyr3-octreotate, Cy5-Tyr3-oc-
treotate, or Cy5-DTPA-Tyr3-octreotate (as appropriate) was cleaved from the resin, and the 
side chains were de-protected with a solution of TFA/H2O/TIS 90:5:1.5 (5 mL) for 3 h. 
The resin was removed from the solution by ﬁltration. The peptides were precipitated with 
MTBE/hexane 1:1 v/v at -20 °C and lyophilized from CH3CN/H2O 1:1 v/v yielding 21.7 
mg of crude peptide for DTPA-Tyr3-octreotate, 25.7 mg for Cy5-Tyr3-octreotate, and 25.5 
mg for Cy5-DTPA-Tyr3-octreotate. The peptides were puriﬁed by preparative HPLC using 
a gradient of 0.1% TFA in H2O/CH3CN 9:1 to 0.1% TFA in H2O/CH3CN 1:9 in 60 min-
utes (DTPA-Tyr3-octreotate, Cy5-Tyr3-octreotate) or 120 min (Cy5-DTPA-Tyr3-octreotate). 
After pooling of the appropriate fractions and lyophilisation, 4.4 mg of pure DTPA-Tyr3-oc-
treotate, 6.8 mg of pure Cy5-Tyr3-octreotate, and 1 mg of pure Cy5-DTPA-Tyr3-octreotate 
was obtained. Further details can be found in the Supplementary Information.
Tyr3-octreotate.
Tyr3-octreotate was puriﬁed from the crude yield of Cy5-DTPA-Tyr3-octreotate. The 
peptide was isolated with preparative HPLC using a gradient of 0.1% TFA in H2O/CH3CN 
9:1 to 0.1% TFA in H2O/CH3CN 1:9 in 180 minutes. 
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Labeling with 111In and 125I
For the binding aﬃnity study, Tyr3-octreotate was labeled with 125I following the chlora-
mine T/method as previously described (21). For 111In radiolabeling, DTPA-Tyr3-octreotate 
or Cy5-DTPA-Tyr3-octreotate were mixed with 111InCl3 (1 eq.) and dissolved in 0.1 M of 
acetic acid. Labeling was performed as previously described (22) and further speciﬁed in the 
Supplementary Information. 
In vitro studies
Fluorescence-based flow cytometry and binding assay. The dissociation constant (KD) was 
determined by a ﬂuorescence-based ﬂow cytometry assay described previously (23). C204 
Luc 189 RR cells were trypsinized and aliquoted in portions of 300,000 cells. For satu-
ration binding experiments, each aliquot received 50 μL of 0.1% bovine serum albumin 
(BSA) in phosphate buﬀered saline (PBS), containing concentrations of Cy5-Tyr3-octreotate, 
Cy5-DTPA-Tyr3-octreotate, or Cy5-In-DTPA-Tyr3-octreotate ranging between 0 – 103 nM. 
For competition binding experiments, each aliquot received 50 μL of 0.1% BSA in PBS con-
taining 100 nM of Cy5-DTPA-Tyr3-octreotate as well as 10-1 – 3*104 nM of Tyr3-octreotate, 
DTPA-Tyr3-octreotate, or In-DTPA-Tyr3-octreotate. Cells were incubated for 1 h at 4 $C, 
after which they were washed twice with 300 μL of 0.1% BSA in PBS and re-suspended in 
300 μL of 0.1% BSA in PBS. Fluorescence was measured using a BD FACSCanto II ﬂow 
cytometer with APC settings (633 nm laser, 660/20 nm ﬁlter). Live cells were gated on a 
Forward Scatter/Side Scatter plot, and 20,000 live cells were analyzed. All experiments were 
performed in duplicate. 
Internalization study.
Rat pancreatic sst2-expressing CA20948 tumor cells were isolated as previously described 
(24) and seeded in six-well plates (0.5*106 cells/well). After 24 h, cells were incubated with 
Cy5-111In-DTPA-Tyr3-octreotate or 111In-DTPA-Tyr3-octreotate for 1 h at 37 °C (per well: 
0.035 nmol, 100 MBq/nmol). Speciﬁc binding was assessed for both tracers by co-incuba-
tion with a 100-fold molar excess of unlabeled peptide. The data was analyzed as previously 
described (25). 
513958-L-sub01-bw-Santini
Processed on: 22-9-2017 PDF page: 46
46
Chapter 2.1
In vivo/ex vivo studies 
Tumor model. Human small cell lung cancer H69 cells (ECACC, Salisbury, UK) were 
cultured under standard conditions in Gibco’s RPMI medium (Invitrogen, Breda, The Neth-
erlands) supplemented with 10% v/v fetal bovine serum and 1% v/v penicillin/streptomycin. 
Prior to tumor inoculation, 2.3*106 cell/mL were suspended in 2:1 v/v Seligmann’s buﬀered 
salt solution medium and Matrigel (BD Biosciences, Mississauga, Canada). The suspension 
was inoculated subcutaneously in 25 young adult male Balb/c-nu mice ( Janvier, France) (100 
μL/mouse). Tumor growth was monitored three-times/week. When tumors reached ~300 
mm3, animals were divided into four groups with similar distributions of tumor volumes: 
two groups of 8 animals for nuclear investigations and two of 4/5 mice each for optical and 
multimodal studies.
All animal experiments were performed in accordance with Dutch animal welfare regula-
tions and approved by the local ethics committee.
SPECT/CT imaging and nuclear-based biodistribution. 
Eight mice were given an intravenous injection of Cy5-111In-DTPA-Tyr3-octreotate 
(per animal: 200 pmol, 30 MBq, 200 μL); another 8 were given an injection of 111In-DT-
PA-Tyr3-octreotate (per animal: 200 pmol, 30 MBq, 200 μL). Animals were anesthetized with 
a mixture of isoﬂurane (Pharmachemie BV, Haarlem, The Netherlands; 4% for induction and 
1.5% for maintenance) and oxygen and scanned for 30 min with SPECT/CT at 2 and 24 h pi 
(NanoSPECT/CT, Bioscan, Washington DC, USA). Further information is available in the 
Supplementary Information. 
After the last scan, animals were euthanized by cervical dislocation, and blood was imme-
diately collected by heart puncture. Several organs and the tumor were harvested and weighed. 
Radioactivity was measured with a gamma counter (Wallac, 1480 Wizard 3”; PerkinElmer, 
Groningen, The Netherlands). Uptake was calculated as percentage of injected dose (% ID/g). 
Optical-based and multimodal imaging. For optical and multimodal analyses, 5 mice were 
injected with Cy5-111In-DTPA-Tyr3-octreotate (per animal: 200 pmol, 30 MBq, 200 μL) 
and another 4 mice with Cy5-Tyr3-octreotate (per animal 200 pmol, 200 μL). All mice were 
imaged at 24 h pi, using a ﬂuorescence tomography device (FMT, 2500XL, PerkinElmer Inc., 
Boston, MA). The mice injected with Cy5-Tyr3-octreotate were euthanized immediately after 
the ﬂuorescence tomography scan, the skin around the tumor was removed, and the tumor was 
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scanned with an IVIS imaging system (Perkin Elmer). The mice injected with Cy5-111In-DT-
PA-Tyr3-octreotate underwent SPECT/CT scanning at 24 h pi before being euthanized. 
Further information is available in the Supplementary Information.
Data analysis and statistical methods
All data collected were processed with Prism version 5 (GraphPad Software, La Jolla, Cal-
ifornia, USA). A two-tailed Student’s t test was used, and p<0.05 was considered statistically 
signiﬁcant.
RESULTS
)PUKPUNHMÄUP[`
Data obtained from the ﬂuorescence-based binding assays were used to generate concen-
tration-binding curves of the various compounds (Fig. 2) and to calculate their KD and IC50 
values. See Table 1 and the Supplementary Information for more details. Based on both KD 
and IC50 values, we observed a reduced receptor binding aﬃnity for the peptide derivatives 
tested: unlabeled Tyr3-octreotate > DTPA-Tyr3-octreotate > Cy5-111In-DTPA-Tyr3-octreo-
tate. 
In vitro tumor uptake
Internalization eﬃcacy of Cy5-111In-DTPA-Tyr3-octreotate was assessed in comparison 
to the nuclear-only tracer 111In-DTPA-Tyr3-octreotate (Fig. 3). First, the total uptake, mea-
sured as fraction of the applied dose (AD), that was retained in the cells was evaluated. 
For 111In-DTPA-Tyr3-octreotate and Cy5-111In-DTPA-Tyr3-octreotate the total uptake was 
33.76 ± 1.22% AD and 1.32 ± 0.02% AD, respectively (Fig. 3). 
Second, we distinguished between the internalized (cell fraction) and the membrane 
bound fraction (membrane fraction). For 111In-DTPA-Tyr3-octreotate the cell fraction and 
the membrane fractions were 30.76 ± 1.02% AD and 3.49 ± 0.3% AD respectively, whereas 
the values for Cy5-111In-DTPA-Tyr3-octreotate were 1.21 ± 0.03% AD and 0.12 ± 0.001% 
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AD, respectively. Co-incubation with an excess of DTPA-Tyr3-octreotate or Cy5-DT-
PA-Tyr3-octreotate unlabeled peptide (‘block’) signiﬁcantly reduced total uptake to 0.15% 
AD for 111In-DTPA-Tyr3-octreotate and to 0.04% AD for Cy5-111In-DTPA-Tyr3-octreotate, 
indicating receptor speciﬁcity for both tracers (Fig. 3). 
Calculating the percentage of internalized tracer versus the total uptake gave similar val-
ues for both tracers (Table 2), revealing that the two tracers have very similar kinetics once 
bound to the receptor.
Figure 2. (A) Fluorescence-based ﬂow cytometry saturation binding assay of Cy5-Tyr3-octreotate, 
Cy5-DTPA-Tyr3-octreotate and Cy5-In-DTPA-Tyr3-octreotate; (B) Fluorescence-based ﬂow 
cytometry competition binding assay. Cy5-DTPA-Tyr3-octreotate was used as the ligand to be 
displaced at increasing concentration of Tyr3-octreotate, DTPA-Tyr3-octreotate, and In-DTPA-Tyr3-
octreotate.
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Figure 3. Uptake of 111In-DTPA-Tyr3-octreotate and Cy5-111In-DTPA-Tyr3-octreotate by CA20948 
cells.
KD ± sd (nM) IC50 (nM),(95% CI (nM))
Tyr3-octreotate 16.2 ± 1.6 20.35 (16.8-24.7)
DTPA-Tyr3-octroetate 120.5 ± 18.1 151.5 (112.6-204.0)
In-DTPA-Tyr3-octreotate 31.2 ± 5.4 39.3 (28.0-55.1)
Cy5-Tyr3-octreotate 106.1 ± 11.7 133.4 (107.5-159.5)
Cy5-DTPA-Tyr3-octreotate 387.7± 97.9 487.7 (400.6-574.8)
Cy5-In-DTPA-Tyr3-octreotate 415.0 ± 90.0 522.0 (399.2-644.9)
Table 1: Receptor binding parameters of diﬀerent tracers, KD and IC50 values expressed in nM.
 Membrane Fraction Cell Fraction
Mean ± sd 
(% total uptake)
Mean ± sd
(% total uptake)
111In-DTPA-Tyr3-octreotate 10.33 ± 0.67 89.67 ± 0.70
Cy5-111In-DTPA-Tyr3-octreotate 8.86 ± 0.97 91.14 ± 0.97
Table 2. Radioactivity in membrane fraction and cell fraction 111In-DTPA-Tyr3-octreotate and Cy5-
111In-DTPA-Tyr3-octreotate expressed as % of total uptake.
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In vivo/ex vivo: tumor uptake and nuclear-based 
biodistribution
SPECT/CT images at diﬀerent time points indicate highly similar in vivo behavior of 
111In-DTPA-Tyr3-octreotate and Cy5-111In-DTPA-Tyr3-octreotate, both showing substantial 
uptake in the tumor and in the kidneys, but generally low radioactivity in background organs 
(Fig. 4). Interestingly, radioactivity was not detectable in the liver, indicating low hepatic 
retention for both tracers. In vivo quantiﬁcation of kidney and tumor radioactivity is shown 
in Fig. 4E: the data conﬁrmed Cy5-DTPA-Tyr3-octreotate to accumulate both in the kidney 
and in the tumor.
Ex vivo biodistribution data of 111In-DTPA-Tyr3-octreotate and Cy5-111In-DT-
PA-Tyr3-octreotate agreed with the pattern observed with the SPECT/CT scans, showing 
low accumulation (<2% ID/g) in organs other than the kidneys (Table 3). Noticeably, liver 
levels were extremely low. For kidneys, a high and consistent retention was visible: 14.25 ± 
2.79% ID/g for 111In-DTPA-Tyr3-octreotate and 52.21 ± 7.85% ID/g for Cy5-111In-DT-
PA-Tyr3-octreotate. Despite the fact that receptor aﬃnity of the hybrid tracer was signiﬁ-
Table 3. Biodistribution (in %ID/g) and Tumor/Tissue Ratios (TTR) of 111In-DTPA-Tyr3-octreotate 
and Cy5-111In-DTPA-Tyr3-octreotate at 24 h pi.
  111In-DTPA-Tyr3-octreotate Cy5-111In-DTPA-Tyr3-octreotate
 
mean ± sd 
TTR
mean ± sd 
TTR
(%ID/g) (%ID/g)
Blood 0.02 ± 0.03 313.84 0.07 ± 0.03 93.72
Spleen 0.11 ± 0.03 46.6 0.56 ± 0.04 12.36
Pancreas 0.29 ± 0.07 17.99 1.90 ± 0.85 3.65
Liver 0.12 ± 0.03 41.97 0.51 ± 0.04 13.57
Kidney 14.15 ± 2.79 0.37 52.21 ± 7.85 0.13
Adrenals 0.40 ± 0.30 12.99 0.62 ± 0.27 11.1
Duodenum 0.13 ± 0.05 38.95 0.49 ± 0.19 14.06
Colon 0.38 ± 0.10 13.51 1.30 ± 0.07 5.32
Caecum 0.17 ± 0.04 31.28 0.43 ± 0.04 16.28
Stomach 0.32 ± 0.06 16.12 1.30 ± 0.31 5.32
Muscle 0.03 ± 0.02 168.68 0.11 ± 0.10 61.87
Tumor 5.16 ± 1.27 1 6.93 ± 2.08 1
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Figure 4. SPECT/CT images of H69 tumor-bearing mice. 111In-DTPA-Tyr3-octreotate (A) 2 h pi 
and (B) 24 h pi; Cy5-111In-DTPA-Tyr3-octreotate (C) 2h pi and (D) 24 h pi; (E) Quantiﬁcation of 
tumor and kidney 2 h and 24 h pi; mean for N=8 of calculated uptake ± standard deviation (sd). Kd: 
Kidney; Tu: Tumor
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cantly reduced as measured in vitro, tumor uptake in vivo was relatively high for both tracers 
(mean ~5% ID/g) and not statistically diﬀerent (p>0.05). The calculated tumor/tissue ratios 
(TTR)—with the exception of the kidney—were always >3 and usually >10 (Table 3), indi-
cating that tumor speciﬁcity was high. 
Optical-based analyses 
Tumor uptake was quantiﬁed based on the FMT signal, and the results are depicted in Fig. 
5A. Optical signal originating from Cy5-111In-DTPA-Tyr3-octreotate and Cy5-Tyr3-octreo-
tate is comparable at 24 h pi. The optical image shown in Fig. 5B was obtained with an IVIS 
imaging system. The image shows a representative mouse of those injected with ﬂuorescent-
ly-labeled octreotate and indicates the potential of visualizing tumor tissue and margins in 
vivo using the ﬂuorescence signal. 
Figure 5. (A) FMT-based quantiﬁcation of Cy5-111In-DTPA-Tyr3-octreotate and of Cy5-Tyr3-
octreotate accumulation in the tumor, 24 h pi; (B) Cy5-Tyr3-octreotate ﬂuorescence imaging via IVIS 
at 24 h pi, after the removal of the skin from the tumor area.
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Multimodal analyses with Cy5-111In-DTPA-Tyr3-
octreotate
The combined optical and nuclear imaging capability of Cy5-111In-DTPA-Tyr3-octreotate 
is shown in Fig. 6. The images indicate that tracer accumulation in the tumor can be detected 
with both nuclear and optical imaging modalities. 
DISCUSSION
In NET, where radical tumor resection is often the only curative option, more reﬁned sur-
gical guidance, with the possibility of real-time tumor margin identiﬁcation, would be highly 
beneﬁcial for patient survival (7). Combined ﬂuorescence–and-nuclear imaging represents an 
attractive approach to improve guidance as it allows for combined pre- and intra-operative 
imaging, with high resolution and real-time feedback provided by ﬂuorescence imaging. The 
correlation we found between optical and nuclear imaging, conﬁrms that the combination 
of the two techniques is a promising approach for pre- and intra-operative imaging in NET. 
One of the main drawbacks of dual-labeled tracers is the potential loss of receptor aﬃnity 
and in vivo targeting capability which has previously been reported for various dual labeled 
tracers (16,17,26,27). Cy5-111In-DTPA-Tyr3-octreotate and 111In-DTPA-Tyr3-octreotate 
showed comparable proﬁles when applied in our in vivo model, especially with respect to 
tumor uptake and limited oﬀ-target uptake; the only major diﬀerence between 111In-DT-
PA-Tyr3-octreotate and Cy5-111In-DTPA-Tyr3-octreotate was the renal uptake, which was 
higher with the dual-labeled tracer than with the nuclear-only tracer. It is known that 
111In-DTPA-Tyr3-octreotate is cleared via and partially retained in the kidneys as a result of 
renal reabsorption in the proximal tubular cells, mostly due to the tracer’s molecular composi-
tion (28). We hypothesize that the three additional negative charges present on Cy5 contrib-
uted to the increased renal retention of Cy5-111In-DTPA-Tyr3-octreotate. A favorable ﬁnd-
ing concerning the hybrid Cy5-111In-DTPA-Tyr3-octreotate is the low level of liver uptake, 
which was comparable to that of 111In-DTPA-Tyr3-octreotate. High hepatic retention has 
Figure 6. Cy5-111In-DTPA-Tyr3-
octreotate in H69 tumor-bearing 
mouse 24 h pi: (A) SPECT/CT 
image; (B) FMT image of tumor 
region.
513958-L-sub01-bw-Santini
Processed on: 22-9-2017 PDF page: 54
54
Chapter 2.1
been reported for several other hybrid tracers (16,18). Such in vivo behavior was explained as 
a result of the hydrophobic nature of cyanine dye and the large non-covalent interaction with 
serum albumin that drives increased retention in all tissues, including the high hepatic uptake 
(18,29). In our study, we used a relatively hydrophilic cyanine dye, speciﬁcally chosen to re-
duce the albumin interaction. The three negative charges which are likely responsible for the 
increased renal retention, therefore also appear to contribute to the limited degree of hepatic 
clearance. Nonetheless, Cy5-111In-DTPA-Tyr3-octreotate was retained in the blood stream 
for longer than the corresponding nuclear-only tracer; such behavior could be explained by 
an interaction with albumin (26). Indeed, in a pilot protein binding study, the serum protein 
fraction contained more than 30 times as much Cy5-111In-DTPA-Tyr3-octreotate than the 
watery fraction of blood (data not shown). The longer circulation time might explain the im-
proved tumor uptake, this longer circulation time resulting from reduced renal ﬁltration and/
or by degradation protection. This hypothesis requires further investigation before deﬁnitive 
conclusions can be drawn. 
Regarding stability in the bloodstream, peptide molecules are known to be vulnerable to 
degradation by peptidases (30). Nonetheless, radiolabeled DTPA- and DOTA-linked Tyr3-oc-
treotide and Tyr3-octreotate have exhibited excellent stability in circulation; they are excreted 
via the urine mostly in the intact form (30-32). Therefore, we expect our hybrid Cy5-111In-DT-
PA-Tyr3-octreotate peptide analogue to exhibit good stability in circulation as well. Indeed, 
the Cy5-111In-DTPA-Tyr3-octreotate biodistribution proﬁle remained comparable with that of 
111In-DTPA-Tyr3-octreotate over time. Moreover, the hybrid probe uptake in tumor could be 
detected using both nuclear and ﬂuorescent imaging modalities, indicating that the radiolabel 
and ﬂuorophore on the hybrid probe were not separated during transit to the tumor. 
Our results on the hybrid Cy5-111In-DTPA-Tyr3-octreotate are particularly promising for 
application to image-guided surgery. For radio- or ﬂuorescence- guided surgery, a signiﬁcant 
diﬀerence in uptake by tumor and normal tissue is needed for discrimination. A TTR value of 
1.5 is generally considered suﬃcient for radioguidance (7), while a TTR value of 3 is thought 
to be needed for ﬂuorescence guidance (5). In our investigation, the nuclear-based TTR was 
always >3 (except for the kidneys) and usually >10. The low liver retention was particularly 
favorable for NETs, which are known to preferentially metastasize to the liver. To improve 
the relatively low (<1 TTR) in the kidneys, thereby making identiﬁcation of tumor lesions 
near the kidney feasible, it might be useful to apply methods that have previously been shown 
to reduce renal uptake of radiolabeled somatostatin analogs, including a hybrid tracer (33). 
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CONCLUSION
We have demonstrated Cy5-111In-DTPA-Tyr3-octreotate can eﬃciently target sst2 on tu-
mor tissue in vivo, allowing nuclear and ﬂuorescence detection. Our study provides insight 
in the inﬂuence of the Cy5-DTPA-label on receptor aﬃnity as well as pharmacokinetics of 
octreotate in vivo. These ﬁndings suggest that this hybrid tracer could be a lead-candidate for 
translation into clinical studies, to achieve more accurate visualization and detection of NETs 
during surgery. 
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SUPPLEMENTAL DATA
General on the synthetic procedures
All chemicals were obtained from commercial sources and used without further puriﬁca-
tion. HPLC was performed on a Waters HPLC system using a 1525EF pump and a 2489 UV 
detector. For preparative HPLC a Dr. Maisch GmbH Reprosil-Pur 120 C18-AQ 10 μm (250 
´ 20 mm) column was used (12 mL/min). For analytical HPLC a Dr. Maisch GmbH Repro-
sil-Pur C18-AQ 5 μm (250 ´ 4.6 mm) column was used and a gradient of 0.1% TFA in H2O/
CH3CN 95:5 to 0.1% TFA in H2O/CH3CN 5:95 in 20 minutes (1 mL/min) was employed. 
Mass spectrometry was performed on a Bruker microﬂex MALDI-TOF.
Synthesis of Cy5-DTPA hybrid label, Tyr3-octreotate, DTPA-Tyr3-
octreotate, and Cy5-DTPA-Tyr3-octreotate
Cy5-DTPA hybrid label Cy5 was synthesized following a procedure described by Mujum-
dar et al. [1].The hybrid imaging label was synthesized using solid phase peptide synthesis 
(SPPS). Tentagel S RAM-Cys(Trt)-Fmoc was purchased from RAPP Polymere (Tuebingen, 
Germany). After Fmoc deprotection (20% piperidine in DMF) Fmoc-Lys(IvDde)-OH (2 
equivalents (eq.)) was coupled overnight using PyBOP (2eq.), HOBt (2 eq.), DiPEA (4 eq.) 
in DMF. After subsequent deprotection of the N-terminus, DTPA (tBu)4 (1.3 eq.) was cou-
pled overnight using PyBOP (1.3 eq.), HOBt (1.3 eq.), DiPEA (3 eq.) in DMF. Next, the 
IvDde protecting group was removed with 2% hydrazine hydrate in DMF. Then Cy5 (1.3 eq.) 
was coupled overnight using PyBOP (1.3 eq.), HOBt (1.3 eq.), DiPEA (10 eq.) in DMF. 
The hybrid label was deprotected and cleaved from the resin by treatment with TFA (92.5%), 
EDT (2.5%), TIS (2.5%) and H2O (2.5%) for 2 hours. Subsequently, the compound was 
precipitated in cold MTBE/hexane (1:1), dissolved in 20% CH3CN in H2O and lyophilized. 
The crude intermediate was used for the next reaction where a reactive linker was introduced. 
N-succinimidyl-4-maleimidobutyrate (2 eq.) was reacted with the free thiol of the cysteine 
in DMSO with DiPEA (4 eq.). 30 mg of the crude product was puriﬁed by reversed phase 
HPLC using a gradient of 0.1% TFA in H2O/CH3CN 95:5 to 0.1% TFA in H2O/CH3CN 
5:95 in 40 minutes. Fractions containing the right mass were pooled and lyophilized to yield 
9.5 mg of a blue ﬂuﬀy solid. MS: [M+H]+ calculated 1650.5, found 1651.5.
cyclo[D-Phe-Cys-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys-Thr(tBu)]-resin (1) Res-
in-bound D-Phe-Cys(Acm)-Tyr(tBu)-D-Trp(Boc)-Lys(Boc)-Thr(tBu)-Cys(Acm)-Thr(tBu) 
was synthesized by SPPS using Fmoc-L-Thr(tBu)-PEG-PS resin (loading 0.16 mmol/g). 
Standard Fmoc/tBu strategy was used with PyBOP as coupling reagent. The linear side 
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chain-protected peptide was cyclized on resin using Tl(TFA)3 [2]: the resin-bound peptide 
(0.1 mmol) was swollen in 3 mL CH2Cl2. Tl(TFA)3 (109 mg, 0.2 mmol) in 3 mL DMF was 
added to the resin and the mixture was stirred for 1 hour at room temperature. The resin was 
washed with DMF (3×) and CH2Cl2 (3×) and dried under vacuum yielding peptidyl resin 1. 
The cyclization was conﬁrmed with analytical HPLC by cleavage and deprotection of a small 
amount of peptide. 
DTPA-Tyr3-octreotate Peptidyl resin 1 (25 μmol) was swollen in CH2Cl2. DTPA-tetra 
(t-Bu ester) (46 mg, 75 μmol), PyBOP (39 mg, 75 μmol) and DiPEA (26 μL, 150 μmol) in 
DMF (3 mL) was added and the mixture was stirred overnight at room temperature. The 
resin was washed with DMF (3×) and CH2Cl2 (3×) and dried under vacuum. The peptide 
was cleaved from the resin and the side chains were de-protected with a solution of TFA/
H2O/TIS 90:5:1.5 (5 mL) for 3 h. The resin was removed from the solution by ﬁltration. 
The peptide was precipitated with MTBE/hexane 1:1 v/v at -20 °C and lyophilized from 
CH3CN/H2O 1:1 v/v yielding 21.7 mg of crude peptide. The peptide was puriﬁed by prepara-
tive HPLC using a gradient of 0.1% TFA in H2O/CH3CN 9:1 to 0.1% TFA in H2O/CH3CN 
1:9 in 60 minutes. After pooling of the appropriate fractions and lyophilisation, 4.4 mg of 
pure DTPA-Tyr3-octreotate peptide was obtained. MS: [M+H]+ calculated 1425.6, found 
1425.6; [M+Na]+ calculated 1447.5, found 1447.9; [M+K]+ calculated 1463.7, found 1463.5.
Cy5-Tyr3-octreotate Peptidyl resin 1 (25 μmol) was swollen in CH2Cl2. Cy5 (38 mg, 50 
μmol), PyBOP (26 mg, 50 μmol) and DiPEA (17 μL, 100 μmol) in DMF (3 mL) was added 
and the mixture was stirred overnight at room temperature. The resin was washed with DMF 
(3×) and CH2Cl2 (3×) and dried under vacuum. The peptide was cleaved from the resin and 
the side chains were deprotected with a solution of TFA/H2O/TIS 90:5:1.5 (5 mL) for 3 
h. The resin was removed from the solution by ﬁltration. The peptide was precipitated with 
MTBE/hexane 1:1 v/v at -20 °C and lyophilized from CH3CN/H2O 1:1 v/v yielding 25.7 
mg of crude peptide. The peptide was puriﬁed by preparative HPLC using a gradient of 0.1% 
TFA in H2O/CH3CN 9:1 to 0.1% TFA in H2O/CH3CN 1:9 in 60 minutes. After pooling of 
the appropriate fractions and lyophilisation, 6.8 mg of pure Cy5-Tyr3-octreotate peptide was 
obtained. MS: [M+H]+ calculated 1797.1, found 1798.4.
Cy5-DTPA-Tyr3-octreotate Peptidyl resin 1 (25 μmol) was swollen in CH2Cl2. Cy5-DTPA 
hybrid label (30 mg, 18 μmol) and DiPEA (44 μL, 255 μmol) in DMF (2 mL) was added and 
the mixture was stirred overnight at room temperature. The resin was washed with DMF (3×) 
and CH2Cl2 (3×) and dried under vacuum. The peptide was cleaved from the resin and the 
side chains were de-protected with a solution of TFA/H2O/TIS 90:5:1.5 (5 mL) for 3 h. The 
resin was removed from the solution by ﬁltration. The peptide was precipitated with MTBE/
hexane 1:1 v/v at -20 °C and lyophilized from CH3CN/H2O 1:1 v/v yielding 25.5 mg of 
crude peptide. The peptide was puriﬁed by preparative HPLC using a gradient of 0.1% TFA 
in H2O/CH3CN 9:1 to 0.1% TFA in H2O/CH3CN 1:9 in 120 minutes. After pooling of the 
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appropriate fractions and lyophilisation 1 mg of pure Cy5-DTPA-Tyr3-octreoatate peptide 
was obtained. MS: [M+H]+ calculated 2586.0, found 2586.1.
In vitro experiments 
Nuclear based imaging
Nuclear SPECT/CT images for in vivo analyses were acquired using were acquired with a 
four-headed helical NanoSPECT system (NanoSPECT/CT, Bioscan, Inc, Washington D.C., 
USA). A multi-pinhole mouse collimator with 9 pinholes (1.4 mm diameter) per head, with a 
matrix of 256 x 256 was used. The machinery was equipped with a heated bed system to pre-
vent hypothermia in the animals. All animals received a SPECT scan of 24 projections (90 sec 
per projection) and a CT scan (240 projections, 500 ms exposure time at 55 kV) for anatom-
ical reference. For those mice that received both SPECT/CT and FMT scan the acquisition 
time of nuclear imaging was reduced to 20 minutes (20 projections, 60 second per projection). 
Optical and multimodal imaging
Optical imaging for in vivo analyses was performed using ﬂuorescence tomography device 
(FMT, 2500XL, PerkinElmer Inc., Boston, MA) and IVIS (Caliper Life Science, Hopkinton, 
MA, USA). For the tomographic analyses with FMT the mice were placed in a supine posi-
tion in the imaging cassette, which was inserted into the docking system of the FMT imaging 
chamber that was saturated with a mixture of isoﬂurane and oxygen (1.5% and 0.8% respec-
tively) The light source consisted of a laser diode (80mW). The region of interest was drawn 
around the tumor, to highlight the uptake. The signals were collected at the opposite side of 
the animal body by a low noise TE-cooled back illuminated high quantum eﬃciency CCD 
camera with air assist. Using the preconﬁgured channel 1 (Ȝex=635 nm, Ȝem=650-670 nm) both 
ﬂuorescent and excitation data sets were collected and multiple source-detector ﬂuorescence 
projections were normalized to laser excitation data. 
In our protocol, for acquisition of optical images with the IVIS system, the mice were 
euthanized and placed supine in the chamber. IVIS system is equipped with a tungsten hal-
ogen lamp and ﬁlters for selection of excitation wavelength. In our evaluation optical images 
were acquired using an excitation length of 640 nm. The animals were top illuminated by the 
excitation light and the emission light subsequently ﬁltered at diﬀerent wavelength from 680 
nm to 780 nm (band pass = 20 nm). Acquisition time was approximately 60 second.
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Data analysis and statistical methods
The competition studies were ﬁtted using the normalized geometric means were ﬁtted 
with equations in the GraphPad Prism 5 software. The KD and IC50 values of Cy5-Tyr3-oct-
reotate, Cy5-DTPA-Tyr3-octreotate and Cy5-In-DTPA-Tyr3-octreotate were calculated us-
ing the ‘Binding – Saturation, One site – Total’ nonlinear regression equation (Eq. 1). 
 (Eq. 1)
Where, y is the normalized ﬂuorescence; Bmax is the maximum speciﬁc binding in the 
units of the y axis; x is the concentration of Cy5-Tyr3-octreotate, Cy5-DTPA-Tyr3-octreo-
tate or Cy5-In-DTPA-Tyr3-octreotate in nM; KD = equilibrium dissociation constant of 
Cy5-Tyr3-octreotate, Cy5-DTPA-Tyr3-octreotate or Cy5-In-DTPA-Tyr3-octreotate in nM; 
NS is the slope of nonspeciﬁc binding; Background is the amount of normalized ﬂuorescence 
with no added compound.
The KD values of Tyr3-octreotate, DTPA-Tyr3-octreotate and In-DTPA-Tyr3-octreotate 
were calculated using the ‘Binding – Competitive, One site – Fit Ki’ nonlinear regression 
equation (Eq. 2 and 3). 
 (Eq. 2)
 (Eq. 3)
Where IC50 is the concentration of competitor that results in binding half-way between 
Bottom and Top; KD is the equilibrium dissociation constant of the competitor in nM; [a] is 
the concentration of Cy5-DTPA-Tyr3-octreotate (100 nM); KD,a is the dissociation constant 
of Cy5-DTPA-Tyr3-octreotate (387.7 nM); y is the normalized ﬂuorescence; Bottom and Top 
are the plateaus in the units of the y axis. 
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Treatment planning options for 
improved 177Lu-DOTA, Tyr3-octreotate 
therapeutic response studied in an 
animal model
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ABSTRACT
Treatment with 177Lu-labelled DOTA, Tyr3-octreotate (TATE) has been shown to be an 
excellent treatment for somatostatin receptor-overexpressing neuroendocrine tumours in case 
surgery, the primary treatment option is not an option anymore. Success full therapy depends 
on delivering high absorbed doses to the tumour metastases relative to a non-toxic absorbed 
dose delivered to normal organs. Patient-speciﬁc treatment planning aimed at increasing the 
absorbed tumour dose while also aiming for a tolerance absorbed dose in organs at risk, 
might enhance the eﬀectiveness of this therapy. The radiobiology of tumour dose-response 
is described by the linear quadratic model. In theory fractionation of the dose delivered or 
changes in dose rate will hardly inﬂuence the tumour response while they do reduce the risk 
for radiation induced adverse events. These tumour radiation response eﬀects are the main 
subject of this study as well as the response eﬀect with time. 
Therefore, we have performed experiments in H69 tumour-bearing nude mice, to study 
the eﬀects of diﬀerent speciﬁc activities on the absorbed doses in the tumour versus normal 
organs as well as on therapeutic responses. Furthermore, diﬀerent treatment schemes were 
studied aiming for the impact of multiple administrations. Finally, all results were compared 
with calculations using the linear quadratic model to verify its usefulness for prospective 
treatment planning. 
Our results indicated that it is possible to model the anti-tumour response by diﬀer-
ent dose rates, due to changes in speciﬁc activity and fractionation. Both tumour growth as 
clearance of dead cells over time in response to radiation exposure were introduced into a 
treatment planning model based on the linear quadratic model. This model appeared to be 
useful in predicting anti-tumour responses and can be applied to calculate optimal therapy 
conditions for future patient studies. 
Key words: speciﬁc activity, multiple dosing, radiobiology, PRRT, neuroendocrine tumor, 
dosimetry
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INTRODUCTION
Peptide receptor radionuclide therapy (PRRT) using radiolabelled peptides speciﬁcally 
targeting receptors overexpressed on tumour cells has been shown to be an eﬀective cancer 
treatment option (1). During PRRT a high radiation dose can be delivered to tumours, with a 
tolerable toxicity in normal non-targeted tissues such as kidneys and pancreas (2). 
In more than 50% of the patients, NETs are diagnosed at a relatively late stage, often with 
metastatic spread, which leaves little chance for curative surgery (3). PRRT has proven to be 
an eﬀective palliative-type of therapy in most patients with NETs even at late stage (4). Com-
plete remissions after PRRT are however still rare (2), indicating that further optimization of 
PRRT is urgently needed. 
PRRT given at a ﬁxed activity dosing scheme of 4x7.4 GBq 177Lu/192 μg TATE has been 
proven to be eﬀective in prolonging survival and delaying progression (2). Attempts to further 
improve treatment for each individual patient have been made by individualized treatment 
planning. This enables possible additional treatment cycles by using patient-speciﬁc dosime-
try to determine the maximally tolerated activity by dose-limiting organs as kidneys and bone 
marrow (5). The absorbed dose to the metastatic tumour is thereby maximized. As far as we 
know there is however no evidence these additional treatment cycles do result in an improved 
response or an increased survival. 
Besides the amount of activity, a patient is treated with, also the amount of peptide this 
activity is labeled to, the so-called speciﬁc activity, is of importance when treating patients 
with PRRT. This as the speciﬁc activity has been shown to inﬂuence the biodistribution of the 
radiopharmaceutical in preclinical studies (6) as well as in patients. To use this inﬂuence for 
further improved of individualized treatment, physiologically based pharmacokinetic models 
have been developed to determine the optimal amount of ligand in PRRT (7). This model 
accounts for perfusion and distribution volumes, receptor aﬃnity and speciﬁc activity to de-
termine time-activity curves for tumours and organs with normal physiological uptake. 
Prospective treatment planning with the aim to reach an eﬃcacious dose in the tumour 
has not been established yet. By getting an idea of anti-tumour response in time, eﬀects of 
potential additional treatment cycles can be determined as well as possibilities to reduce tox-
icity by dose fractionation, as applied for external beam radiation therapy. In external beam 
radiotherapy, fractionation of the absorbed dose lowers the incidence of normal organ toxicity 
at comparable therapeutic eﬀects (8). The linear quadratic model (LQM) forms the basis for 
this observation (8), and the LQM also plays a role in the dose limit for radiation-induced 
nephritis after 90Y-DOTATOC therapy (9). 
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In the current study, we performed multiple experiments in SSTR-expressing H69 tu-
mour-bearing nude mice to examine the inﬂuence of speciﬁc activity of the radiolabelled 
peptides and of fractionation of the treatment on anti-tumour response. These experiments 
were primarily used to tailor the linear quadratic model to predict anti-tumour response over 
time and investigate its value for prospective treatment planning. 
MATERIALS AND METHODS
Tumour Cell Line and in vivo tumour model 
Human small cell lung cancer cell line H69, overexpressing the somatostatin receptor 
type 2 (SSTR2) was obtained from ECACC (Salisbury, UK) and grown in RPMI medium 
(Gibco, Invitrogen Corp., Breda, NL) supplemented with 10% heat-inactivated fetal bovine 
serum. Male NMRI Nu/nu (Harlan, Heerlen, NL) were inoculated subcutaneously with 107 
H69 cells in a suspension of 1:2 v/v Seligmann’s buﬀered salt solution and Matrigel (BD Bio-
sciences, Missisauga, CA). Mice and tumour growth were monitored three times per week for 
three weeks. All animal experiments have been conducted with prior approval of the animal 
ethics committee of our institution. Further information of animal handling and tumour 
model can be found in the Supplementary Information (SI).
Radionuclides and peptides
DOTA,Tyr3-octreotate was obtained from BioSynthema, (St Louis, MO, USA) and 
177LuCl3 was obtained from IDB Holland (Baarle-Nassau, NL). 177Lu-TATE was prepared 
as described previously (10). Activities of 30 and 26 MBq 177Lu-TATE have been used. These 
activities resulted in our previous experiments in appropriate anti-tumour responses (11). 
SPECT/CT imaging 
 A small-animal SPECT/CT camera (BioScan, Washington DC, USA) was used to image 
and quantify the distribution of radiolabelled peptides in vivo. See SI for further information 
on SPECT/CT speciﬁcations.
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Experimental set-up
The set-up of the experiment is summarized in Table 1. Further details on experimental 
settings can be found in the SI.
Dosimetry calculations
Dosimetry in normal organs and tumours was performed according to the MIRD-scheme 
(12). Time-activity curves of organ and tumour distribution were determined on the com-
bination of biodistribution data and quantitative SPECT. A more detailed description on 
“Dosimetry calculation” can be found in SI.
Groups Treatment Number of mice
Eﬀect of diﬀerent speciﬁc activity 
Control Saline 5
0.5 μg peptide 30 MBq 177Lu 20 (8 +12)
1.0 μg peptide 30 MBq 177Lu 20 (8 +12)
2.0 μg peptide 30 MBq 177Lu 20 (8 +12)
Split-dose experiment: Comparison 
single-dose vs. split-dose 
Control Saline 8
Single-dose 26 MBq 177Lu/0.7 μg TATE 8
Split-dose 2x 13 MBq 177Lu/0.35 μg TATE 
(5 d interval)
8
Double-dose experiment: Comparison 
single-dose vs. double-dose 
Control Saline 5
One-dose 30 MBq 177Lu/0.825 μg TATE 8
Double-dose 2x30 MBq 177Lu/0.825 μg TATE (14 
d interval)
8
TATE: octreotate; d: day(s)
Table 1 Experimental setup 
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model (LQM)
The tumour growth curves V(t) were modelled with exponential growth functions from 
the normal growth equation. The LQM is used to predict the tumour volume as a function 
of time, taking into account a lag-time in response due to removal kinetics and a fraction of 
non-responding tumour cells. In SI a more detailed description of the “Tumor growth curve 
ﬁtting”, “Time-dependent tumor response” and on the “Kinetics of radioactivity of 177Lu-
TATE” can be found.
Statistics
Data regarding the tumour uptake were analysed with one-way ANOVA, with p<0.05 
considered as statistically relevant. See further information of statistical method in SI. 
RESULTS
,MMLJ[VMZWLJPÄJHJ[P]P[`
In all experimental groups, treated with diﬀerent peptide amounts of 177Lu-TATE (0.5, 
1.0 and 2.0 +g), the highest amount of radioactivity uptake was measured in the tumour 
(Figure 1A). Stomach and pancreas are normal SSTR2-expressing organs showing a low, but 
signiﬁcant amount of 177Lu-TATE uptake (>0.1% IA/g), but not detectable using SPECT/
CT imaging (Figure 1B). Clearance of the radiopeptides via the kidneys results in retention of 
radioactivity, also identiﬁable in the SPECT/CT scan (Figure 1B). At 7 d pi, tumour uptake 
was twice as high in the 0.5 +g peptide group as in the other groups. The ﬁt of the curves 
describing the kinetics of the radioactivity in selected organs was described by single-expo-
nential curves (See Figure S1 in SI).
For all peptide amounts the tumour showed the highest absorbed dose; this resulted in 
592±84 mGy/MBq (0.5 μg), 471±130 mGy/MBq (1 μg) and 321±138 mGy/MBq (See Table 
S1 in SI). The kidneys had the highest absorbed dose in normal tissue: 140±39 mGy/MBq. 
Only the tumour and the pancreas and stomach showed the maximum absorbed dose in the 
0.5 μg group. All other absorbed doses appeared to be similar between the three groups. 
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The tumours in the control group showed an exponential growth with a mean doubling 
time (Td) of 9±2 d (Figure 2A). After initial response to therapy with a volume nadir at 
T1=13±2 d, regrowth occurred in all three experimental groups with a Td of 9±3 d. The median 
time to reach a volume above 1800 mm3 was 13 d (range: 11-34) for the control group, 49 d 
(range: 38-62) with 0.5 μg, 42 d (range: 24-65) d with 1.0 μg and 31 d (range: 24-42) with 
2.0 μg (p=0.002 for 0.5 μg vs 2.0 μg group)(Figure 2B). 
Figure 1. Uptake of 177Lu-TATE applied at diﬀerent. A: Percentage of injected activity per gram 
tissue (%IA/g) in tumour and normal organs at 2, 4 and 7 days after administration of 30 MBq 177Lu-
TATE: 0.5 μg peptide (red), 1.0 μg peptide (blue), 2.0 μg peptide (green); B: Uptake of radioactivity 
shown by the SPECT/CT scans (corrected for decay) after injection with 0.5, 1.0, 2.0 μg of 177Lu-
TATE. Images are acquired at 4, 48 and 96 h pi. Tu: tumour; Kd: kidney; Bl: bladder; Ar: artefact.
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Figure 2. Tumour growth and survival curve after therapy using 30 MBq of 177Lu labeled to 
0.5, 1.0 or 2.0 μg TATE. A: Volume of H69 xenografts in mice after 30 MBq 177Lu-TATE at 0.5 
(red), 1.0 (blue) and 2.0 (green) μg. Regrowth occurred with doubling time Td=9±3 days (n=8). The volume nadir for all groups was: 13±2 d. The control group growth (n=5) (black) with a Td of 9±2 d. Dots represent the measured values, dashed line represents the ﬁtting (see text for details), dotted 
line represents the 95% conﬁdence interval for the control group; B: The time to reach the median 
maximum volume of 1800 mm3 was 49 (38-62) d with 0.5 μg (red), 42 (24-65) d with 1.0 μg (blue) 
and 31 (24-42) d with 2.0 μg (green). Between the 0.5 and the 2.0 μg group there was a signiﬁcant 
diﬀerence (p=0.002). pi: post injection
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Effect of treatment scheme 
Split-dose
Tumours in the control group showed exponential growth, with an average Td of 6.4±2.1 
d. These results were reﬂected in the median survival time: 17 d (range: 11-35) for the control 
group, 41 d (range: 25-71) for the 1x26 MBq group and 37 d (range: 27-50) for the 2x13 MBq 
group; the latter was not signiﬁcantly diﬀerent (p=0.56)(Figure 3A). Both treatment groups 
showed a signiﬁcantly longer time to reach a tumour volume of 1800 mm3 compared to the 
control group (p=0.001 for both groups) (Figure 3B). The group treated with 1x26 MBq/0.7 
μg 177Lu-TATE, showed a tumour volume nadir at 14±2 d after which regrowth occurred with 
an average Td of 6 d (range: 2.8-10). In the 2x13 MBq/0.35 μg 177Lu-TATE group the volume 
nadir was at 15±3 d. Regrowth occurred with a Td of 6 d (range: 2.4-30). Further information 
on growth parameters after administration of the split-dose of 177Lu-TATE are summarized 
in Table 2S in SI.
Double-dose 
When comparing the two experimental groups, the 2x30 MBq 177Lu-TATE group showed 
a signiﬁcantly longer time to reach 1800mm3 (p=0.04) compared to the1x30 MBq group. Me-
dian survival time was 32 d (range: 25-47) for the controls, 53 d (range: 47-75) for 1x30 MBq, 
and 75 d (range: 46-95) for 2x30 MBq (Figure 4A).Both the 1x30 MBq and 2x30 MBq/0,825 
μg 177Lu-TATE groups showed a signiﬁcantly longer time to reach the tumour volume of 1800 
mm3, in comparison with the control group (p=0.008 and p= 0.002, respectively) (Figure 4B). 
Further information on growth parameters after administration of the double-dose of 177Lu-
TATE are summarized in Table 2S and 3S in SI.
Dosimetry
No diﬀerence was found in radioactivity measured in the tumour after the second admin-
istration of 30 MBq, using SPECT/CT after 24 h pi, at 1.79±0.21 kBq/mm3 (Figure 5). This 
is a factor 1.14 above the 24 h value extrapolated from the biodistribution data. Correcting 
with this factor 1.14 results in an absorbed dose of 12.3 Gy for the group treated with one 
dose, whilst the double-dose corresponds to an absorbed dose of 25 Gy. 
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Figure 3. Tumour growth and survival curve after the therapy using 26 MBq (single-dose) or 
2x13 MBq (split-dose) of 177Lu-TATE. A: Tumour volume of H69 xenografts treated with 26 MBq 
177Lu/0.7 μg TATE (red) given and 2x13 MBq (blue). After the single therapy 7 (of 8) (red) tumours 
showed median regrowth with a doubling time Td of 6 days (range: 2.4-30 d), all starting regrowth after volume nadir at 14±2 d. All tumours showed regrowth with Td=6 d (2.8-10 d; n=8) after the 2x13 MBq with a nadir in the tumour volume after: 15±3 d. The tumour volume in the control group 
(n=8) showed a mean doubling time of Td=6.4±2.1 d; B: Median time for the tumour to reach a volume of 1800 mm3 in control group (black), single-dose (red) and split-dose (blue). The values of 
the median were 17, 37 and 41 d respectively. D0: day 0; pi: post injection.
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Figure 4. Tumor growth and survival curve after therapy using single- or double-dose of 30 MBq 
177Lu-TATE. A: Tumour volume of H69-tumours (n=8) treated with 30 MBq 177Lu/0.825 μg TATE 
(100 MBq/2.75 μg)(red) or 2x30 MBq 177Lu/0.825 μg TATE with 14 days (d) interval (blue). Volume 
is expressed as % of the tumor volume at day 0 (D0). All tumours after 1x30 MBq showed regrowth with Td = 9.4±2.5 d, after the volume nadir at 15 d (11-20). After two doses, the Td was 7.5±2 d, with a nadir of 33 d (14-59). In the control group (black) tumours growth with a doubling time of 11.6±3 
d; B: Median time to achieve a tumour volume of 1800 mm3 was respectively 32, 53 and 74 d. pi: post 
injection.
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Comparison of response predicted by the LQM and 
average tumour volume 
The average tumour volumes respond as a function of time following the LQM predic-
tion (See equations in SI) with a mean _=0.14±0.03 Gy-1 (`=0 Gy-2) in all cases, under the 
assumption that all tumour cells respond to the radiation exposure (Figure 6). Fit parameters 
of LQM are represented by the propagation factor (q), the median clearance time (Tclearance) 
and the linear component to the growth curve in the linear quadratic model (_). The values 
of the ﬁt parameters of the predicted response curve are shown in Table 4S in SI. Clear-
ance of non-dividing cells from the tumour volume proceeded with a median Tclearance=3.5 d 
(range: 0.9-7.1). The cells that keep on proliferating without response to the absorbed dose is 
q=5.5±2.4%, except for 2.0 +g (30 MBq) and 30 MBq in double-dose experiment (See Table 
S4 in SI). The radiation sensitivity was set at _=0.21 Gy-1. The 2 +g group could be ﬁtted 
by q=22% and the 30 MBq group in the double-dose expetiment by q=19%. Clearance of 
Figure 5. Uptake of activity after each dose in mice 24 h after administration of 30 MBq of 177Lu-
TATE. A: On top: SPECT/CT image 24 h pi of a mouse treated with a single administration of 30 
MBq of 177Lu-TATE; below concentration of radioactivity measured in the tumor 24 h pi (purple 
bar); B: On top: SPECT/CT image 24 h pi of a mouse treated with two administrations of 30 MBq 
of 177Lu-TATE with 14 d in between; Below: concentration of radioactivity measured in the tumor 24 
h pi (orange bar) and 14 d +24 h (spotted orange bar). After the ﬁrst administration, as well as after 
the second, tumour uptake in mice treated with two doses was comparable with the uptake in mice 
treated with one dose.
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Figure 6. Comparison of response predicted by the linear quadratic model (LQM) and responses 
measured in the diﬀerent evaluations. A: The tumor growth after the treatment 30 MBq of 177Lu 
labeled to diﬀerent amount of peptides: 0.5 μg (red) the 1.0 μg (blue) and the 2.0 μg groups (green) 
are compared; B: The response to 1x 26 MBq (red) is compared with response to 2x 13 MBq (blue); 
C: Response as predicted by the LQM with the average tumour volume measured for the mice treated 
with 1x (red) or 2x (blue) 30 MBq 177Lu-TATE. The LQM ﬁt was performed by either using the 
radiation sensitivity _ as free parameter (uniform cell response) or by using the percentage of non-
responding cells p as free parameter with _=0.21 Gy-1 (uniform radiation sensitivity). Response as 
predicted by the LQM is given as a line whilst the response as measured during the experiments is 
given as dots. Tx: therapy with the dose mention after; pi: post injection.
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non-dividing cells from the tumour volume proceeded in this case with a median Tclearance=5.5 
d (range: 1.5-9.0). The double-dose group (2´30 MBq) showed no delay in clearance from 
the tumour.
DISCUSSION
In this study, we investigated the relation between the absorbed dose in tumours response. 
At 48 h pi, for the 0.5 μg, the 1.0 μg as well as for the 2.0 μg group, there was an underes-
timation of tumour concentration of activity when comparing the SPECT results with the 
results from the biodistribution. A possible explanation for this underestimation could be a 
user dependent threshold setting for the 3D quantiﬁcation. 
As human NETs are slowly proliferating tumours (with a proliferation factor (Ki-67)< 3% 
for grade 1) (13), the relatively fast proliferating H69 tumour model, with a Ki-67 of 70-90% 
(14), has some limitations as a general model for NETs. Keeping this in mind, the two-weeks 
interval we applied in the double-dose experiment, might be comparable with the 6-8 weeks 
interval that is being applied in clinical PRRT for NET patients (15).
In earlier preclinical studies receptor saturation has been shown to be a limiting factor 
for tumour uptake of radiopeptides (16). In a CA20948 rat model, Müller et al. (17) also 
showed that a diagnostic dose of 177Lu-TATE (3 MBq/0.5 μg peptide) resulted in a relatively 
high accumulation of radioactivity in SSTR2-positive tissues compared with a therapeutic 
peptide amount (300 or 555 MBq/15 μg). This suggests that therapeutic amounts are in the 
concentration range which saturates SSTR2 in the tumour. In patients the tumour capacity of 
SSTR2 seems not to be reached Kratochwil et al. (18) however reported receptor saturation 
of liver tumours when radiolabelled peptides were intra-arterially administered via the hepatic 
artery. The physiologically based pharmacokinetic model for radiolabelled octreotide studied 
by Kletting and collaborators (7), showed that also in clinical setting receptor saturation may 
cause reduced uptake in well perfused tumours (7, 19). 
Since the majority of PRRT patients suﬀer from metastases, in most cases the evaluation 
of the therapy is focused mainly on the larger tumour masses with relative high uptake of ra-
dionuclides. However, this information may not apply to the uptake in the smaller metastases 
which could be less perfused or suﬀer from SSTR saturation. 
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In the second part of our investigation, we ﬁrst adjusted the treatment scheme by admin-
istering the treatment in two half doses (in the split-dose experiment) and second a dou-
ble-dose (in the double-dose experiment) twice the activity was given with 14 days interval. 
The results we obtained in the split-dose experiment, demonstrated that this variation 
had no inﬂuence on the anti-tumour response. This means that for clinical application the 
same therapeutic eﬀect may be obtained but with reduction of the risk on toxicity to healthy 
tissue by the principles of the LQM, assuming that the _/` value for tumours is larger than 
for normal tissue. 
Despite the assumed improvement of tumour perfusion after radiolabelled peptide treat-
ment, as reported earlier (20), in the double-dose experiment we observed that the tumour 
uptake of 177Lu-TATE after the second dose did not increase. 
The tumour volume as a function of time can be described by using the LQM to translate 
the absorbed dose rate in the tumour into the number of killed cells, leading to volume re-
duction. The derived LQM parameters for H69 diﬀer hugely from those reported in literature 
for cell survival. We found _=0.14±0.03 Gy-1 without any indication for a quadratic dose 
response (`=0), much lower than the previous reported _ of 0.21±0.16 Gy-1 and `=0.06±0.05 
/Gy-2 for H69 tumours (21), although the diﬀerence is not signiﬁcant. The diminished qua-
dratic response could also be explained by a low sub-lethal damage repair half-life (Trep); the 
quadratic part of the LQM (equation 4 in SI) diminishes when Trep is below 6 h. Splitting 
the delivery of an absorbed dose, following our results, will have no inﬂuence on the tumour 
cell kill according to the LQM. Further experiments should consider whether the other asset 
of the LQM, reduction of late-occurring toxicity, also holds for 177Lu-TATE. An individually 
optimized treatment scheme together with an individually optimized speciﬁc activity, should 
result in an increased absorbed dose by the tumour and optimal PRRT. For pancreatic NETs, 
this increased absorbed tumour dose has been related to an increased response (15). The re-
sults from our studies and the use of the LQM oﬀer possibilities for further improved indi-
vidualized treatment. Tumour biopsies can be used to determine its radiosensitivity, helping 
to predict what response a certain dose of activity will render. Furthermore, the determination 
of tumour radiosensitivity can indicate if dose fractionation does aﬀect tumour response for 
each patient. Breeman al. (22) have shown that it is possible to label 177Lu-TATE at a higher 
speciﬁc activity than the currently used 37 MBq/μg. 
Treatments given at the maximal tolerated dose (for the kidneys and bone marrow), like 
in some institutes is performed (23, 24) , remains to form a matter of debate. Considering 
overall survival, there is some evidence that therapy at a maximal tolerated dose leads to a 
higher success rate in e.g. tumour lesion ablation. Tumour recurrence often is the result of 
just some (clusters of ) untreated cells not yet visible with imaging methods or not expressing 
the targeting vector’s receptor. Treatment with `-radiating radionuclides is not optimal to kill 
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individual cells or small clusters below 1.2 mm diameter (25). Therefore, a more prudent ap-
proach is advisable to stay below the full tolerable maximum, and thereby keeping treatment 
options behind for a potential recurrence. Most importantly personalized dosimetry should 
be the guidance in these treatment planning approaches.
CONCLUSION
The absorbed dose and the linear quadratic model can be used to predict anti-tumour 
response and optimize speciﬁc activity for each individual patient. Furthermore, splitting 
of the dose, did not aﬀect anti-tumour response indicating a negligible quadratic dose re-
sponse parameter. Our current ﬁndings validate the use of an individualized speciﬁc activity 
and treatment scheme based on patient and tumour speciﬁc characteristics in dosimetry and 
radiobiology. Prospective treatment planning for radionuclide therapies is feasible when all 
relevant tumour radiobiology parameters are known, like the radiation sensitivity _/` and the 
sub-lethal damage repair half-life. 
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SUPPLEMENTARY INFORMATION
Animals and tumour model
Male NMRI Nu/nu mice were obtained from Harlan (Heerlen, the Netherlands). One 
week after arrival, mice were inoculated subcutaneously with 107 H69 cells in a suspension 
of 1:2 v/v Seligmann’s buﬀered salt solution (SBSS) and Matrigel (BD Biosciences, Missi-
sauga, Canada) while anesthetized with a mixture of isoﬂurane/O2: 2.0% at 0.5 mL/min. For 
all experiments, animals were randomized into matching treatment groups with regard to 
tumour size. Three times a week mice were weighed and tumour size was measured using a 
calliper ruler by a person blinded for the treatment groups. Body weight of the mice at start 
of treatment was between 28.1 and 35.6 g. Tumour volume was calculated using the formula: 
(length*width) ^1,5)* π/6 (1). Tumours were allowed to develop until a maximum of 1800 
mm3. Mice also were euthanized after >10% loss of body weight since start of the experiment 
or in case of other serious discomfort. Administration of saline and 177Lu-TATE was per-
formed intravenously via the tail vain. 
SPECT/CT imaging
SPECT/CT images were performed  with the four-headed NanoSPECT/CT system (Bi-
oScan, Washington DC, USA). Multi pinhole mice collimators with 9 pinholes (diameter 
1.4 mm) per head were used: 24 projections, 120 sec per projection were applied. The scans 
were obtained with a quality factor of 0.7. SPECT scans were reconstructed iteratively on a 
256x256 matrix, using HiSPECT NG software (Scivis, GmbH Göttingen, DE) and ordered 
subset expectation maximization (OSEM). The total amount of radioactivity in the tumour 
was quantiﬁed on SPECT/CT images by tri-dimensional (3D) quantiﬁcation using InVivo-
Scope software (IVS, Bioscan, Washington DC, USA). To achieve accurate quantiﬁcation, the 
camera was calibrated by scanning a 20 mL polypropylene tube phantom ﬁlled with a known 
amount of 177Lu activity. Before each SPECT acquisition, a CT scan was performed for ana-
tomical reference. The scan was performed using 240 projections with a standard resolution. 
Tube voltage was 45 kVp and exposure time was 500 ms. During scanning, the mice were 
anesthetized with a mixture of isoﬂurane/O2: 2.0% at 0.5 mL/min. and body temperature was 
maintained using a heated bed. 
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Experimental Settings
,MMLJ[VMZWLJPÄJHJ[P]P[`VU[\TV\YNYV^[OHUKKVZPTL[Y`VM[OL
tumour and normal organs (Table 1, Experiment 1)
Three experimental groups of H69 tumour bearing mice (n=8 per group) were treated 
with 30 MBq 177Lu-TATE, labelled to either 0.5, 1.0 or 2.0 μg of peptide, which was diluted 
in 0.2 mL saline. A control group of H69 tumour bearing mice (n=5) received 0.2 mL saline. 
To study the kinetics of radioactivity uptake and retention by the tumour, SPECT/CT scans 
were acquired at 4 h, 2 and 4 days (d) post injection (pi). Monitoring of body weight and 
tumour size were performed three times a week for 65 d.
For biodistribution studies, three additional groups of H69 tumour bearing mice (n=12 
per group) also received 30 MBq 177Lu-TATE, labelled to 0.5, 1.0 or 2.0 μg peptide. At 2, 4 
and 7 d pi four mice per group were sacriﬁced, tumours and selected organs were harvested 
and weighed and the amount of retained radioactivity was counted using a gamma counter 
(Wallac, 1480 Wizard 3”, Perkin Elmer, Groningen). Tissue uptake of 177Lu-TATE was cal-
culated as % injected activity per gram of tissue (% IA/g).
Evaluation of variations in treatment schedules
To study the eﬀect of a split-dose compared with the full dose administered at once, two 
groups of H69 tumour-bearing mice (n=8 per group) (Table 1, Split-dose experiment) were 
treated with a total amount of 26 MBq/0.7 μg 177Lu-TATE in 0.2 mL saline, either in one 
single-dose of 26 MBq (single-dose group) or as two doses of 13 MBq with 5 d interval 
(split-dose group). A control group (n=8) received 0.2 mL of saline. Monitoring of body 
weight and tumour size was performed three times a week for 100 days, or until tumours 
reached a volume >1800 mm3.
To study the eﬀect of an additional treatment on tumour response and absorbed dose in 
critical organs, we performed further analysis on speciﬁc data from an earlier study (Table 
1, Double-dose experiment) (1), in which two groups of H69 tumour-bearing mice (n=8 per 
group) were treated either with a single-dose of 30 MBq/0.825 μg 177Lu-TATE in 0.2 mL 
saline or double the dose, in two cycles with a 14 d interval. A control group (n=5) received 
0.2 mL of saline. Monitoring of body weight and tumour size were performed three times a 
week for 100 d, or until tumours reached a volume >1800 mm3.
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Dosimetry calculation 
Dosimetry in normal organs and tumours was performed according to the Medical Inter-
nal Radiation Dose (MIRD)-scheme (2):
 (1)
with h the decay constant for 177Lu: h =0.00434/h. The time-speciﬁc activity 
curves ܣ݅Ȁ݉i(ݐ) were obtained by ﬁtting the biodistribution data (speciﬁc radio-activity uptake in the organs) with a single exponential curve. The time-activi-
ty curve for the tumour was based on the combination of biodistribution and 
SPECT data. The SPECT-based activity measurement at 4 hours was normal-
ized by the biodistribution / SPECT ratio of the activities at 48 h. The resulting 
4 tumour data were ﬁtted with a 3-parameter exponential curve including a re-
sidual plateau. The Aikake Information Criterion was used to decide between a 
2-parameter and a 3-parameter exponential ﬁt. This curve was used for determin-
ing the time-integrated activity concentration, otherwise (if R2 <0.7) the integral 
was performed by the trapezoidal method, assuming zero speciﬁc activity at 360 
h. Absorbed doses (in Gy) to normal organs per administered activity were calcu-
lated with the S-values for a 25 g mouse phantom (3). Also, the reference organ 
masses in this model were used, thereby making the dose calculation indepen-
dent of the actual organ mass. The absorbed dose to the tumour was calculated 
for a 200 mg sphere with the S-values for spherical nodes from OLINDA/EXM 
(4), the S-value of 0.114 mGy/MBq was obtained by linear interpolation, only 
the self-dose by the radioactivity in the tumour was calculated.
To calculate the absorbed dose in the third experiment, the original 1.0 +g 
dose value was multiplied with the ratio of the result of the SPECT quantiﬁca-
tion after 24 h and the 24 h time point of the ﬁtted activity curve for the 1.0 +g 
biodistribution data. 
;\TV\YNYV^[OJ\Y]LÄ[[PUN
The tumour growth curves V(t) were modelled with exponential growth func-
tions from the normal growth equation. The data were further extrapolated be-
yond the censoring end-times to calculate a common growth curve. 
 (2)
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being Td the tumour volume doubling time. The ﬁtted growth patterns were extrapolated 
beyond the censoring end-times to calculate a common growth curve. The treatment groups 
were modelled with exponential growth functions for both the initial growth the therapy 
eﬀect and the regrowth by:
 (3)
with k1 the rate of tumour shrinkage and k2 - k1 the tumour growth rate setting in after the 
volume nadir time T1. The time post injection needed to achieve the lowest tumour volume for 
each mouse is expressed as “nadir” for each treatment group (median and range). 
Dose-response model for tumour volume
The LQM is used to predict the tumour volume as a function of time after start of the ir-
radiation. The tumour volume is linked to the survival S of irradiated tumour cells. The LQM 
links the cell survival to the absorbed dose which builds up exponentially in radionuclide 
therapy with an eﬀective decay constant leff of the radiopharmaceutical:
 (4)
The repair of sub-lethal damage occurs during the dose delivery with time constant lrep. The 
quadratic term expresses the combinatorial eﬀect of unrepaired sub-lethal radiation damage 
and this eﬀect is more prominent in normal tissue than in tumours (5, 6). Administering 
the absorbed dose in small fractions will therefore increase the survival more prominently in 
normal tissue than in tumours. 
The tumour volume is represented by proliferating cells and dead or dying cells due to 
the irradiation. It is assumed that proliferation of alive cells will continue with the growth 
constant k and that dead cells will be cleared with clearance constant m (= ln(2)/Tclearance, where 
Tclearance is median clearance time). The tumour volume as a function of irradiation time T after 
administration of the activity can then be expressed by (7);
 (5)
with the survival and the absorbed 
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dose to the tumour: . The Lea-Catcheside factor 
G(T) expresses the probability for combinatorial damage caused by two or more repairable 
lesions as a function of time. In radiation therapy _ is deﬁned as linear component to the 
growth curve in the linear quadratic model and ` as the quadratic part of the growth curve 
in the linear quadratic model. The _/` ratio is a theoretical measure of a tissue’s predicted 
response to a dose rate. The _ and ` for H69 tumours were taken from literature _ = 0.21 ± 
0.16 /Gy and ` = 0.06 ± 0.05 /Gy2 (_/` = 3.01 ± 3.42 Gy)(8). As the time for repair (Trep) is 
much lower than the eﬀective time (Teﬀ), G(T) rapidly goes to 0 and the quadratic term of 
the LQM can be neglected. This simpliﬁes V(T) considerably:
,  (6)
for a single exponential dose rate with eﬀective decay constant leff, this expression can be 
approximated by:
 
 (7)
 (8) 
The absorbed dose is assumed to be homogeneously distributed over the tumour volume 
and also the response of tumour cells to radiation does not allow any heterogeneity. Both 
heterogeneities are introduced in the volume dose response model by a propagation factor p. 
A fraction of the cells, representative for the propagation factor (q), are assumed to remain 
unresponsive to the radiation exposure and grow undisturbedly following equation 2, whereas 
the complementary fraction 1-q will show a growth response following the LQM equation 8. 
Statistics
Prism software version 5.0 (Graph Pad, La Jolla, California, USA) was used to analyse 
tumour growth and determine statistical signiﬁcance between the treatment groups. One way 
ANOVA was used for statistical analysis of tumour uptake. Results are given as mean ± stand-
ard deviation (SD) when the SD is <40% and as median and range (min-max) for the survival 
curves or when the SD is >40%. Signiﬁcant results were considered for p>0.05. A log-rank 
test was performed for comparison of the survival curves. Goodness of ﬁts by the least-squares 
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method was judged by the Pearson R2 method. The corrected Aikake Information Criterion 
was used to decide on the complexity of the ﬁts. Growth delay was calculated as the diﬀerence 
in median time needed to reach a tumour volume >1800 mm3 in the treated groups compared 
with this median time for the control group. This value was given with the range of the single 
tumours compared with the median time of the control group. 
Kinetics of radioactivity of 177Lu-TATE 
The clearance kinetics of the radioactivity from the kidneys, pancreas and stomach were de-
scribed by single-exponential curves (Figure S1), with half-lives of 38±8 h, 50±16 h and 59±16 
h, respectively. The clearance half-lives were independent of the applied peptide amounts. To 
calculate the clearance kinetics of the H69-tumour SPECT/CT and tumour biodistribution 
data were combined. SPECT/CT quantitative imaging of the tumour uptake at 48 h (Figure 
1B) resulted in 1.0±0.2% IA/g (0.5 +g), 0.9±0.2% IA/g (1 +g) and 0.68±0.04% IA/g (2 +g), 
Figure S1. Radioactivity concentration as percentage injected activity per gram (%IA/g) over time 
in selected organs and tumor. Injected activity per group: 30 MBq of 177Lu. Amount of injected 
octreotate: 0.5 μg  (red line); 1.0 μg (blue line); 2.0 μg (green line). Tumour values are based on the 
combination of biodistribution and SPECT data. pi: post injection.
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respectively a factor 3.9, 4.6 and 5.6 less than found in the biodistribution study. The SPECT/
CT derived tumour uptake at 4 h pi was adjusted with these factors (Figure 3). The 0.5 +g 
study group showed a rapid initial tumour clearance with a half-life of 23±4 h, leading to a 
plateau uptake of 2.1±0.3% IA/g (20% of the projected initial uptake). The higher amount of 
peptides showed slower initial clearances of 28±4 h and 27±6 h, for 1 and 2 +g respectively, 
leading to a lower plateau value at only 7% of the projected initial uptake.
Tables
Table S1. Absorbed dose (in Gy) after administration of 177Lu labeled to 0.5, 1.0 or 2.0 μg TATE
Absorbed dose, mean 
± SD[Gy]/
peptide amount [μg]
Pancreas Stomach Kidneys Tumour
0.5 0.5±0.1 1.6±0.5 4.2±1.0 17.8±2.5
1.0 0.4±0.1 1.2±0.3 4.3±1.2 14.1±3.9
2.0 0.3±0.2 0.8±0.2 4.2±1.3 9.6±4.1
Absorbed dose to normal organs and 200 mg of tumour per administered activity of 30 MBq 
was calculated with a 25 g mouse phantom. The dose to the tumour was calculated based on the 
combination of SPECT and biodistribution data.
Group Median doubling 
time [days, range 
(min-max) or 
SD*]
Time to 10 x V0 
[days, range
(min-max)]
Nadir
[days, SD]
Growth delay 
[days, range
(min-max)]
Control 6.4±2.1 21.1±6.9 - -
1x26 MBq 6 (2.4-30) 37 (31-151) 14±2 24 (8-56)
2x13 MBq 6 (2.8-10) 39 (32-47) 15±3 20 (10-33)
Tumour characteristics after treatment with 26 MBq of 177Lu-TATE administered at once or 
administered in two doses of 13 MBq with 5 days interval, compared with a control group. min: 
minimum; max: maximum; SD: standard deviation. *see the main text for details.
Table S2. Growth parameters after treatment with 26 MBq of 177Lu/0.7 μg TATE (Split-dose 
experiment) 
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Group Doubling time 
[days, SD]
Time to 10 x V0 [days, SD]
Nadir
[days, range
(min-max)]
Growth delay 
[days, range
(min-max)]
Control 11.6±3.0 39±7
30 MBq 9.4±2.5 59±13 15 (11-20) 21 (15-43)
2x30 MBq 7.5±2.0 73±17 33 (14-59) 42.5 (14-63)
Table 3S. Tumour characteristics after treatment with one or two doses of 30 MBq 177Lu/0.825 μg 
TATE (double-dose experiment)
Tumour characteristics after treatment with 30 MBq of 177Lu-TATE administered at once or 
administered in two doses of 30 MBq with 14 days in between, compared with a control group. min: 
minimum; max: maximum
Uniform cell response (q=0) Uniform cell sensitivity (a=0.21 
Gy-1)
Curves ﬁt R2 a [Gy-1] Tclearance [d] q (%) Tclearance [d]
A: 0.5 mg 0.49 0.14 3.5 7% 6.3
A: 1.0 mg 0.37 0.14 7.1 9% 9.0
A: 2.0 mg 0.75 0.10 2.7 22% 4.0
B: 1 ´ 26 MBq 0.28 0.18 3.9 3% 4.6
B: 2 ´ 13 MBq 0.40 0.19 6.1 2% 8.1
C: 1 ´ 30 MBq 0.22 0.11 0.9 19% 1.5
C: 2 ´ 30 MBq 0.34 0.10 3.1 7% ¥
Table 4S. Fit parameters of the LQM predicted response curve (based on equation 8) and measured 
response of all performed experiments
R2 represents the quality of the ﬁt. a represents the radio sensitivity of the tumour cells; p stands for 
the percentage of cells which do not respond to treatment but continue proliferating; a was calculated 
assuming a uniform cell response (q=0) and p values were calculated assuming a uniform cell 
sensitivity (a=0.21 Gy-1). For both calculations, the median clearance halve life Tclearance, representing the removal of death cells from the tumour mass, is given. A, B, C refer to the panels in Figure 6 in 
the main text. q: propagation factor; a: linear component to the growth curve in the linear quadratic 
model; Tclearance: median clearance time.
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biodistribution and tumor retention
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ABSTRACT
Pluronics P94 are block-copolymer showing prolonged circulation time and tumor-cell in-
ternalization in vitro, suggesting a potential for tumor accumulation and as a drug carrier. Here 
we report the results of the radiolabeled-P94 unimers (P94-111In-DTPA) on tumor uptake/
retention and biodistribution after intravenous and intratumoral administration to tumor- 
bearing mice. Intravenous administration results in a high radioactive signal in the liver; 
while in tumor and other healthy tissues only low levels of radioactivity could be measured. 
In contrast, the intratumoral injection of P94 resulted in elevated levels of radioactivity in 
the tumor and low levels in other organs, including the liver. Irrespective of the injection 
route, the tumor tissue presented long retention of radioactivity. The minimal involvement 
of oﬀ-target tissues following injection of P94, together with the excellent tracer retention 
over-time in the tumor designates Pluronic P94 copolymer as a highly promising carrier for 
anti-tumor drugs.
Keywords: Pluronics, unimers, intratumoral injection, intravenous injection, tumor reten-
tion
Abbreviations: P94: Pluronics P94; EPR: Enhanced Permeability and Retention; IV: 
intravenous; IT: intratumoral; DTPA: diethylenetriaminepentaacetic acid; PPO: poly(pro-
pylene oxide; PEO: poly(ethylene oxide); SPECT/CT: Single-Photon Emission Computed 
Tomography/Computed Tomography.
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BACKGROUND 
Safe, speciﬁc and more eﬀective treatment is a well-recognized need in oncology and 
many eﬀorts are being made towards the development of such therapeutic approaches. In 
this direction, the ﬁeld of nanomedicine has grown considerably in the last decades. Many 
nano-sized particles showing great potential for the treatment of tumors are available for in 
vivo applications, including nanoparticles (liposomes, polymeric micelles) but also polymers. 
Among nanomedicines, structures based on Pluronics block copolymers have gained consid-
erable interest due to their versatility, large availability, desirable biological properties and 
potential translation to the clinic (1-3). Some formulations of Pluronic are used in cosmetics, 
in pharmaceutical application and in clinics as a coadjutant for injections (4, 5). 
Recently, it was shown that Pluronic P94 copolymers (P94) could be eﬃciently internal-
ized by tumor cells in vitro and that exposure of tumor spheroids to P94 copolymer caused 
cellular disaggregation and size reduction of the spheroids (6, 7). Additionally, in vivo studies, 
performed with 111In radiolabeled Pluronic copolymers in healthy mice, demonstrated high in 
vivo stability and long circulation time of P94 copolymer (detectable in the circulation up to 
48 h post injection (pi)), with relatively limited liver and spleen accumulation and no evidence 
of acute toxicity (8). Altogether, these results suggest that P94 copolymers might be suitable 
for the delivery of therapeutic agents to cancers, and encourage further investigations of this 
compound. 
When developing nanomedicines for the treatment of solid tumors, the capacity of the 
nanodevice to reach the tumor at high concentrations is a ﬁrst requirement and has been 
proven challenging with various nanoparticles before (9).
Following IV administration, accumulation of nanoparticles in tumor tissue occurs via 
a phenomenon known as the Enhanced Permeability and Retention (EPR) eﬀect (10). This 
eﬀect results from the large fenestrations between endothelial cells from the newly-formed 
vessels and the lack of functional lymphatic vessels in and around the tumor (11). This spe-
ciﬁc combination of conditions in the tumor tissue, ensures and enhanced extravasation and 
speciﬁc retention of nanosized particles within the tumor mass (10, 12-14). The optimal size 
for EPR-eﬀect-mediated extravasation was roughly estimated between 5 and 50 nm; ex-
travasation substantially reduces above 200 nm, although a certain level of extravasation was 
observed for particles above 500 nm as well (13, 14). 
 Because of the nature of the EPR eﬀect, nanoparticles that beneﬁt from that phenom-
enon do not require molecular interactions with tumor receptors and the attachment of tar-
geting agents is not needed. EPR eﬀect therefore can be used to target lesions that do not 
(over)express tumor-speciﬁc targets. Despite the well-recognized value of the EPR eﬀect, 
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the uptake of nanoparticles in tumors is rarely beyond the 10% ID/g (15), and in most cases 
between 1-5 % ID/g (11), often with limited tissue penetration (16). 
Loco-regional administration of drugs is also commonly used approach in speciﬁc situa-
tion of clinical practice. Intratumoral (IT) administration overcomes most of the limitations 
of IV injections (being the poor accumulation in the tumor and the elevated retention in the 
oﬀ-target), improves the safety and the eﬃcacy of treatment in localized solid tumors and is 
increasingly also being considered for nanoparticles (17, 18). The IT injection enhances the 
amount of an agent delivered to the tumor and, upon eﬀective retention in the tissue, results 
in higher therapeutic doses at the lesion site. Additional beneﬁt would result from reduction 
of the systemic spread via blood circulation, which, ultimately, leads to reduced exposure/
accumulation of normal tissue to the therapeutic agent, and thus low(er) whole body toxicity.
To further assess the potential of P94 copolymer in cancer therapeutics we used the ability 
to functionalize P94 copolymer with the diethylenetriaminepentaacetic acid (DTPA) radio-
chelator, making it suitable for radiolabeling with 111In. This radionuclide is broadly used in 
preclinical setting because of its favorable emission of gamma photons, suitable for SPECT 
imaging. Moreover 111In has a physical half-life of ~68 h, which allows for long lasting fol-
low up. The radiolabeling of P94 with 111In allowed us to perform a detailed analysis of the 
biodistribution and tumor uptake characteristics of P94 copolymers in tumor bearing mice 
following systemic (IV) injection or loco-regional (IT) administration. 
METHODS
Functionalization and radiolabeling of Pluronic P94 
copolymer with DTPA chelator (P94-DTPA)
Pluronic P94 (PEO26PPO48PEO26; Mn PEO blocks: 2200 Da; Mn PPO block: 2800 Da 
(19), where PEO is poly(ethylene oxide) and PPO is poly(propylene oxide)) was supplied by 
BASF and end-functionalized with the chelator DTPA and radiolabeled with 111In following 
procedures described previously (8, 20) and further speciﬁed in Supplementary Materials 
(Supp) (Figure ure 1). 
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In vivo tumor model 
Human small cell lung cancer cells H69 (ECACC, Salisbury, UK (~3×106 cell/mouse) 
were inoculated subcutaneously in 20 young adult male Balb/c-nu mice ( Janvier, France), 
3x107 cell/mL and 100 μL/mouse (see Supp for tumor model details). Tumor growth was 
monitored and measured with a caliper ruler three times per week. When the average tumor 
volume reached 300 mm3, the mice were randomly subdivided in three groups: one experi-
mental group (IV group) was subjected to intravenous injection of P94-111In-DTPA (n=8); 
a second experimental group (IT group) was subjected to intratumoral injection P94-111In-
DTPA (n=8); the third group was used as control group and received an IT injection of 
111In-DTPA (n=4). All animal experiments were performed in accordance with Dutch animal 
welfare regulations and approved by the local ethics committee.
Figure 1. Diagram of the successive modiﬁcations of Pluronic P94 copolymer (PEO26PPO48PEO26). A) Schematic representation of the plain P94 copolymer. PEO: hydrophilic part; PPO: 
hydrophobic part; B) Attachment of DTPA chelator (P94-DTPA); C) Radiolabeled P94-DTPA 
with 111In (P94-111In-DTPA). PEO: poly(ethyleneoxide); PPO: poly(propylene oxide); DTPA: 
diethylenetriaminepentaacetic acid.
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Experimental plan
IV experimental group. Mice from the IV injection group received an injection of ~200 μL 
(~0.2 mg and ~15 MBq/animal) of P94-111In-DTPA in the tail vein. Six out of eight mice 
were randomly chosen to undergo imaging studies and subjected to a whole body Single-Pho-
ton Emission Computed Tomography/Computed Tomography (SPECT/CT) scans at diﬀer-
ent time points prior to biodistribution studies. The remaining two animals were subjected 
to biodistribution studies only (see Supp for SPECT/CT parameters). All mice selected for 
imaging studies (n=6) received a scan at 4 h, 24 h and 48 h pi. After the acquisitions at 48 h 
pi, three mice out of the six chosen for imaging studies and one out of the two excluded from 
the imaging studies, were randomly chosen and sacriﬁced for biodistribution evaluation at 48 
h pi (n=4). The remaining three mice from the imaging group were subjected to one further 
SPECT/CT scan at 120 h pi. Biodistribution study at 120 h pi for the remaining mice of the 
IV group (n=4) was performed immediately after the last acquisition (Figure 2)(see Supp for 
biodistribution details).
IT experimental group. Mice from the IT group received ~100 μL (~0.1 mg and ~7.5 MBq/
animal) of P94-111In-DTPA in one single injection in the center of the tumor. Similarly as 
for IV studies, six out of eight mice were randomly chosen for imaging studies and two were 
used for biodistribution studies only. All mice selected for imaging studies (n=6) received a 
whole body CT scan and one focused SPECT scan in the region of the tumor at 0.5 h pi (see 
Supp for SPECT/CT parameters). Then, whole body SPECT/CT scans were performed at 
24 and 48 h pi. After the acquisitions at 48 h pi, three mice out of the six chosen for imaging 
studies and one out of the two excluded from the imaging studies, were randomly chosen and 
sacriﬁced for biodistribution evaluation at 48 h pi (n=4). The remaining three mice from the 
imaging group were subjected to one further SPECT/CT scan at 72 h pi. Biodistribution 
study at 72 h pi was performed immediately after the last acquisition in the remaining mice 
of the IT group (n=4) (Figure 2) (see Supp for biodistribution details).
Control group. Mice of the IT control group were injected IT with 100 μL of 111In-DTPA 
(200 pmol and ~3 MBq). The four mice of the control group were subjected to one focused 
SPECT scan in the region of the tumor at 0.5 h pi and a whole body CT scan. Whole body 
SPECT/CT was performed at 24 and 48 h pi (see paragraph 2.5 for SPECT and CT param-
eters). The whole group was sacriﬁced 48 h pi studies for biodistribution evaluation (Figure 2) 
(see Supp for biodistribution details).
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Data analyses
All data were processed with Microsoft Excel 2010 and Prism version 5 (GraphPad Soft-
ware, La Jolla, California, USA). To characterize the kinetics of P94-111In-DTPA after IV and 
IT injection over-time, time-activity curves based on SPECT signal quantiﬁcation were ﬁtted 
with diﬀerent curves: the one-phase-decay exponential curve was used for the data of tumors 
(IV and IT group) and the data from the IV injection; the linear regression was used for other 
IT results (see Supp for more details)
Biodistribution data were used to evaluate the diﬀerence in retention of P94-111In-DTPA 
between the last two time points. Statistical diﬀerence was tested via the Mann-Whitney U 
test, setting p<0.05 as statistically signiﬁcant. 
Figure 2. Temporal diagram of injection and scans of the Experimental groups (IV group and IT 
group) and control group.
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RESULTS
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After functionalization, P94-DTPA was successfully radiolabeled with 111In (labeling 
yield >90%). P94-111In-DTPA copolymers were injected in tumor bearing mice either IV or 
IT. The levels of radioactivity reached in selected organs were followed over-time and mea-
sured (Figure 3-4; Table 1-3). 
In the SPECT/CT images, made 4 h pi of mice injected IV with P94-111In-DTPA, we 
observe a strong radioactive signal in liver (~0.3 kBq/mm3) and bladder (~0.6 kBq/mm3), 
compatible with the clearance pathway of P94 copolymer (8) (Figure 3A; Table 1). At this 
time point radioactivity in the tumor was measured at <0.06 kBq/mm3, or ~1.8% ID/g. Con-
siderable levels of radioactivity were measured in other normal tissues such as heart (~0.17 
kBq/mm3), lungs (~0.14 kBq/mm3) and kidney (~0.12 kBq/mm3) (Figure 3B; Table 1). At 
subsequent time points, radioactivity decreased following one-phase decay curve in all in-
vestigated tissues (healthy and tumor), however at diﬀerent decay rates (Figure 3B; Table 3). 
We observed highest retention of radioactivity in liver and tumor with a T½ of 75 h (95% CI: 
  4 h 24 h 48 h 120 h
kBq/mm3 Median Range Median Range Median Range Median Range
Bladder 0.590
0.197-
0.744 0.056
0.044-
0.079 0.032
0.055-
0.035 0.027
0.020-
0.077
Heart 0.178
0.119-
0.206 0.094
0.046-
0.104 0.037
0.027-
0.135 0.025
0.015-
0.118
Liver 0.355
0.277-
0.374 0.292
0.277-
0.250 0.261
0.214-
0.331 0.192
0.214-
0.331
Lungs 0.142
0.130-
0.170 0.050
0.049-
0.084 0.039
0.027-
0.096 0.027
0.018-
0.104
Kidney 0.125
0.096-
0.224 0.070
0.051-
0.091 0.051
0.032-
0.068 0.032
0.026-
0.041
Tumor 0.051
0.040-
0.059 0.038
0.026-
0.055 0.032
0.021-
0.041 0.019
0.018-
0.038
Table 1. Biodistribution of P94-111In-DTPA at diﬀerent time points after intravenous injection (IV) 
in mice
Data represent the median and the range (minimum-maximum) of radioactive signal determined 
from SPECT/CT images. Radioactive signal is expressed as kBq/mm3; n=6 at 4 h, 24 h and 48 h pi; 
n=3 at 120 h pi.
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51-141 h) for tumor tissue and a T½ of 102 h (95% CI: 77-152) for liver. Other normal organs 
showed much faster clearance with a T½ between 6 and 28 h (Table 3). 
Table 2. Biodistribution of P94-111In-DTPA at diﬀerent time points after intratumoral injection (IT)
  0.5 h 24 h 48 h 72 h
kBq/mm3 Median Range Median Range Median Range Median Range
Bladder * * 0.017
0.013-
0.066 0.014
0-  
0.021 0.007
0-  
0.011
Heart * * 0.042
0.027-
0.056 0.045
0.013-
0.055 0.011
0.007-
0.015
Liver * * 0.125
0.084-
0.143 0.123
0.074-
0.153 0.108
0.099-
0.117
Lungs * * 0.035
0.02-
0.066 0.047
0.023-
0.066 0.016
0.013-
0.018
Kidney * * 0.046
0.035-
0.025 0.032
0.029-
0.059 0.037
0.031-
0.041
Tumor 3.02 2.9-4.27 0.544
0.403-
0.621 0.418
0.378-
0.479 0.374
0.326-
0.421
Data represent the median and the range (minimum-maximum) of radioactive signal determined 
from SPECT/CT images. Radioactive signal is expressed as kBq/mm3 (n=6) at 0.5 h, 24 h, 48 h pi; 
(n= 3) at 72 h pi. *: SPECT scan focused on the tumor region, organ not detectable.
T½[h]
T½ (95% CI)[h]
Plateau 
[kBq/mm3]
A
[kB/mm3]
R2
Bladder 6.5 3-23 0 0.83 0.83
Liver 102 77-152 0 0.36 0.76
Heart 11.4 5-159 0.04 0.16 0.75
Kidney 28 19-51 0 0.14 0.68
Lungs 7.8 4-56 0.04 0.14 0.81
Tumor (IV ) 75 51-141 0 0.05 0.61
Tumor (IT) 0.2 0.19-0.23 0.4 15.54 0.99
Table 3. T½, Plateau, Amplitude and R2 of P94-111In-DTPA after IV injection in diﬀerent organs and after IV or IT injection in the tumor
The half-lives of P94-111In-DTPA in the diﬀerent organs and in the tumor were calculated on the 
one phase decay ﬁtting curve (equation 1). T½ represents the clearance half-life expressed in hours and the 95% CI is given; Plateau: limtĺ∞y(t); A: amplitude of the function between t=0 and Plateau; R2: coeﬃcient of determination; CI: conﬁdence interval.
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Figure 3. P94-111In-DTPA biodistribution after intravenous (IV) injection. A) Whole body 
maximum intensity projection SPECT/CT images of randomly selected mice at 4, 24, 48 and 120 
h pi, after the IV injection of P94-111In-DTPA; B) Kinetics of measured activity based on images 
in selected organs. The points represent the mean of the measured values for each organ ± standard 
deviation. The data are ﬁtted using a one-phase decay curve (gray line); spotted lines represent the 
95% conﬁdence interval. MIP: maximum intensity projection.
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Figure 4. P94-111In-DTPA biodistribution after intratumoral (IT) injection. A) Focused SPECT 
images at 0.5 h pi in the tumor region; margins of the scan are delimited in the image by the pink 
lines. Whole body CT was performed for anatomical reference. From top to bottom: maximum 
intensity projection (MIP), transversal view (Tr) and coronal view (Cr); B) Whole body SPECT/
CT (24, 48 and 72 h pi) images of randomly selected mice. From top to bottom: MIP, Tr view and 
Cr view; C) Kinetics of measured activity based on images in tumor and liver. The tumor is ﬁtted 
following a one-phase-decay curve (gray curve). Liver is ﬁtted with a linear curve (gray curve). The 
points represent the mean measured values for each organ ± standard deviation; spotted lines represent 
the 95% conﬁdence interval. MIP: maximum intensity projection. Cr: coronal view; Tr: transversal 
view
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Following IT injection of P94-111In-DTPA, a marked presence of radioactivity in the tumor 
was detected (between 2.9 and 4.27 kBq/mm3 or 10-12% ID/g) from the early time point of 
0.5 h pi to 72 h pi (Figure 4A). At later time points, radioactivity was discernable or measurable 
also in other organs although at a low level, and only the liver was visible in the images (Figure 
4B). In the tumor, most of the radioactivity in the SPECT/CT images was seen towards the rim, 
suggesting a fast redistribution of radioactivity from the center to the periphery (see coronal 
and transversal images in Figure 4A-B). The analyses over the ﬁtted curves, indicated that the 
radioactivity in the tumor halved in the ﬁrst 0.2 h, and rapidly reached a plateau at a level of 
~0.4 kBq/mm3 (around 12% ID/g) in the ﬁrst hours (Figure 4C; Table 2-3). In liver at later time 
points, the measured signal is most likely resulted from the activity released from the tumor 
shortly after IT injection. By ﬁtting the levels of radioactivity in the liver over-time no further 
increase in radioactivity uptake in this organ was found (Figure 4C).
In contrast to the results obtained with P94-111In-DTPA, IT injection of 111In-DTPA did 
not result in prolonged presence of radioactivity in the tumor (Figure 5). Only in the SPECT/
CT images taken shortly after injection (0.5 h pi) (Figure 5A) radioactive signal in the tumor 
mass could be detected. At the later time points (≥24 h pi) no activity in any anatomical loca-
tion was detectable in the SPECT/CT images (Figure 5B). 
Figure 5. Biodistribution of 111In-DTPA after intratumoral (IT) injection. A) Focused SPECT/
CT images at 0.5 h pi in the region of the tumor; margins of the scan are delimited in the image by 
the pink lines. CT was performed for anatomical reference. From top to bottom: Tr view; MIP; B) 
SPECT/CT whole body MIP image (24 and 48 h pi) of a randomly selected mouse of the control 
group. Tr: transversal view; MIP: maximum intensity projection.
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Biodistribution results
Analysis of radioactivity in isolated organs and tissues 48 and 72/120 h pi conﬁrmed 
uptake and retention proﬁles seen in SPECT/CT images. At 48 h post IV injection, we 
measured a considerable radioactive signal (median >2% ID/g) in the clearance organs (repre-
sented by liver, spleen and kidney), but also in other oﬀ-target tissues, were the median of the 
measured radioactivity was generally above 1% ID/g (Table 4). In the tumor the median of the 
measured radioactivity after IV injection of P94-111In-DTPA was around 1% ID/g (Table 4). 
In contrast, the biodistribution of P94-111In-DTPA after IT injection showed high sig-
nal in the tumor mass that reached values up to ~30% ID/g (Table 4). Within the clearance 
organs, we could measure considerable radioactive signal only in the liver (~5% ID/g), while 
in the other clearance organs, spleen and kidney, the measured radioactivity was <1% ID/g 
(Table 4). 
Measurements made on the heart after IV and IT injection revealed a substantial level of 
radioactivity even at 48 and 72/120 h pi (Table 4) suggesting that a the tracer is probably still 
in the circulation even at relatively late time points.
Data from tumors isolated at 48 h and 72/120 h pi revealed no statistically signiﬁcant 
diﬀerence (p>0.05) in levels of radioactivity between the two time points, irrespective of the 
injection route used. This indicates that after radioactivity is in the tumor (either because 
of the contribution of EPR eﬀect or because of a direct injection) P94-111In-DTPA is well 
retained over-time.
In the oﬀ-target tissues after the IV injection, we measured a reduction of radioactivity 
between 48 and 120 h pi (p<0.05) indicating a substantial clearance (Figure 6A). The only 
exception, showing no signiﬁcant diﬀerence between the two investigated time point (p>0.05) 
and therefore a stable level over that time-window was represented by the organs involved in 
the clearance of P94 polymers: namely liver and spleen. Much lower levels in general were 
found in normal organs after IT; however, at the studied time points, a signiﬁcant decrease 
in activity was seen only for the kidney, while no signiﬁcant diﬀerence was measured for all 
other organs (Figure 6B).
The biodistribution analyses of the control group after IT injection of 111In-DTPA at 48 h 
pi, conﬁrmed the results already obtained by SPECT/CT imaging (Figure 5). The radioactivi-
ty measured in the tumor was ~0.4% ID/g, and very low levels of radioactivity were measured 
in any of the organs and tissues <<0.01% ID/g, and considered negligible (Figure 6C).
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Figure 6. Biodistribution results obtained from selected organs at 48 and 72/120 h. A) Intravenous 
(IV) injection of P94-111In-DTPA; B) intratumoral (IT) injection of P94-111In-DTPA; C) IT 
injection of 111In-DTPA. Note the scale diﬀerence between the graphs. Bars represent mean ± 
standard deviation. *: statistical signiﬁcance between the two time points (p<0.05), 48 vs 120 h pi for 
IV and 48 and 72 for IT.
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DISCUSSION
The results recently obtained with P94 copolymer have underlined valuable properties of 
this copolymer for in vivo application as nanocarrier (8). These properties are represented by 
the long lasting stability and potential anti-cancer cell eﬀect, strongly indicating that P94 
copolymer has the potential to be a carrier for drug delivery in tumors (7, 8). Successful ap-
plication of a nanocarrier in vivo, however, depends on its capacity to target tumor tissue, in a 
safe, eﬃcient and speciﬁc way. This includes, next to a suﬃciently high delivery to the tumor, 
low accumulation of the nanocarrier in oﬀ-target tissue in order to maximize the amount that 
is available for tumor uptake but also to reduce toxicity to healthy tissues. 
In this study we tested the potential of P94 copolymer to accumulate in tumor tissue following 
IV injection, which is the most commonly used administration route of anticancer drugs. How-
ever, upon direct injection in the circulation, elevated accumulation of nanoparticles in clearance 
organs is a known eﬀect (21, 22), and consistent accumulation of P94-111In-DTPA in liver, spleen 
and kidney was shown in previous studies as well (8). In order to reduce the accumulation in 
clearance organs and potentially improve the tumor retention, we also studied the biodistribution 
of P94-111In-DTPA after injection via a diﬀerent route, namely following IT injection (17, 18).
To accommodate the requirement for EPR-mediated tumor delivery of the radiolabeled 
polymer, we performed the studies in the subcutaneous, H69 xenograft tumor model. This tu-
mor model in mice has already been described as a relevant model to study EPR-mediated ac-
cumulation with other nanoparticles (23). H69 tumors are characterized by a fast growth rate 
and early formation of a network of immature and leaky vessels, which favor the enhanced 
extravasation of nanosized particles and, ultimately, their retention in the tumor tissue (24). 
The results obtained after the IV injection of P94-111In-DTPA showed durable presence 
of radioactivity in the tumor, with the level of radioactivity remaining stable between 48 and 
120 h pi. The levels of activity reached in the tumor after IV injection were fairly low (up to 
2.8% ID/g) but are in line with the average levels of accumulation of various nanoparticles 
due to the EPR eﬀect (11) and indicated P94-111In-DTPA accumulation.
Following IV injection relatively high levels of radioactivity were found in the liver 
throughout the follow-up period, probably as a result of clearance via the hepatobiliary system 
and stable accumulation of P94-111In-DTPA (8). Radioactivity in other oﬀ-target tissues was 
often not directly attributable to tissue accumulation of P94-111In-DTPA, but was instead the 
result of the long lasting circulation of radioactivity or physiological clearance mechanism. A 
speciﬁc example of the latter is the radioactivity measured in the digestive tract, which is most 
likely resulting from the hepatobiliary excretion, as has been shown before to be a common 
excretion pathway (8). The radioactivity found in the stomach at a relatively high level in 
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comparison with other tissues can in part be explained by the phenomenon of self- and social 
grooming often occurring between mice (23). 
In comparison to the result obtained with IV injection, local (intratumoral) injections of 
P94-111In-DTPA provided a markedly diﬀerent biodistribution proﬁle. After IT injection 
of P94-111In-DTPA, we found high levels of radioactivity in the tumor which were up to 10 
times higher than the levels found in other organs. Moreover, the radioactivity found in the 
oﬀ-target tissues was roughly three times lower for IT compared to IV, indicating a preferen-
tial biodistribution proﬁle of P94-111In-DTPA when it is injected locally.
The presence of radioactivity in the oﬀ-target tissue after IT injection, and especially in 
the liver, which is involved in the clearance of P94 copolymer, is an indication that the inject-
ed P94-111In-DTPA is released from the tumor in to the systemic circulation. This assumption 
is supported by SPECT/CT images showing a fast relocation of signal from the center to the 
tumor rim, alongside a rapid reduction of radioactivity (~70-95%) within the ﬁrst 0.5 h pi. 
This eﬀect is probably the result of the intra-tumor pressure, driving ﬂuids to the periphery as 
a consequence of the diﬀerences in hydrostatic pressure between the tumor and the intersti-
tium (25, 26). Despite the extensive release of radioactivity from the tumor after IT injection, 
still ~10% (range 3-30%) of the injected dose is stably retained in the tumor for at least 72 h. 
This is much higher than levels found with other radiolabeled agents injected IT (27), where 
only ~1% of the injected agent was detectable at 24 h pi. Our ﬁndings therefore conﬁrm the 
potential of P94-111In-DTPA to improve the retention within tumor tissues. 
The results obtained following injection with 111In-DTPA, further suggested that retention 
in the tumor is mediated by the P94 copolymer. From previous investigation, it is known that 
111In-DTPA when in circulation is rapidly cleared via the renal path (28). After the injection 
of 111In-DTPA we observed a considerable reduction of radioactivity in the tumor between 
the 0.5 and 24 h pi (less than 0.5% ID/g was found 48 h after the injection of 111In-DTPA), 
which suggest a rapid release of 111In-DTPA from the tumor to the blood stream. In our bio-
distribution studies with the control group injected with 111In-DTPA, we also measured low 
levels of radioactivity at 48 h pi in the kidney; which was indicative of release from the tumor 
to the circulation and renal clearance. 
These results suggest that the P94 copolymer plays a decisive role in the retention within 
the tumor. In line with previous in vitro result, the long lasting retention might be associated 
to with the ability of P94 copolymer to be internalized by tumor cells (7), although further 
studies would have to be performed to determine if and to which extent the internalization 
occurs in in vivo settings as well. 
The clearance/retention of P94 copolymer in normal tissue and in the circulation is ﬁnally 
an important parameter to consider for further application. In previous investigations it was 
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shown that after IV injection of P94-111In-DTPA, it was still detectable at considerable levels 
at 48 h pi in the heart region (8) suggesting a long lasting presence of the copolymer in the 
circulation. In line with that ﬁnding, we could detect a considerable amount of radioactivity 
in the heart at 48 h, and up to 120 h pi, supporting the elevated in vivo stability of P94-111In-
DTPA. Radioactivity in the heart at 48 and at 72 h pi could be measured after IT injection as 
well, further conﬁrming the substantial leakage from the tumor. However, in both the IV and 
IT groups, the signal measured in the heart was largely below the levels of tumor and liver, but 
it was comparable to that of the other oﬀ-target tissue. The circulation might, therefore, give 
an important contribution to the levels of radioactivity measured in every tissue.
Part of the measured radioactivity in oﬀ-target tissue would therefore result from the 
circulation and, over-time, it would follow the trend of biodistribution found heart (i.e. circu-
lation). Together with the signiﬁcant decrease of radioactivity found in the heart, between the 
last two time points, after IV injection of P94-111In-DTPA, in many of the other investigated 
organs we also found a correspondent signiﬁcant reduction of radioactivity. In contrast, no 
signiﬁcant diﬀerence in radioactivity levels was found in the heart between the last two time 
points after IT injection of P94-111In-DTPA, and no diﬀerence in the oﬀ-target tissue levels 
was found. The results, moreover, suggest that eﬀective accumulation in oﬀ-target tissues only 
occurs in speciﬁc organs (namely clearance organs, and especially liver), while it only limitedly 
aﬀects the other tissues in the body. 
Of note, independently from the injection route, we found no diﬀerence in the levels 
measured in the tumors between the last two time points. This results probably from the poor 
clearance occurring from the tumor (11), but also indicates stable retention of P94-111In-DT-
PA over-time and further underlines the potential of this polymer for the delivery of drug in 
tumors. On the other hand IT is eﬃcient only in speciﬁc cancer types, which may limit the 
applicability of that injection route. 
In conclusion, IV injection of P94-111In-DTPA does not result in a particularly favor-
able biodistribution proﬁle when compared to other nanoparticles, but showed a long lasting 
retention of radioactivity in the tumor. IT injection of P94-111In-DTPA does result in pro-
longed high levels of activity in the tumor together with low involvement of oﬀ-target tissue. 
Our results conﬁrm the potential of P94 copolymer as a carrier following both IV and IT 
injection routes, possibly for the delivery of drugs or other therapeutic agents to solid cancers. 
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ABSTRACT
Background: Single photon emission computed tomography (SPECT) is an indispens-
able tool in the determination of the in vivo fate of polymeric micelles. However, for this pur-
pose, the micelles need to be radiolabeled, and almost all radiolabeling procedures published 
to date involve the conjugation of a chelating agent to the constituting polymer, which could 
actually aﬀect their biodistribution. In this paper, we report a new facile method for radiola-
beling polystyrene-b-poly(ethylene oxide) diblock copolymer micelles without the necessity 
of any chemical modiﬁcation. Instead, we entrap the radiolabel (i.e., 111In) in the micellar core 
during the formation of the micelles by using tropolone as lipophilic ligand. 
Methods: Micelles were prepared by emulsifying a polymer solution in chloroform with a 
buﬀer containing 111In and lipophilic ligand tropolone, by stirring for about 2 h. The produced 
micelles were physically characterized by means of dynamic light scattering and transmission 
electron microscopy. The biological properties of the radiolabeled micelles were determined by 
means of in vivo and ex vivo evaluation. SPECT analysis was done on Balb/c-nu mice, after 
administration of 1 mg micelles containing 22 MBq of 111In. SPECT images were obtained 
over 24 h. Biodistribution of the micelles was assessed also ex vivo. 
Results: The radiolabeling method is robust and reproducible with constant radiolabeling 
eﬃciency (~30 %) even at indium concentrations that are much higher than the necessary for 
in vivo studies, and the radiolabel retention is more than 80% in mouse serum at 48 h. Radio-
labeled micelles having hydrodynamic radius of 97 ± 13 nm have been successfully evaluated 
in vivo and ex vivo in non-tumor-bearing mice, revealing signiﬁcant blood circulation up to 
at least 24 h post injection, with low accumulation in most organs except for the liver and 
spleen, which are the natural organs for clearance of nanoparticles. Conclusions: An easy 
and robust radiolabeling method has been developed, and its applicability is demonstrated in 
animal studies, showing its value for future investigation of polymeric micelles as nanocarriers 
in tumor-bearing mice.
Keywords: radiolabeling, polymeric micelles, amphiphilic diblock copolymers, SPECT
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BACKGROUND
Polymeric micelles are promising nanocarriers for pharmaceutical formulations due to 
their ability to encapsulate hydrophobic substances, overcoming in this way the poor solubili-
ty of some drugs and allowing transport through the blood stream to the site of interest (1,2). 
These micelles are constituted by amphiphilic block copolymers, which in aqueous solutions 
are able to self-assemble into supramolecular structures. In contrast to self-assemblies com-
posed of low molecular weight surfactants, diblock copolymer micellar aggregates usually 
exhibit a low critical micelle concentration (CMC) which enhances their integrity even at low 
concentration (3). By varying the composition, the size, and the structure of the block copoly-
mers, i.e., tuning the hydrophilic and hydrophobic block ratio, and/or by adjusting the micelle 
production method, it is possible to design polymeric micelles with well-deﬁned dimensions 
and morphologies (4,5). These favorable characteristics of polymeric micelles have already led 
to clinical applications for systemic chemotherapy (6,7). 
In these applications, bringing the micelles to the desired site is essential for therapeutic 
success, which can be accomplished by exploiting either active or passive targeting pathways. 
Nanocarriers in general can accumulate in diseased tissue due to the enhanced permeability 
and retention (EPR) eﬀect, also referred to as passive targeting. Growing tissue, especially 
tumors, can establish new vascular systems to supply themselves with oxygen and nutrients. 
The newly formed vessels, however, have a discontinuous endothelium and lack of lymphatic 
drainage, enhancing in this way extravasation and retention of large particles over time (8,9). 
Long blood circulation time can increase the needed in vivo availability and is therefore an 
important factor to improve accumulation in tumor tissue. In active targeting, antibodies or 
peptides are used to ensure tumor uptake, but in the case of nanoparticles even when such tar-
geting vectors are present, it is still imperative that these entities remain in blood circulation 
for suﬃciently long time (10). 
Even though the scientiﬁc community is gaining considerable knowledge about the var-
ious factors that can aﬀect the biodistribution of nanoparticles, it is still diﬃcult to predict 
the in vivo behavior of new formulations, making pre-clinical evaluation absolutely essential. 
Nuclear imaging approaches such as SPECT (single photon emission computed tomography) 
and PET (positron emission tomography) are very suitable for this purpose, since they oﬀer 
high detection sensitivity at high temporal and spatial resolution. These techniques do, how-
ever, require radiolabeling of the micelles prior to imaging. Several methods for radiolabeling 
of polymeric micelles are described in the literature, all involving the conjugation of the mi-
celles with a chelate or complexing agent (e.g., DOTA or DTPA) which requires additional 
synthetic steps (11). In addition, the attachment of such a chelate could alter the corona of the 
micelles and hence their biodistribution and pharmacokinetics (12-14).
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In this paper, we present a new, facile radiolabeling method based on passive loading 
that is applied to micelles composed of the diblock copolymer polystyreneblock- poly(eth-
ylene oxide) (PS-b-PEO). The non-ionic hydrophilic corona of the micelles is composed of 
PEO, often referred to as poly(ethylene glycol), which is commonly used in nano-particle 
formulations to enhance their stealthy surface chemistry(2,13). The hydrophobic counterpart 
is formed by the PS, which has a high glass transition temperature (Tg) and is extremely hy-
drophobic, ensuring stability of the micelles and a low release rate of any hydrophobic load 
(14). The radiolabeling method described here bypasses the covalent attachment of a chelat-
ing agent since a lipophilic ligand (tropolone) complexed with the radionuclide (in this case 
111In) is entrapped in the micellar core leaving the PEO corona unaﬀected. In this paper, we 
describe this radiolabeling strategy and demonstrate the ease and eﬃciency of this procedure 
as well as an initial in vivo evaluation of these micelles in healthy mice using SPECT. 
EXPERIMENTAL SECTION
Chemicals
The block copolymer PS-b-PEO with a Mn (number average molar mass) of 9500-b-
18,000 g/mol was purchased from Polymer Source (Quebec, Canada). The block copolymer 
was nearly monodisperse with a M w /M n ratio (Mw is the weight average molar mass) of 
1.09. The 111In Cl3 was obtained as solution in 10 mM hydrochloric acid from Mallinckrodt 
Pharmaceuticals (Petten, The Netherlands) with a speciﬁc activity of 1.72 MBq/pmol. Indium 
chloride, Sephadex G-25 and Sepharose 4B size exclusion chromatography resins, 4-(2-hy-
droxyethyl)-1-piperazine ethanesulfonic acid (HEPES), and 1,4-piperazinediethanesulfonic 
acid sodium salt (PIPES) were purchased from Sigma Aldrich, and tropolone from Merck. 
Ultrapure water was prepared with the in-house Milli-Q system from Merck Millipore.
Production and radiolabeling of micelles
Formation of 111In-tropolone complexes was executed by adding 50 kBq 111InCl3 to 2.3 
mL of 10 mM HEPES buﬀer solution (pH 7.4) containing 0.8 mM of tropolone. The sample 
was incubated for about 5 min at room temperature. Subsequently, 100 μL of a solution of 
PSb- PEO block copolymer in chloroform was added to reach a polymer concentration of 4.3 
mg/mL. The mixture was stirred at room temperature in a fume hood using a glass stirring 
bar in an open glass vial for about 2 h until the chloroform had evaporated. Unencapsulated 
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111In-tropolone was removed from the radiolabeled micelles by means of size exclusion chro-
matography (SEC) using a Sephadex G-25 column with a diameter of 1 cm and a length of 
30 ± 1 cm, using 10 mM HCl as eluent. The 111In activity in the eluted fractions was analyzed 
using a Wallac WIZARD2 2480 Automatic Gamma Counter (PerkinElmer), by measuring 
the peak area of the 171- and 245-keV photon peaks. The labeling eﬃciency was determined 
as the amount of 111In encapsulated in the micelles relative to the total amount of 111In added 
to the sample.
Physical characterization of the micelles
Samples used for the physical characterization of the micelles were prepared exactly the 
same way as described above but using non-radioactive indium chloride. The sample used in 
the dynamic light scattering (DLS) studies was prepared in duplicate and contained 4.3 mg/
mL PS-b-PEO. Prior to the measurements, the sample was diluted 10, 50, and 200 times 
using HEPES buﬀer and each diluted sample was measured three times following protocols 
described previously [15]. The DLS apparatus consisted of a JDS Uniphase 633 nm 35 mW 
laser, an ALV sp 125 s/w 93 goniometer, a ﬁber detector, and a PerkinElmer photon counter. 
An ALV-5000/epp correlator and software completed the set-up. The DLS sample cell was 
placed in a temperature-regulated bath containing toluene as the index-matching ﬂuid. The 
intensity autocorrelation function, g(2) (Ĳ), was determined at 90°. The measurements were 
performed at 22 ± 1°C. The RH of the micelles was determined using the CONTIN method, 
and the radius was calculated from the diﬀusion coeﬃcient of the particles using the Ein-
stein-Stokes equation. 
The samples used in the transmission electron microscopy (TEM) analysis contained 
1.1 mg/mL and 4.3 mg/mL PS-b-PEO. Prior to analysis, a ﬁve-time dilution was made in 
HEPES buﬀer. A drop of the micellar solution was pipetted onto a carbon-coated copper 
grid of 200 mesh (Quantifoil, Jena, Germany). Excess liquid was removed with a tissue, and 
the grid was left to dry before placing the specimen into the microscope. A JEM 1400 TEM 
( JEOL) was used with a LaB6 electron source, operated at an acceleration voltage of 120 keV.
Partition studies
For the partition study, 4 mL of either PIPES or HEPES buﬀer, containing 0.8 μM tro-
polone and 5 kBq 111In was mixed with an equal volume of chloroform during 30 s using a 
vortex. The aqueous and organic phases were left to separate gravimetrically, after which 1 mL 
of each phase was transferred into a counting vial and measured using the automatic gamma 
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counter described previously. The distribution ratio (D) of the 111In was calculated according 
to the following equation:
 ( 1 ) 
In which [ 111In]chloroform is the concentration of 111In in the chloroform phase, and [111In] 
HEPES buﬀer is the concentration of 111In in the aqueous phase. The D was assessed at pH 4.5, 
5.5, 6.5, 7.4, and 8.5.
Optimization of the radiolabeling parameters
In the optimization studies, the following parameters were sequentially tested: the poly-
mer concentration, the 111In activity (i.e., the amount of indium), the tropolone concentration, 
and the pH. The polymer concentration varied from 0.22 to 8.7 mg/mL. In the optimization 
of the indium activity studies, non-radioactive indium was used in addition to 111In for safety 
reasons. The indium concentration ranged from 1.3 pM to 130 nM, corresponding to 5 kBq 
and 500 MBq 111In per sample of 2.3 mL, respectively, which is referred to as 111In equivalent. 
Stock solutions of non-radioactive InCl3 were prepared in 10 mM HCl, and for quantiﬁca-
tion, either 5 or 50 kBq of 111In was added to the sample. The tropolone concentration was 
varied from 0.8 nM to 80 μM, using stock solutions of tropolone in HEPES. PIPES buﬀers 
at pH 4.5, 5.5, and 6.5 and HEPES buﬀers at pH 7.4 and 8.5 were used in the pH optimi-
zation studies.
Radiolabeling of preformed micelles
The micelles were prepared as follows: 100 μL of a PSb-PEO block copolymer solution 
in chloroform was added to 2.3 mL of HEPES buﬀer containing 0.8 mM tropolone. The 
mixture was stirred until the chloroform had evaporated. To this solution, 111In-tropolone 
chloroform solution was added in portions of 2 μL, which was itself prepared by extracting the 
111In into chloroform from a solution containing 1 mM tropolone in HEPES. The addition 
was done at 30-s intervals, until an activity of 50 kBq was reached. The unencapsulated 111In- 
tropolone was removed from the radiolabeled micelles by means of SEC. The 111In activity was 
measured as previously described using an automated gamma counter. Labeling eﬃciency was 
calculated relative to the total amount of 111In added to the sample.
D =
111In chloroform
111In HEPES buﬀer
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Retention studies
The retention of the 111In radiolabel in the micelles was assessed in PBS and in mouse 
serum. For both samples, 3 mL of the radiolabeled micelles solution was mixed with an equal 
volume of either PBS or serum. As control, 1 mL of the same sample was analyzed on the day 
of preparation. The samples were stored in an incubator at 37 °C, and after 24 and 48 h, the 
retention of the radiolabel was analyzed. The micelles in the serum samples were separated 
from the released 111In using a Sepharose 4B gel SEC column with a diameter of 1 cm and a 
length of 30 ± 1 cm. The micelles in the PBS were separated from the released 111In by using 
a Sephadex G-25 SEC column having the same dimensions as in the serum studies, using 10 
mM HCl as eluent.
In vivo and ex vivo evaluation
Micelles for in vivo tests were prepared as described in the “Production and radiolabeling 
of micelles” section, using a starting concentration of polymer adjusted to the number of ani-
mals and the required ﬁnal polymer amount of 1 mg per animal. The sample was centrifuged 
for 90 min at 2300 g using Amicon® Ultra-4 centrifugal ﬁlter devices (Merck Millipore). 
The concentrated micellar solution was recovered from the ﬁlter and ﬁlled up to the required 
injection volume with PBS.
The biodistribution of PS-b-PEO micelles was tested in Balb/c-nu mice ( Janvier Labs, 
Le Genest-Saint-Isle, France). Three mice received an injection of 200 μL of solution con-
taining 22 MBq of 111In in 1 mg of micelles. Immediately after the injection, the mice were 
anesthetized with a gas mixture of isoﬂurane (Pharmachemie, Haarlem, The Netherlands) 
(4 % induction, 2 % maintenance) and oxygen (0.8 %) and subjected to SPECT/CT scan 
(NanoSPECT/CT, Bioscan Inc., California, USA). One mouse, randomly chosen, was sub-
jected to a dynamic scan during the ﬁrst 60 min post injection (pi) using a matrix of 256 × 
256 pixels, 16 projections, 20 s per projection. Static images were further acquired 30 min pi, 
4 h pi, and 24 h pi, using a matrix of 256 × 256 pixels, 20 projections with 60 s per projec-
tion. A CT scan (240 projections, 500 ms exposure time 55 kVp tube voltage) was performed 
for anatomical reference. For biodistribution analyses after the last SPECT/CT acquisition, 
the mice were euthanized by cervical dislocation. Blood was immediately drawn via heart 
puncture and stored in a collection vial, then both the cadaver and the vial containing the 
collected blood were measured in a dose calibrator (Comecer VDC-404, COMECER Neth-
erlands, Joure, The Netherlands) to have a measure of retention of radioactivity in the body. 
After the total body count, a selection of diﬀerent organs was harvested. The uptake of the 
micelles in diﬀerent tissues was calculated using the Wallac Wizard 1480 automated gamma 
counter (PerkinElmer) by measuring the emitted radiation. Part of the spleen, part of the 
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liver, and the complete right kidney of one mouse were collected and stored at −80 °C for 
ex vivo autoradiography evaluation. From the frozen tissues, 15-μm tissue sections were cut, 
mounted on glasses, and processed for ex vivo autoradiography. The slides were placed in a 
sensitive phosphor-imaging screen (PerkinElmer), and read out was performed 3 days later 
using the Cyclone Storage Phosphor System (Packard). Quantiﬁcation of the autoradiograms 
was carried out with Optiquant (Software version 5.0. PerkinElmer). All animal experiments 
were performed in accordance with the Dutch animal welfare regulations and approved by the 
Central Animal Testing Committee (Dutch: Centrale Commissie Dierproeven).
DATA ANALYSIS
The obtained in vitro data were processed with Microsoft Excel (Microsoft Oﬃce Profes-
sional Plus 2010 package). ANOVA was used for statistical evaluation. All the in vivo data 
collected were analyzed with GraphPad Prism (GraphPad Software, version 5).
RESULTS
Physical characterization of the micelles 
The morphology of the micelles has been assessed by DLS and TEM. Figure 1 shows the 
RH of the micelles for diﬀerent dilutions. According to the DLS analysis, the micelles appear 
to have good stability upon dilution, having variations in the hydrodynamic radius within the 
measurement uncertainty. The overall average hydrodynamic radius has been found to be 97 
± 13 nm (N = 18).
Three representative TEM images of the micelles are given in Figure 2, in which the PS 
core is clearly visible as dark stains on a grey background. The PEO corona has lower electron 
density compared to the PS, and hence, it is (nearly) invisible. Most of the micelles appear to 
have spherical shape with diameter of the PS core ranging from 25 to 40 nm, irrespective of 
the polymer concentration. A small number of rod-like micelles with diﬀerent lengths have also 
been observed (Figure 2c). Their presence can explain the larger dimensions of the micelles mea-
sured by DLS since the presence of a small number of large objects can contribute signiﬁcantly 
to the scattered light signal leading to a shift of the apparent hydrodynamic size to larger values.
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Radiolabeling
Prior to the optimization of the radiolabeling parameters, the distribution ratio, D, of 111In 
in a mixture of chloroform and HEPES buﬀer containing tropolone had been determined. 
The obtained distribution ratio is 4.8 ± 0.5 indicating that in the presence of tropolone, in-
dium has a clear preference for the organic phase, due, most likely, to the formation of an 
In-tropolone complex having lipophilic character. The results for D at pHs other than 7.4, 
given in Additional ﬁle 1: Table S1, show a comparable D values for pH 4.5 to 7.4 and a lower 
D for pH 8.5, i.e., 2.9 ± 0.2. 
Figure 1. Size distribution of the PS-b-PEO micelles at a concentration of 4.3 mg/mL as determined 
by DLS, at three diﬀerent dilutions.
Figure 2. TEM images of PS-b-PEO micelles. a) spherical micelles, b) magniﬁed image of A and c) 
a rod-like micelle between a few spherical ones. The concentration of A and B is 4.3 mg/ml and in C 
1.1 mg/ml.
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The radiolabeling eﬃciency increases with the polymer up to a value of 1.1 mg/mL, after 
which the encapsulated percentage remains constant, reaching a plateau at about 30% (Fig. 3a). 
At a block copolymer concentration of 4.3 mg/mL, there is an excess of micelles compared to the 
number of 111In atoms (see Additional ﬁle 2 for the calculations), which implies that the labeling 
eﬃciency should be independent of the amount of indium. Indeed, the labeling eﬃciency appears 
to be the same up to the equivalent activities of 500 MBq (see Additional ﬁle 3: Figure S1). 
The optimal tropolone concentration has been determined to be between 0.1 and 10 mM 
(Figure. 3b). At the lowest tested tropolone concentrations (0.8 μM), more than 50 % of 111In 
has been found to stick to the glass vial or the stirrer, while above 10-mM free tropolone is 
expected to compete with 111In-tropolone leading to a decrease in loading. Figure 3c shows 
the eﬀect of the pH on the radiolabeling eﬃciency, revealing that even at pH 4.5, the labeling 
eﬃciency is still 34 ± 1 %, and it remains constant up to pH of 7.4. Only at higher pH values, 
>8, the eﬃciency slightly decreases to 29 ± 4 %. 
As an alternative to the passive loading method, the radiolabeling of preformed micelles, 
referred to as ‘active loading’ has also been tested since it has previously been successfully 
applied in the radiolabeling of liposomes and polymersomes (15). In active loading, the 111In-
tropolone complex in chloroform is added to the preformed micelles to transport the 111In 
into the core of the micelles. The labeling eﬃciency of this method has been shown to be 
somewhat lower than the passive loading, 22 ± 3 % versus up to 32 ± 2 %.
Retention of  111In
The loss of radiolabel has been assessed in both phosphate-buﬀered saline solution and 
in mouse serum (Figure 4). In saline, the micelles are stable having 95 ± 4 % of the 111In still 
encapsulated in the micelles after 2 days of incubation. The retention of 111In in serum is 83 ± 
3 % and 81 ± 1 % after 1 and 2 days, respectively. In all samples, the same trend is observed: a 
fast release rate in 24 h followed by a negligible loss in the next 24 h.
In vivo evaluation
Dynamic SPECT/CT images in the ﬁrst 68 min pi show that most of the activity is still in 
circulation (Fig. 5). Up to 4 h pi circulation is clearly detectable in the scans, making the ma-
jor blood vessels and the heart chambers visible (Figures 5, 6a, b), while at 24 h, the SPECT 
data suggests that the micelles have primarily accumulated in the spleen and liver and are not 
found in the blood (Figures 6b, c). 
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Figure 3. The radiolabeling eﬃciency as function of the PS-b-PEO micelles concentration (a), as 
function of the tropolone concentration and (b) as function of the pH (c). Default parameters are 
4.3 mg/mL PS-b-PEO micelles, 0.8 mM tropolone in HEPES buﬀer at pH 7.4, containing 50 kBq 
111PIn. The uncertainty bars are the standard deviations (N=3).
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Whole-body retention of activity at 24 h pi has been estimated by measuring radioactivity 
levels in the extracted blood and the cadavers of euthanized animals, which show that more 
than 85 % of the injected activity has been retained in the body after 24 h. Ex vivo biodistri-
bution analysis 24 h pi, expressed as a percentage of injected dose per gram of tissue (% ID/g), 
conﬁrmed the observation made using SPECT/CT imaging, i.e., elevated spleen (176 ± 97 % 
ID/g) and liver uptake (30 ± 6 % ID/g) (Figures 7). Surprisingly, although circulation is not 
detectable via nuclear imaging at 24 h pi, the blood samples reveal relatively high percentage 
of activity (21 ± 8 % ID/g), indicating clearly that the micelles are still in circulation at this 
time point. The stomach also showed relatively high uptake being on average around 22.96 
% ID/g.
Figure 4. Retention of 111In on micelles as function of time. The 111PIn activity was 50 kBq per sample. 
The uncertainty bars are the standard deviations (N=3).
Figure 5. Four frames of a dynamic SPECT/CT scan of a non-tumor-bearing mouse, up to one hour 
pi.
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Figure 6. SPECT/CT scans of a non-tumor-bearing animal at time points 0 (a); 4 h (b) and 24 h (c) 
pi of a dose of 1 mg micelles containing 22 MBq of 111PIn.
Figure 7. Biodistribution results of 111PIn-PS-b-PEO micelles 24 h pi in non-tumor-bearing mice. 
Bar represent the average values of the calculated % ID/g ± standard deviations (N=3).
513958-L-sub01-bw-Santini
Processed on: 22-9-2017 PDF page: 130
130
Chapter 3.2
Ex vivo autoradiography
Ex vivo autoradiography has been carried out in the sections of the spleen, liver, and 
kidney. Accumulation in the liver and the kidney tissue appears to be homogeneous. In con-
trast, the spleen has non-homogenous staining pattern having areas with elevated uptake and 
smaller zones with lower retention. The observed staining pattern coincides with the anatom-
ical architecture of the spleen with red pulp and white pulp zones, indicating high accumula-
tion in the red pulp and low accumulation in the white pulp (Figure 8).
DISCUSSION
The aim of this study was to develop a simple and fast radiolabeling method for PS-b-
PEO micelles which does not interfere with the intrinsic properties of micelles, allowing their 
evaluation in vivo using SPECT. Radiolabeling of polymeric carriers is typically carried out 
by the conjugation of a chelating molecule on their outer surface which has two main disad-
vantages: the properties of the nano-entities are altered and therefore possibly their behavior, 
and radiolabel integrity in vivo is often compromised (16). For instance, recently, it has been 
shown that polymersomes composed of the same block copolymer and having the same size 
exhibit diﬀerent biodistribution and loss of radiolabel when radiolabeling is on the outer 
Figure 8. Autoradiography images; distribution of 111In-PS-b-PEO micelles in liver, kidney and 
spleen 24 h pi. Two sections per organ are shown. The intensity scale is expressed in Digital Light 
Unit per surface (DLU/mm2): (a) liver (min: 31; max 143); (b) kidney (min 8; max 81); (c) spleen 
(min 262; max 490).
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surface versus enclosure in the aqueous cavity of the vesicles. The introduction of a chelating 
agent (i.e., DTPA) in this case resulted in somewhat negatively charged micelles which led 
to signiﬁcantly higher liver uptake than when the PEG chains were not modiﬁed, preserving 
their neutrality (16). The potential of polymeric micelles as carriers for therapeutic agents, 
especially when envisioning drug delivery applications, should, hence, be assessed without 
changing their inherent qualities. In this study, we make use of the physical characteristics 
of the block copolymer, PSb-PEO (i.e., high Tg and extreme hydrophobicity) toencapsulate 
radionuclides in the micellar core, providing a novel and facile radiolabeling method that does 
not require chemical modiﬁcations, keeps the PEO corona intact, and protects the radiolabel 
from the biological environment. 
The synthesis of the polymeric micelles is based on the spontaneous self-assembly of am-
phiphilic block copolymers into micellar structures due to formation of interfacial instabilities 
in chloroform-in-water emulsion droplets (17). When the PS-b-PEO block copolymers dis-
persed in chloroform are emulsiﬁed in water, they distribute at the (water-chloroform) inter-
face in order to reduce the entropy of the system, which eventually leads to the formation of 
micelles as the chloroform evaporates. The mobility of the PS-b-PEO unimers in the micellar 
core is virtually non-existent due to the glassy behavior of polystyrene, leading to kinetically 
trapped structures having exceptionally high stability (18). This micellization process can be 
used to entrap lipophilic entities, such as in this case tropolone, which are present in the 
chloroform solution. Tropolone, being a ligand often used in radiolabeling, can be applied to 
passively bring a radio-metal to the micellar core, which is initially chloroform-rich, provided 
that the tropolone-metal complex has aﬃnity for chloroform. The ﬁnal evaporation of chloro-
form from the micellar structures results then in radiolabeled micelles. In this work, tropolone 
is complexed with indium ( 111In) and their distribution ratio has been determined to be above 
1, showing a tendency to accumulate in the chloroform phase. Since radiolabeling is in this 
case a passive process, the radiolabeling eﬃciency will be limited by the distribution ratio and 
the amount of chloroform present in the micellar core during micellization, which naturally 
will depend on the number and size of the micelles. This inherent limitation, however, makes 
the radiolabeling procedure highly reproducible, since there is only a slight dependence on 
the diﬀerent radiolabeling parameters such as polymer, tropolone, and indium concentration, 
and surprisingly, also pH, as long as suﬃcient micelles are formed. For instance, the eﬃcien-
cy remains nearly the same for tropolone concentrations ranging from 0.1 to 10 mM. Only 
at higher amounts a decrease is seen which is explained by the fact that if there is an excess 
of free tropolone, i.e., percentage-wise less 111In-labeled tropolone will be encapsulated, as-
suming that both species behave in a similar way (i.e., have a similar D value). The lack of 
dependence on indium concentration is logical since there is always a large excess of tropolone 
and polymer in the studied range, which allows encapsulating suﬃcient amount of activity 
at radiolabeling eﬃciency of 30%. One of the parameters expected to aﬀect the radiolabeling 
eﬃciency is the pH, simply based on the pKa value of tropolone and the speciation of indium. 
In the tested pH range of 4.5 to 8.5, the radiolabeling eﬃciency remains the same between 
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pH 4.5 and 7.4 and only at pH 8.5 a small decline is observed. The same trend is observed 
for the distribution ratio, which is constant between pH 4.5 and 7.4 and is lower at pH 8.5. 
This decrease in the distribution ratio and in the labeling eﬃciency can be explained by the 
fact that at alkaline pH In(OH) 4 - is formed which is unable to complex with the negatively 
charged ropolone (see Additional ﬁle 4: Figure S2 for the speciation chart). The anticipated 
reduction of labeling
eﬃciency at lower pH (<6.8) based on previous studies and the pKa value of tropolone 
(i.e., pKa 6.9) have not been observed. The structure of tropolone suggests that it will be 
partially situated at the water-chloroform interface and as such might have a diﬀerent pKa 
value, enabling it to still extract indium even at somewhat acidic pH. This assumption also 
seems to be supported by the indium retention studies in serum, which reveal initial fast loss 
of radiolabel in the ﬁrst 24 h followed by nearly no loss of any indium in the following 24 h. 
Such a loss proﬁle can be ascribed to the distribution of In-tropolone in the micelles, i.e., it is 
very likely that some 111In-tropolone complexes will be situated at the interface between the 
PEO corona and the PS core and will be much more prone to be taken from the micelles by 
scavenging proteins. Nevertheless, the loss of radiolabel is still limited (<19 %) and acceptable.
The radiolabeling procedure described in this manuscript is based on some general chem-
ical principles and may be applicable to other block polymers exhibiting similar behavior as 
PEO-b-PS, i.e., having very slow exchange kinetics. In addition, this procedure would also be 
suitable for (simultaneous) encapsulation of a variety of radionuclides, provided that they are 
capable of complexing with tropolone or similarly behaving lipophilic ligands.
The success of any micellar formulation in systemic application is mainly dependent on 
the capacity of carriers to accumulate in diseased tissue with limited retention in healthy 
organs. The blood residence time has been identiﬁed as one of the most crucial aspect in 
achieving high tumor uptake (19), which in turn depends on the capability of the micelles to 
escape the body clearance mechanisms. Carriers of the size of PS-b-PEO micelles are usually 
cleared by macrophages in the liver and spleen, often also referred to as the mononuclear 
phagocyte system (MPS). PS-b-PEO micelles show a substantial retention in MPS organs, in 
line with previous observations evaluating the in vivo behavior of other nanoparticles similar 
in size and composition (20,21). In this respect, the morphology of the micelles inﬂuences the 
circulation time and the presence of rod-like micelles in our case might aﬀect the circulation 
time; however, as the number of elongated species is low, the eﬀect on the average circulation 
time is considered to be negligible. A particular pattern of accumulation has been observed 
in the spleen conﬁrming the possible uptake by the splenic resident macrophages as a result 
of unspeciﬁc ﬁltration process (22). This spleen uptake is in general higher when compared 
to other block copolymer micelles that have been investigated, which tend to exhibit more 
pronounced liver uptake (23). This discrepancy in biodistribution can be due to diﬀerences in 
charge of the investigated systems, and as mentioned earlier, all other systems include chelates 
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present on the surface of the micelles, which typically result in negatively charged micelles. In 
addition, the rigidity of the PS-b-PEO particles makes them more prone to spleen ﬁltration. 
Apart from the blood, liver, and spleen, however, all the investigated organs show a low uptake 
proﬁle (in average below 5 % ID/g) and little standard deviations indicative of a diﬀerential 
but homogeneous uptake in the various tissues. The surprisingly elevated stomach uptake is 
the result of one single animal, which explains as well the high standard deviation reported 
in the graph. This unexpected ﬁnding is probably not the result of tissue uptake/retention but 
could be ascribed to mice feeding behavior, i.e., daily coprophagy and social grooming (24). 
Although we have not determined the half-live of the micelles, the measured retention in 
blood is at 24 h still above 20 % ID/g which indicates that a large percentage of the micelles 
are still in circulation, which is comparable to a number of studies on polymeric micelles (23). 
Based on these results, we expect that these micelles will have long enough circulation time to 
ensure high tumor uptake, which should be further tested in tumor-bearing mice.
CONCLUSION
We have developed a new, easy, fast, and robust method to produce and radiolabel spher-
ical PS-b-PEO block copolymer micelles. The radiolabeling eﬃciency is suﬃcient to achieve 
micelle activities of up to several hundred megabecquerel. Ex vivo results show blood circu-
lation even 24 h pi, with high accumulation in the spleen and liver. Overall, these results are 
promising for further investigation of radiolabeling polymeric micelles and for the assessment 
of their fate in vivo.
SUPPORTING INFORMATION
A graphical representation of the eﬀect of the indium activity on the radiolabeling eﬃ-
ciency, a calculation of the number ratio of 111In nuclides and micelles, and speciation chart 
of indium over the full pH range. This material is available free of charge via the Internet at 
http://pubs.acs.org.
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SUPPORTING INFORMATION
Calculation of the number ratio of 111In nuclides and micelles
For calculation of the number of micelles we have used the aggregation number from the 
publication by Wilhelm et al.(25) For a PS-b-PEO block copolymer with a comparable size, 
i.e. for PS-b-PEO 11200-17500 an average aggregation number of 290 was reported. At a 
PS-b-PEO 9500-18000 concentration of 1.1 mg/mL in a default volume 2.3 mL the number 
of micelles will be:
The number of 111In nuclides is directly proportional to the activity and can be calculated 
with the decay constant, Ȝ, which for 111In is 2.86 x 10 -6 s -1 , for 50 MBq the number of nu-
clides is:
In this example there is about ten times excess of micelles compared to the number of 
111In nuclides, this means that part of the micelles will be present without radiolabel. In most 
practical situations the ratio will even be higher, so relatively more micelles will by without 
radiolabel.
1.1×1 0-3 g /mL×2.3 mL
(9500 + 18000) g /mole X
6.0 22×1 023 n/mole  
290 n/micelle = 1.9 1×1 0
14  micelles
N = AȜ =
50×1 06s -1
2.8 6×1 0-6s -1
= 1.7 4×1 013nuclides 
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The inﬂuence of the indium activity on the radiolabeling eﬃciency
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Figure s1. The labeling eﬃciency as function of the indium activity. The uncertainty bars correspond 
to standard deviations determined for three separate experiments. The samples were prepared in 
HEPES buﬀer pH 7.4 with 0.8 mM tropolone and 50 kBq 111In activity (5 kBq for the lowest data 
point), containing 4.3 mg/mL PS-b-PEO micelles. Increasing amounts of non-radioactive indium 
was added equivalent to an 111In activity up to 500 MBq.
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Speciation chart of indium over the full pH range
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Figure s2. Speciation chart of indium at a concentration of 1 μM. The speciation chart is created 
with Cheaqs Next software version 2014.0.9.4. Input values for the concentration of both indium and 
chloride were 1x10 -6 M, and for each pH the regarding H + input value was set as free activity, the 
concentration of all other elements was set to 0 M for this evaluation.
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biodistribution and tumor uptake of 
polymeric micelles
In preparation for submission to EJNMMI Research
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ABSTRACT
Background. Polystyrene block-poly(ethylene) oxide (PS-b-PEO) amphiphilic block co-
polymers can aggregate into stable supramolecular aggregates. Such aggregates can be labeled 
with tracking agents, including radionuclides, allowing for in vivo follow-up using nuclear 
imaging techniques, and can be easily varied in size without changing the block length of 
the forming block copolymer. The possibility to tune the particle size further conﬁrmed the 
versatility and the potential of PS-b-PEO micelles as a drug carrier. The carrier size is often 
indicated as one of the most important properties, having a signiﬁcant eﬀect on biodistribu-
tion and tumor accumulation. In contrast, little is known on the eﬀect of particle dose. More 
knowledge on this speciﬁc topic would help in determining the optimal delivery eﬃcacy and 
may enable improvement of tumor uptake and avoiding toxicity in healthy tissues. In this 
study, we assessed the diﬀerences in tumor uptake after varying the size and applied dose of 
PS-b-PEO micelles. For the ﬁrst time, 111In radiolabeled PS-b-PEO micelles of two diﬀerent 
sizes (106 nm and 170 nm in diameter) were evaluated at two diﬀerent doses (1.7 mg/mL 
and 7 mg/mL) in mice bearing tumor xenografts. Using SPECT imaging and ex vivo studies, 
biodistribution of micelles were followed quantitatively over a period of 48 h. 
Results. Images and biodistribution studies showed tumor uptake up to 4.15 % IA/g, as 
well as low oﬀ target accumulation, but relatively high uptake in the clearance organs (liver 
and spleen) for the four micellar samples. The levels of uptake in diﬀerent tissues were sig-
niﬁcantly diﬀerent for the four micellar formulations, they appeared highly dependent on size 
and dose. 
 Conclusions. PS-b-PEO micelles were found to accumulate in tumor tissue, they were 
found to have a biodistribution dependent on particle size and dose. These eﬀects might be 
relevant for other nanoparticles as well. 
Keywords: polymeric micelles, SPECT, size, dose, tumor uptake, uptake limit
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BACKGROUND
The delivery of curative doses of therapeutics with tolerable toxicity in normal organs 
is still one of the biggest challenges in the treatment of solid tumors (1). In this respect, 
drug-encapsulating nanoparticles (nanocarriers) such as liposomes, dendrimers, or polymeric 
micelles, have shown better outcomes than free drugs, especially because of improved tumor 
uptake and reduced oﬀ target toxicity (2, 3). 
Polystyrene block-poly(ethylene) oxide (PS-b-PEO polymers) are amphiphilic di-block 
copolymers that can form kinetically stable, nanosized micellar structures (1-3). Next to the 
easy and fast (radio)labeling method shown in previous studies (1, 4), the synthesis of PS-
b-PEO polymer-based aggregates can be easily modulated to enable diﬀerent morphologies 
(diﬀerent size or shape) that might be of relevance for in vivo application,  especially for the 
delivery of radionuclides to tumors (3). 
Nanoparticle size is, among others, a main factor that can inﬂuence the level of accumu-
lation in the tumor and the in vivo behavior, e.g. circulation time, clearance pathway, and bio-
availability. Tumor accumulation of nanoparticles occurs as a result of a phenomenon known 
as the Enhanced Permeability and Retention (EPR) eﬀect (5). In many tumors newly formed 
vessels are characterized by large fenestrae, lack of lymphatic drainage and irregular blood 
ﬂow (6, 7), which favor the enhanced extravasation of particles from the circulation to the 
tumor tissue and subsequent retention of nanosized structure in the size range of ~50 to 500 
nm (8). While nanoparticles below 50 nm show deep penetration in tissues and in tumors, 
compared to larger particles they also show faster washout and poor persistence in tissues (9). 
The size of particles is one of the parameters determining not only the clearance pathway, 
but also the circulation time and the eﬃcacy of accumulation in the tumor. Nanoparticles, be-
cause of their nanometric-size, often undergo limited excretion via the kidney as they exceed 
the renal ﬁltration threshold; they are preferentially cleared via other pathways, i.e. via liver 
and spleen (10). These organs also show size-depended clearance patterns; particles above 50 
nm up to ~100-150 nm are preferentially cleared from the circulation by the liver, while par-
ticles above ~180-200 nm are generally retained at a high level in the spleen (10, 11). 
  In a previous study, we generated PS-b-PEO micelles of 180 nm in diameter to develop 
and evaluate a facile method for radiolabeling of PS-b-PEO micelles. Following in vivo injec-
tion of these radiolabeled micelles in healthy mice, we observed preferential accumulation of 
radioactivity in the spleen and (at a lower level) in the liver (1, 3). This pattern of accumulation 
was the result of normal clearance pathways of nanosized particles, and inﬂuenced in vivo 
application of nanoparticles in two ways.  On the one hand liver and spleen toxicity as a result 
of accumulation of carrier or carrier’s payload might occur; the availability of nanoparticles 
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for target (tumor) accumulation is dependent on clearance; fast clearance might reduce the 
availability for target accumulation. Since these eﬀects are strongly size-dependent, changing 
the size outside the liver and spleen accumulation range, can be a solution to reduce the ac-
cumulation in clearance organs, reduce the potential toxicity and improve the bioavailability 
for tumor accumulation (10, 12). While several studies have shown the importance of the 
size of the nanoparticle for in vivo applications, the role of the injection dose has been poorly 
investigated and has never been related to the size (13). 
The dose of encapsulating nanoparticles directly determines the amount of the payload 
(speciﬁcally drugs) and plays a signiﬁcant role in the delivery of drugs to the tumor. How-
ever, in contrast to expectations, previous studies indicated that injection of higher doses of 
nanocarrier (and drug) did not always result in higher accumulation in tumor tissue and better 
curative outcomes (14). These results indicated that other parameters also play a role in the 
biodistribution and tumor delivery eﬃcacy of nanoparticles. In this study, we investigated the 
potential of PS-b-PEO micelles to target tumor tissue in a human tumor xenograft model in 
mice. We synthesized PS-b-PEO micelles of two diﬀerent sizes, large micelles (LM, around 
170 nm), and small micelles (SM, around 100 nm) to study how in vivo biodistribution was 
inﬂuenced by the size of the nanoparticles. We also studied the eﬀect of PS-b-PEO particle 
dose on biodistribution and tumor uptake. We used a dose, matching that used in a previous 
study (1) and compared it to a four times lower injection dose.
MATERIALS AND METHODS 
Chemicals
The block copolymer PS-b-PEO with a Mn (number-average molar mass) of 9500-b-
18000 g/mol was purchased from Polymer Source (Quebec, Canada). The block copolymer 
was near monodisperse with an Mw/Mn ratio (Mw is the weight-average molar mass) of 1.09. 
Indium chloride, Sephadex G-25 and Sepharose 4B size exclusion chromatography resins, 
4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) were purchased from Sigma 
Aldrich; tropolone was purchased from Merck. Ultrapure water was prepared with the in-
house Milli-Q system (Merck Millipore). 111InCl3 was obtained as solution in 10 mM hydro-
chloric acid from Mallinckrodt Pharmaceuticals (Petten, The Netherlands).
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Synthesis, labeling and quality control of micelles
Synthesis, radiolabeling and puriﬁcation of the two diﬀerent micellar sizes was performed 
as previously described (1, 3). Brieﬂy, 100 μl of a polymer solution in chloroform was added 
to 2.3 ml of HEPES buﬀer pH 7.4, containing the lipophilic ligand tropolone (0.8 mM) 
and 111InCl3. The concentration of polymer solution was adjusted to obtain the required ﬁnal 
micelle concentration: 1.25 mg/mL for in vitro stability test; 7 and 1.7 mg/mL for the in 
vivo study at high and low micellar concentration, respectively. For in vitro evaluation 50 
kBq of 111InCl3 solution was added to the sample.  For in vivo studies 154 MBq of 111InCl3 
solution was added to each of the four samples, namely: large micelles at high dose (LMH), 
large micelles at low dose (LML), small micelles at high dose (SMH) and small micelles at 
low dose (SML). The solutions were then emulsiﬁed using a glass stirrer until all chloroform 
had evaporated. The two diﬀerent micellar sizes were obtained by manipulating the speed of 
chloroform evaporation: the duration for complete evaporation was approximately 2 h (fast 
evaporation) for LM, and approximately 20 h (slow evaporation) for SM. The characterization 
of LM and SM was assessed by dynamic light scattering (DLS) and transmission electron 
microscopy (TEM) following the procedure previously described (1) (Figure 1). 
In vitro stability tests 
The retention of 111In in labeled micelles was assessed in PBS and in mouse serum, fol-
lowing the previously described procedure (1). Brieﬂy, 3 mL of the radiolabeled micelles (LM 
and SM) were mixed with an equal volume of PBS or serum. Both samples were placed in an 
incubator at 37 °C, and then analyzed after 24 and 48 h. The micelles in the serum samples 
were separated from the released 111In using a Sepharose 4B gel SEC column (1 cm diame-
ter and a length of 30 ± 1 cm), using 10 mM HEPES buﬀer pH 7.4 as eluent. For the same 
procedure, the micelles in PBS were puriﬁed with a Sephadex G-25 SEC column having the 
same dimensions as in the serum studies and using 10 mM HCl as eluent. The retention of 
radiolabel for the two diﬀerent micellar sizes was calculated by measuring emitted radiation 
with a gamma counter (Wallac, 1480 Wizard 3”; PerkinElmer, Groningen, The Netherlands).
Tumor and animal model 
The human small cell lung cancer cell line H69 xenografted in nude mice (ECACC, 
Salisbury, UK) was chosen as tumor model, because of the high tumor yield and fast growth 
in mice. This model is also known to develop tumors with aberrant vascularization with en-
hanced EPR eﬀect (15). The cells were cultured under standard conditions in Gibco’s RPMI 
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medium (Invitrogen Corp., Breda, The Netherlands) supplemented with 10% v/v fetal bovine 
serum and 1% v/v penicillin/streptomycin. Cells were suspended in a 2:1 v/v Seligmann’s 
buﬀered salt solution (SBSS) medium and Matrigel (BD Biosciences, Mississauga, Canada) 
at a concentration of 25.7*106 cell/mL and inoculated subcutaneously in 20 young adult male 
Balb/c-nu mice ( Janvier, France) (100 μL/mouse, ~2.6*106 cell/mouse). Tumor growth was 
monitored and measured with a caliper ruler three times/week. All animal experiments were 
performed in accordance with Dutch animal welfare regulations and approved by the local, 
ethics committee.
Figure. 1. Experimental overview. On the left: synthesis of PS-b-PEO micelles of diﬀerent sizes. On 
the right: overview of in vivo evaluation, experimental groups and image acquisition schedule. LMH: 
large micelles, high dose; LML: large micelles, low dose; SMH: small micelles high dose; SML: small 
micelles, low dose.
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When the average tumor volume reached 300 mm3, mice were randomly subdivided in 
four groups of ﬁve animals each, one for each of the four diﬀerent micellar combinations. 
Mice received an injection of 200 μL of selected sample in the tail vein. Averages of radio-
activity injected in each group are summarized in Table 1. After injection of radiolabeled 
nanoparticle, three out of ﬁve mice per group were randomly selected and subjected to nu-
clear imaging by single photon emission computed tomography combined with computed 
tomography (SPECT/CT). The nuclear images were acquired using the U-SPECT-II sys-
tem (MiLabs B.V., Utrecht, The Netherlands) equipped with the new ultra-high-sensitivity 
collimator Mouse 2.0, having 54 conical pinholes of 2.0 mm diameter (16). The U-SPECT 
system has a heating system to prevent hypothermia of the animals during the scan. During 
scanning, mice were anesthetized with a gas mixture of isoﬂurane (Pharmachemie, Haarlem, 
The Netherlands) (4% induction, 2% maintenance) and oxygen. Mice were subjected to static 
SPECT/CT at diﬀerent time points: 0.5 h post injection (pi), 24 h pi and 48 h pi (Figure 1). 
Acquisition time was approximately 35 minutes (40-42 positions, 52 sec/position); CT 
scan was approximately 3 minutes (240 projections, 500 ms exposure time, 55 kVp tube volt-
age). 
CT images were reconstructed using a ﬁltered back projection (FBP) algorithm; SPECT 
images were reconstructed using the pixel-based ordered subsets expectation maximization 
(POSEM) algorithm with 30 iterations and 4 subsets (17). Both photo peaks of 111In were 
used (171 and 245 keV). SPECT was registered to CT, corrected for scatter using the tri-
ple energy window method and for attenuation using the CT (18). All images shown were 
corrected for decay of 111In, and scaled based on the image showing the highest radioactivity 
concentration. 
Table 1. Summary of dose injected for each formulation
LMH: large micelles at high dose; LML: large micelles at low dose; SMH: small micelles at high 
dose; SML: small micelles at low dose. sd: standard deviation
Group Injected dose
[mg/ml]
Injected activity/mouse
(mean ± sd) [MBq]
LMH 7 mg/mL (1.4 mg/mouse) 8.7 ± 0.37
SMH 7 mg/mL (1.4 mg/mouse) 6.38 ± 0.21
LML 1.7 mg/mL (0.34 mg/mouse) 2.34 ± 0.41
SML 1.7 mg/mL (0.34 mg/mouse) 4.24 ± 0.12
513958-L-sub01-bw-Santini
Processed on: 22-9-2017 PDF page: 148
148
Chapter 3.3
Biodistribution studies
After 48 h pi all mice were euthanized by cervical dislocation; as a measure for biodistri-
bution of the labelled micelles, the level of radioactivity present in blood and selected organs 
was measured. Samples of the collected blood and organs were weighed and the gamma radi-
ation emitted from these samples was measured with a gamma counter. For the selected tissue 
samples the uptake of micelles was calculated as the percentage of injected activity measured 
per gram of tissue (% IA/g). Hereby assuming that measured radioactivity is a measure for the 
presence of radiolabeled micelles.
Ex vivo autoradiography
Autoradiography studies were conducted as previously described (19). In short, tumors 
were stored at -80°C for two weeks; then tissues were sliced into 15 μm thick sections and 
mounted on glass slides for autoradiography analyses. The slides were placed in a sensitive 
phosphor-imaging screen (PerkinElmer). The read out was performed using the Cyclone 
Storage Phosphor System (Packard) and images were processed with Optiquant (Software 
version 5.0, Perkin Elmer).
Software and statistical analyses of in vivo/ex vivo 
data
All data collected were processed with Prism version 6 (GraphPad Software, La Jolla, Cal-
ifornia, USA). Diﬀerences in the level of uptake of radioactivity of the diﬀerent formulations 
were determined for each collected organ/tissue (biodistribution assay) using a One-Way 
Anova test (p<0.05 considered as statistically signiﬁcant) and further post-hoc analyses using 
Bonferroni correction where appropriate (p<0.01 considered as statistically signiﬁcant). 
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RESULTS 
Synthesis and in vitro characterization of the 
micellar formulations
Using a one-step synthesis and labeling procedure, we successfully generated radiolabeled 
micelles of two sizes. The hydrodynamic diameter of the micelles measured via DLS was 170 
± 8 nm for LM and 106 ± 7 nm for SM; TEM analysis showed diameters of the polystyrene 
(PS) core to be between 31 and 37 nm for SM and between 40 nm and to 65 nm for LM 
(Figure 2A-B). 
 The radiolabeling yield for LM was 32.7 ± 0.7% and for SM it was 11.3 ± 0.3%. The 
retention of 111In-tropolone in both PBS and serum remained stable over time, being always 
above 85% up to at least after 48 h exposure (Figure 2C-D). 
Imaging studies: SPECT/CT and tumor 
autoradiography  
Following injection of LM or SM, the SPECT/CT images showed already at the early 
time points an elevated signal in the area of the mice corresponding to the heart, major ar-
teries, liver and spleen (Figure 3-4, SPECT/CT images). At later time points (24 h and 48 
h pi) the radioactivity in the heart and major arteries, representative for radioactivity in the 
circulation, was not detectable anymore in the scan. The area corresponding to liver and spleen 
showed high signal up to at least 48 h pi. Radioactivity in the area of the tumor could not be 
detected by SPECT/CT. Radioactivity in the tumor was detectable through autoradiography 
analyses in all four samples. In the tumor rim more radioactivity was observed than in the 
tumor center (Figure 3-4, Autoradiography).
Biodistribution studies
An overview of biodistribution results obtained at 48 h pi is shown Table 2. The levels 
of radioactivity reached in selected organs and tumor are represented in diﬀerent graphs in 
Figure 5. For all healthy organs and tumor, with exception of liver and spleen, we recognized 
a speciﬁc pattern in uptake values after low dose and high dose: with LM values decreased or 
remained stable with high dose, whereas for SM values increased at higher dose. The increase 
in uptake observed for SM when comparing low and high dose was statistically signiﬁcant 
513958-L-sub01-bw-Santini
Processed on: 22-9-2017 PDF page: 150
150
Chapter 3.3
(p<0.01) for most organs, including kidney, lungs, muscle and tumor. For LM, the increase 
of the injected dose from low to high resulted in signiﬁcantly diﬀerent values (p<0.01) only 
for muscle and colon, while for all other organs the values showed no signiﬁcant diﬀerence 
(p>0.01).
In contrast to the pattern observed in the majority of oﬀ target tissues, in the spleen we 
observed a diﬀerent trend: the values of radioactivity reached in the spleen by LM (blue lines) 
increased signiﬁcantly (p<0.01) going from low to high dose. In contrast, for the SM (red 
line) the values remained similar; there was no signiﬁcant diﬀerence (p>0.01) between the 
values measured at low dose and high dose (Figure 5, Spleen).
Figure 2. In vitro characterization of PS-b-PEO micelles. TEM images of LM (A) and SM (B); 
stability over time in PBS (C) and serum (D). LM: large micelle; SM: small micelles.
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Liver presented another pattern: the uptake values of radioactivity measured in the liver 
remained similar (p>0.01) when the LM and SM were applied at low or high dose (Figure 5, 
Liver). However, we observed that the level or radioactivity measured in the liver after injec-
tion of SM was higher compared to that of LM (Figure 5, Liver).
Figure 3. Biodistribution of 111In-labeled micelles in tumor-bearing mice as assessed by SPECT/
CT imaging and tumor autoradiography. A) Whole body SPECT/CT maximum intensity projection 
images (left panel) of tumor-bearing mice taken at various time points after injection with 111In-
labeled large micelles at a dose of 7 mg/mL (~8.7 MBq/mouse). On the right: autoradiogram of a 
tumor section, resected at 48 h pi.  B) Whole body SPECT/CT maximum intensity projection (left 
panel) of tumor bearing mice take at various time point after the injection with 111In-labeled large 
micelle  at the dose of 7 mg/mL (~6.3 MBq/mouse). On the right: autoradiogram of a tumor section, 
resected at 48 h pi. LMH: large micelles, high dose; SMH: small micelles high dose; pi: post injection: 
min: minimum; max: maximum.
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Figure 4. Biodistribution of 111In-labeled micelles in tumor-bearing mice as assessed by SPECT/
CT imaging and tumor autoradiography. A) Whole body SPECT/CT maximum intensity projection 
images (left panel) of tumor-bearing mice taken at various time points after injection with 111In-
labeled small micelles at a dose of 1.7 mg/mL (~2.3 MBq/mouse). On the right: autoradiogram of 
a tumor section, resected at 48 h pi. B) Whole body SPECT/CT maximum intensity projection 
(left panel) of tumor bearing mice take at various time point after the injection with 111In-labeled 
large micelle at the dose of 1.7 mg/mL (~4.2 MBq/mouse). On the right: autoradiogram of a tumor 
section, resected at 48 h pi. LMH: large micelles, high dose; SMH: small micelles high dose; pi: post 
injection: min: minimum; max: maximum.
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By comparing the diﬀerences in the uptake due to the variation in micellar size, we ob-
sered that the eﬀect of size is most prominent at the higher injection dose. Statistically higher 
uptake values (p<0.01) were found for SM compared to LM in caecum, kidney, muscle, colon, 
and tumor. Signiﬁcant diﬀerence (p<0.01) in uptake at high dose was also found in the spleen, 
but here LM showed higher uptake values than SM (Figure 5).
At low dose, tatistical diﬀerences (p>0.01) in the uptake were found between LM and SM, 
for liver, heart and tumor, with LM showing higher uptake (Figure 5).
Figure 5. Biodistribution of radioactivity 48 h pi in selected organs and tumor after the injection of 
LMH (n=5), LML (n=5), SMH (n=5) and SML (n=5) in tumor bearing mice. Dots represent % IA/g 
expressed as mean ± standard deviation. Statistical signiﬁcance in uptake between LM and SM, when 
applied at the same dose: * (black) signiﬁcant diﬀerence p<0.01 for LM vs SM applied at the same 
dose; * (red): signiﬁcant diﬀerence (p<0.01) in the uptake of SM between low and high dose; * (blue): 
signiﬁcant diﬀerence (p<0.01) in the uptake of LM between low and high dose; LMH: large micelles, 
high dose; LML: large micelles, low dose; SMH: small micelles high dose; SML: small micelles, low 
dose; pi: post injection; IA: injected activity.
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Discussion 
This study represents the ﬁrst preclinical evaluation of radiolabelled PS-b-PEO micelles 
in tumor bearing mice, we investigated their biodistribution related to both particle size and 
applied dose. 
The micelles we used in our evaluation had a diameter of ˜100 nm (SM) and 180 nm 
(LM). These sizes are within the upper size-limit range for retention of particles in the liver 
and in the preferential size range of uptake in the spleen (10, 20).
In the liver, we found higher levels of SM compared to those of LM, an eﬀect that reﬂects 
the capacity of the liver to trap particles of ˜100 nm with higher eﬃciency compared to those 
of ˜200 nm (10). For both LM and SM, the increase of the dose resulted in limited eﬀect on 
Table 2. Biodistribution of the four combinations expressed in % IA/g, 48 h pi. 
  LMH LML SMH SML
% IA/g Mean sd Mean sd Mean sd Mean sd
Caecum 1.37 0.24 2.33 0.57 2.68 0.21 1.38 0.76
Liver 14.33 3.96 14.78 2.91 22.72 4.46 26.83 3.45
Kidney 5.13 0.54 7.23 1.20 9.24 1.31 4.59 1.57
Lungs 0.95 0.13 1.17 0.21 1.38 0.18 0.67 0.32
Muscle 0.20 0.06 0.39 0.06 0.78 0.05 0.33 0.06
Stomach 0.87 0.23 1.48 0.23 1.39 0.48 0.56 0.35
Colon 1.39 0.50 2.07 0.37 2.59 0.66 1.02 0.66
Rectum 0.83 0.30 1.36 0.18 1.73 0.37 0.77 0.46
Pancreas 0.46 0.13 0.69 0.13 0.84 0.25 0.33 0.11
Heart 0.86 0.12 1.11 0.08 1.17 0.20 0.66 0.15
Skin 8.33 4.22 6.83 2.10 8.63 0.40 2.96 1.69
Bone 1.00 0.17 1.77 0.88 2.22 0.42 1.42 0.69
Spleen 80.28 16.20 36.57 1.26 47.90 3.62 57.36 14.06
Tumor 1.22 0.45 1.95 0.36 4.15 0.99 0.69 0.29
LMH: large micelles at high dose; LML: large micelles at low dose; SMH: small micelles at high 
dose; SML: small micelles at low dose; sd: standard deviation.
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liver uptake as we did not see an increase in the levels of radioactivity when SM and LM were 
administered at low or high dose. 
In the spleen and in the liver we detected diﬀerences in uptake for diﬀerent micellar sizes, 
whereas in the spleen values also diﬀered with variations in the dose. LM showed higher 
uptake in the spleen (1), also increasing with higher dose. In contrast with the results of LM, 
however, the uptake of SM in the spleen did not increase at the higher dose. 
In contrast with the uptake of LM and SM in liver and spleen, other organs and tumor 
did not show signiﬁcant values for LM and SM at low or high dose. This might be due to 
diﬀerent penetration capacities of the two micellar sizes. Diﬀerent penetration capacities due 
to the size were visible only at high dose. Probably at the low dose other aspects play a more 
important role. Further studies, focusing in such aspects are needed to clarify the eﬀect of the 
clearance organs at low dose.
 Another interesting aspect that we observed in our study was the limited eﬀect on accu-
mulation of LM at the higher dose. High uptake in the spleen might strongly inﬂuence the 
remaining amount of circulating LM, thus reducing the uptake in other tissues. Moreover, 
because of their bigger size, LM show a lower penetration in tissues compared to SM, which 
further hampers accumulation. Our results indicate that a critical design and evaluation of 
nanoparticles as carriers is therefore warranted. The uptake value in the tumor is of course 
an important parameter to evaluate, but other factors may also be of importance and should 
be considered when selecting nanocarriers as well.  The chemical and physical properties of 
nanoparticles, such as the synthesis time or the loading yield, as well as the uptake in healthy 
tissues, can strongly steer the selection process of nanoparticles. 
In our study, among all formulations tested, SMH showed the highest tumor uptake. 
However, the uptake in normal tissue was also very high, resulting in a low tumor/tissue ratio. 
A dose reduction on the other hand, resulted in lower uptake in normal organs (except for 
liver and spleen), but had a dramatic eﬀect on tumor uptake as well. These aspects, together 
with the low labeling yield and the long synthesis time, do not support the use of SM for in 
vivo use.
In contrast, LM had lower levels of tumor uptake than SM, but they presented higher tu-
mor/tissue ratios. Moreover, LM showed higher labeling yields compared to SM and shorter 
synthesis time, suggesting LM to be more eﬃcient as carrier for tumor delivery.
Low levels of tumor uptake of nanoparticles are often seen, but it has been shown that this 
limitation can be overcome by temporarily improvement of tumor vasculature. The method is 
known as “intratumoral vascular normalization” and have been shown to be eﬀective in improv-
ing the accumulation of nanoparticles similar to PS-b-PEO micelles in the tumor (20, 22). 
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CONCLUSIONS
In conclusion, we have shown that PS-b-PEO micelles provide a versatile platform to 
generate micelles of diﬀerent size. For the sizes tested, PS-b-PEO micelles could accumulate 
in tumors and showed to have suitable properties as a drug carrier. Both tumor and regular 
tissue uptake, however, was dependent on particle size and applied dose. The eﬀects of both 
parameters should therefore be taken into account when evaluating carriers for drug delivery 
in general.
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SUMMARY, CONCLUDING REMARKS
Cancer is an important cause of death worldwide, with an increasing number of new cas-
es every year. Diﬀerent approaches have been developed for detection and treatment of the 
disease. 
Nuclear medicine techniques can be applied for both imaging and therapy, they can also 
be employed to improve other cancer therapy methods (i.e. nuclear imaging-guided surgery). 
For delivery of radioactivity to tumor cells often radiolabeling of speciﬁc molecules, acting as 
carriers for targeting to the tumor, is employed. 
The carriers presented in this thesis can be subdivided into two main categories: 1) small 
peptide-based carriers that speciﬁcally accumulate in tumor tissue via interaction with tumor 
receptors. Their main clearance pathway is via the kidneys; 2) nanosized carriers (molecular or 
supramolecular nanoparticles) that can aid in accumulation of radioactivity in the tumor via 
passive mechanisms. They can suﬀer from high uptake in liver and spleen . 
The aim of our preclinical studies was to develop, further improve and evaluate carriers for 
delivery of radionuclides for tumor imaging and/or therapy at the tumor site. 
Chapter 1 of this thesis provides an introduction to radioactivity and the two categories 
of carriers. We describe relevant aspects of biodistribution mechanisms involved in tumor 
accumulation and clearance pathways. 
In Chapter 2 we present two studies performed with two radiolabeled peptide-based car-
riers (i.e. somatostatin analogues) for imaging and therapy of neuroendocrine tumors (NETs). 
Chapter 2.1 describes a preclinical evaluation study using the hybrid label (nuclear and 
optical), somatostatin analogue Cy5-111In-DTPA-Tyr3-octreotate in comparison to 111In-DT-
PA-Tyr3-octreotate. Nuclear imaging with radiolabeled somatostatin analogs is successfully 
applied in the clinic for tumor visualization, surgical planning and staging in patients with 
NETs. The integration of nuclear techniques with optical techniques may help to further im-
prove imaging for intraoperative guidance. Hybrid molecules that consist of e.g. a DTPA che-
lator and Cy5 optical dye can be used to generate dual-labeled peptides (i.e. Cy5-111In-DT-
PA-Tyr3-octreotate) for multimodal molecular imaging applications. These bulky hybrid-im-
aging molecules however substantially reduced receptor aﬃnity in in vitro studies. On the 
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other hand in vivo studies in a mouse model with Cy5-111In-DTPA-Tyr3-octreotate showed 
good nuclear and optical imaging potential with good tumor uptake. The results therefore 
indicated that Cy5-111In-DTPA-Tyr3-octreotate is a promising compound for image-guided 
resection of neuroendocrine tumors, allowing for combined visualization of lesions by Single 
Photon Emission Computed Tomography/Computed Tomography (SPECT/CT) (surgical 
planning, intraoperative guidance and treatment evaluation) and ﬂuorescence imaging (in-
tra-operative surgical guidance).
In Chapter 2.2 we describe the eﬀects of speciﬁc activity and treatment schedules on the 
therapeutic eﬃcacy of 177Lu-DOTA-Tyr3-octreotate in tumor-bearing mice. For eﬀective tu-
mor treatment a high level of radiation should be delivered to the tumor, while normal organs 
should receive a non-toxic dose. Increasing the tumor/normal-organ ratio will therefore en-
hance the therapeutic window of this therapy. Increasing the speciﬁc activity of administered 
peptide was shown to improve the dose to the tumor and in general resulted in higher tumor/
normal organ ratios compared to treatment with radiolabeled peptides with low speciﬁc ac-
tivity. Fractionation of the dose can play a role as well in potential improvement of the ther-
apeutic eﬀects as dose fractionation did not aﬀect anti-tumor responses, but can reduce the 
radiation eﬀects of the dose delivered to diﬀerent normal organs in mice. 
Chapter 3 describes the in vivo behavior of two diﬀerent nanostructures for tumor target-
ing: the Pluronic P94 block-copolymer and Polystyrene-poly(ethylene oxide (PS-b-PEO)-
based supramolecular aggregates.
In Chapter 3.1 we present the eﬀects of diﬀerent administration routes (either intrave-
nous (IV) or intratumoral (IT)) of radiolabeled Pluronic P94 copolymer on tumor uptake/
retention and biodistribution in vivo in a mouse tumor model. Pluronic P94 is a triblock 
copolymer that, as unimer, has shown tumor cell internalization in vitro and prolonged blood 
circulation in vivo, being promising for tumor drug delivery applications. IV injection of ra-
diolabeled unimers, however, resulted in limited tumor uptake whereas IT administration of 
the radiolabeled unimers resulted in substantial radioactivity levels in tumor tissue. The min-
imal oﬀ-target tissue involvement and excellent radioactivity retention in the tumor after IT 
administration indicated the potential of Pluronic P94 copolymer as a carrier of radioactivity 
for tumor imaging and/or therapy.
In Chapter 3.2 we report a new facile method for radiolabeling PS-b-PEO-based supra-
molecular aggregates with 111In for SPECT. PS-b-PEO diblock copolymers are amphiphilic 
block copolymers that can aggregate into stable nanoparticles. During the aggregation pro-
cess they can incorporate diﬀerent agents, including radionuclides, with the advantage that 
chemical modiﬁcation of the carrier (e.g. covalent attachment of a chelator) is not needed. 
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The in vivo evaluation of the nanoparticles via SPECT imaging showed long circulation in 
vivo in a mouse model, no acute toxicity and relatively low accumulation in the liver. These 
observations conﬁrmed the potential of PS-b-PEO structures for delivery of imaging and/or 
therapeutic radionuclides to solid tumors. 
Next to the ease of radiolabeling, PS-b-PEO supramolecular structures can be simply 
varied regarding size. Size is considered one of the main factors inﬂuencing biodistribution 
of nanoparticles and tumor delivery eﬃciency. Little is known however regarding the eﬀects 
of diﬀerent applied doses in in vivo applications; high doses may saturate uptake in diﬀerent 
tissues. The study presented in Chapter 3.3 is the ﬁrst assessing the in vivo biodistribution 
and tumor uptake of PS-b-PEO supramulecular aggregates of two diﬀerent sizes, applied at 
two diﬀerent doses in a mouse model in vivo. Our result indicated PS-b-PEO aggregates to 
show a speciﬁc size-and-dose-dependent biodistribution proﬁle, with a tendency of more de-
sirable tumor-to-normal-tissue distribution patterns at lower doses and for smaller particles.
CONCLUDING REMARKS 
In this thesis work, we designed and evaluated carriers from two categories, i.e. small, 
speciﬁc, receptor-targeting peptides and larger non-speciﬁc-targeting agents, including nano-
sized particles (nanoparticles). Some main characteristics of these carrier types are listed in 
Table 1. The two categories show profound diﬀerences regarding their in vivo behavior in 
mice, including the mechanisms and level of accumulation in tumor cells, longevity in the 
circulation and clearance pathways. As a result, depending on the conditions (i.e. tumor type 
with or without a certain receptor), one of the two types of carries will be preferred over the 
other for delivery of imaging and/or therapeutic radionuclides. In tumors overexpressing spe-
ciﬁc receptors, targeting peptides will be the ﬁrst choice; in tumors with low or no (known) 
receptor expression, a nanoparticle showing longer circulation time and passive targeting 
properties might be preferable.
Of the ﬁrst category, we evaluated the potential of radiolabelled somatostatin analogues 
for two diﬀerent approaches: intraoperative imaging and improved radionuclide therapy in a 
mouse model of neuroendocrine tumors (NETs).
Multimodal intraoperative or guided surgery is an emerging and promising ﬁeld of inter-
ventional surgery. In our research, the aﬃnity between receptor and peptide was employed to 
deliver a multimodal probe that can be used before and during surgery to guide and improve 
the resection of lesion(s) [1, 2]. In our study the “multimodal” part was a nuclear-and-optical 
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platform that was covalently bound to a somatostatin analogue [3]. The attachment of this 
bulky structure to the ligand resulted however in a signiﬁcant reduction of receptor aﬃnity. 
The results of the in vivo study in mice were nevertheless promising: despite the reduction of 
receptor aﬃnity, the nuclear images obtained with the multimodality somatostatin analogue 
were comparable to those obtained with a radiolabelled somatostatin analogue. These results 
strongly support further research on the use of multimodality somatostatin analogues for 
imaging and for guided surgery, in comparison to radiolabeled counterparts. For the nuclear 
part diﬀerent chelators (such as the DOTA) might be used for incorporation of diﬀerent 
radionuclides, to open also the possibility of positron emission tomography (PET) -based 
nuclear imaging.
A major drawback of the novel multimodality somatostatin analogue was represented by 
the high uptake/retention in the kidney compared to the radiolabelled counterpart. Kidneys 
EPR: enhanced permeability and retention; ID; injected dose.
Table 1. Summary of properties of small targeting peptides versus non-targeting nanoparticles
Targeting agents
(peptides)
Non-targeting nanoparticles
Size < 1 nm > 50 nm
Main accumulation method in 
tumor tissues
Ligand-receptor interaction EPR eﬀect
Main clearance pathways Kidney Liver and Spleen
Potential of application Tumors with elevated receptor 
expression
Tumor presenting good EPR 
eﬀects
Level of accumulation in target 
tissues 
Up to 30% ID/g Up to 10% ID/g 
(in average 3-5% ID/g)
Main strengths Target speciﬁc
Low oﬀ target accumulation
Rarely side eﬀects are seen
No target needed, potentially 
eﬀective in more tumor types
Possibility to load with multiple 
agents at the same time with 
minimal eﬀect on biological 
behavior
Main limitations Native molecules vulnerable to 
degradation 
Eﬀective in a restricted number 
of tumor types
Potential radiation-induced 
toxicity to the kidneys and bone 
marrow
Potential reduction of aﬃnity for 
the receptor after modiﬁcation 
(stabilization and labeling)
Low accumulation in the tumor
Elevated and long lasting 
accumulation in liver and spleen
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are known to have relatively high uptake of radiolabelled somatostatin analogues [4-6], the 
elevated renal radioactivity can hide lesions that are close to kidneys and can damage kidneys 
due to a high radiation dose delivered (by therapeutic radionuclides) [3]. A signiﬁcant reduc-
tion of renal uptake of these radiopeptides can be obtained using positively charged amino ac-
ids that counteract their reabsorption in the proximal tubules [7]. We assume our multimodal 
somatostatin analogues might beneﬁt from a similar approach as well [3].
Radiolabeled somatostatin analogues have shown to be highly eﬀective for radionuclide 
therapy of NETs; they can reduce tumor growth and improve quality of life of patients [8, 
9]. On the other hand, complete regression of metastasized disease is still rare. The under-
standing of radiation eﬀects in tumor lesions and healthy tissues can be an important factor 
to reduce normal tissue toxicity and also improve the therapeutic success. Changes in the ad-
ministration schedules of therapeutic somatostatin analogues can increase the ratio between 
tumor versus normal organ radiation eﬀects, with signiﬁcant improvement of the therapeutic 
window. Increasing the speciﬁc activity and modiﬁcation (e.g. fractionation of the dose) of the 
treatment plan can improve therapeutic responses. In our study we applied a tumor-response 
model that linked the absorbed dose to the observed tumor volume response over time. Our 
ﬁndings strongly underline the importance of a more personalized treatment planning based 
on physical and biological tumor characteristics.
Of the second category of carriers, polymeric molecular and supramolecular structures, 
we investigated accumulation in the tumor and biodistribution in preclinical models. Both 
Pluronics and PS-b-PEO supramolecular aggregates are structures that can be labeled with 
radionuclides [10, 11], showing long lasting stability in vivo. They can selectively and sta-
bly accumulate in tumors via a passive mechanism, the enhanced permeability and retention 
(EPR) eﬀect [12, 13]. However, both Pluronic P94 and PS-b-PEO supramolecular aggre-
gates presented relatively low tumor/normal tissue ratios, as tumor accumulation was gener-
ally below 5% of the injected dose and retention in liver and spleen was high [14].  With the 
aim to improve the tumor to tissue radioactivity ratio, we evaluated the eﬀects of local (IT) 
versus IV injections. We showed the eﬀect of systemic and local administrations on tumor 
and normal tissue accumulation/retention of the radiolabeled polymeric carrier Pluronic P94 
(P94-111In-DTPA) in its unimeric form. As previously shown, systemic administration result-
ed in limited uptake of radioactivity in the tumor and a substantial dose to liver and spleen. 
In contrast, local IT administration of the radiolabeled polymer substantially improved the 
dose to the tumor with minimal oﬀ-target tissue involvement. A control group injected intra-
tumorally with 111In-DTPA conﬁrmed the need of the polymeric carrier for a long retention 
of radioactivity in the tumor. Pluronic P94 therefore presents promising potential for delivery 
of radioactivity in tumors when injected IT. This approach obviously presents limitations as 
it is not appropriate for targeting metastatic cancer, nevertheless it can be a valid method in 
speciﬁc cases where systemic application is not suitable. So, intratumoral injection of drugs 
(or drug-loaded carriers) is applied in the clinic in the treatment of brain cancers [15]. 
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The low level of accumulation in the tumor can be caused by poor permeability, high in-
ternal pressure or impaired blood ﬂow [16, 17]. Improvements in the delivery have been made 
by speciﬁc intervention at the level of the tumor, applying hyperthermia, or by normalization 
of tumor vasculature/blood ﬂow [17, 18]. Poor accumulation of nanoparticles in tumors might 
also be caused by high uptake and retention in clearance organs. Reducing this high uptake 
that depletes nanoparticles from the circulation and therefore the delivery to the target, is 
crucial to improve the level of accumulation in the tumor. Sizes, shape, stiﬀness, structure of 
the outer part (i.e. the components that are in direct contact with the host environment) are 
morphological and structural aspects that have shown to signiﬁcantly inﬂuence clearance of 
the nanoparticle from liver and spleen [13, 14].
We furthermore presented a method for the synthesis and facile radiolabeling of PS-b-
PEO-based supramolecular aggregates and demonstrated their potential for in vivo appli-
cation as carriers for delivery of radionuclides to target tissues. The aggregates showed long 
lasting circulation in mice and could be detected via nuclear imaging up to at least 24 h pi. 
Results encouraged further evaluation of the potential of PS-b-PEO-based supramolecu-
lar aggregates to deliver (radioactive) agents to tumors. Recent studies demonstrated that 
PS-b-PEO-based supramolecular aggregates could be tuned in size during their synthesis 
[13]. Size is considered one of the most important properties when dealing with delivery of 
nanoparticles. It aﬀects the biodistribution including tumor targeting capabilities, but also 
determines clearance from the circulation and uptake in clearance organs. In contrast, little 
is known on the eﬀects of the applied dose, high doses may lead to saturation of tissues and, 
as a consequence, inﬂuence the potential therapeutic eﬃcacy and toxicity. We studied the 
eﬀects of diﬀerent sizes and applied doses on biodistribution and tumor uptake of PS-b-PEO 
base nanoparticles in mice bearing a tumor xenograft. Our results indicate that PS-b-PEO 
aggregates have a speciﬁc size-and-dose-dependent behavior. In terms of tumor uptake the 
smaller nanoparticles presented the best outcome at a higher dose, suggesting that reducing 
the size and increasing the dose might be beneﬁcial to improve tumor uptake. On the other 
hand, elevated oﬀ-target accumulation of small particles was seen, especially at the higher 
dose, raising concerns regarding oﬀ target toxicity. The best performance was therefore ob-
tained using the bigger particles at the lower dose, showing the second-best tumor uptake, 
but a considerably lower oﬀ target accumulation. Our results indicate that dose is as crucial 
as size for delivery of radioactivity to the tumor and the success of PS-b-PEO nanoparticles. 
Further studies should provide insight on the curative potential of these nanoparticles and 
the level of toxicity.
In general, the peptides performed better than the nanoparticles applied in our studies 
regarding tumor uptake and retention, as well as regarding tumor to normal organ ratios. 
Peptides, however, are only suitable for imaging and therapy of speciﬁc tumor types that over-
express a characterized targeting receptor. In other conditions, nanoparticles can be interest-
ing devices for imaging and therapy of solid tumors. Our results demonstrated that Pluronic 
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polymers as well as supramolecular aggregates of PS-b-PEO can successfully be taken up in 
tumor tissue and encourage further studies to evaluate their potential as carriers of curative 
drugs.
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SAMENVATTING
Kanker is wereldwijd een belangrijke doodsoorzaak; bovendien stijgt het aantal patiënten 
met kanker nog ieder jaar. Er wordt hard gewerkt aan betere methoden voor het opsporen en 
behandelen van deze ziekte.
Nucleair geneeskundige technieken kunnen toegepast worden voor beide toepassingen, 
zowel voor beeldvorming (imaging) als voor behandeling. Ze kunnen ook worden gebruikt 
om andere kankertherapiemethoden te verbeteren (bijv. chirurgische geleiding met behu-
lp van nucleaire beeldvorming). Speciﬁeke moleculen kunnen radioactief gelabeld worden, 
deze tracers kunnen fungeren als dragers van radioactiviteit naar bijvoorbeeld een receptor op 
de tumorcel. De tracers die in dit proefschrift worden gepresenteerd, kunnen onderverdeeld 
worden in twee hoofdcategorieën: 1) kleine peptide-gebaseerde dragers die speciﬁek in tu-
morweefsel accumuleren na binding aan hun bindingsplaatsen op de cellen, de tumorrecep-
toren. Hun belangrijkste klaringsroute uit het lichaam is via de nieren. 2) nanosized dragers 
(moleculaire of supramoleculaire nanodeeltjes) die kunnen zorgen voor accumulatie van ra-
dioactiviteit in de tumor via passieve mechanismen (dus niet via receptoren). Bekend van deze 
deeltjes is dat ze snelle en hoge lever- / miltopname kunnen vertonen, wat ongunstig is tijdens 
zowel imaging als therapie.
Het doel van onze preklinische studies was om verschillende radioactief gelabelde tracers 
voor tumorbeeldvorming en therapie te ontwikkelen, te verbeteren en te evalueren.
Hoofdstuk 1 van dit proefschrift geeft een introductie met betrekking tot radioactiviteit, 
het gebruik daarvan in de geneeskunde en de twee categorieën tracers die hierboven genoemd 
zijn. Verschillende aspecten van opname- en accumulatiemechanismen van radioactiviteit in 
tumoren en de organen die zorgen voor de klaring uit het lichaam zijn beschreven. 
In Hoofdstuk 2 presenteren we twee studies uitgevoerd met twee radioactief gelabel-
de peptide-tracers (d.w.z. somatostatine-analogen) voor beeldvorming en therapie van neu-
roendocriene tumoren (NETs). Hoofdstuk 2.1 beschrijft een preklinische evaluatie studie 
waarin het nieuwe hybride, d.w.z. radioactief en optisch gelabeld, somatostatine analoog 
Cy5-111In-DTPA-Tyr3-octreotaat is vergeleken met 111In-DTPA-Tyr3-octreotaat. Nucleaire 
beeldvorming met radioactief gelabelde somatostatine analoga wordt reeds met veel suc-
ces toegepast in de kliniek voor tumorvisualisatie, chirurgische planning en behandeling 
van patiënten met NETs. De integratie van nucleaire technieken met optische technieken 
kan bijdragen tot verdere verbetering van beeldvorming tijdens chirurgie. Hybride molecu-
len die bijvoorbeeld de DTPA chelator en Cy5 voor optische beeldvorming bevatten, kun-
nen gebruikt worden voor het genereren van dergelijke dubbel gelabelde peptiden (d.w.z. 
Cy5-111In-DTPA-Tyr3-octreotaat) voor multimodale beeldvorming. Het relatief grote hy-
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bride molecuul bleek echter de aﬃniteit voor de receptoren op tumorcellen in in vitro studies 
(bijvoorbeeld in cellen in kweekbakjes) aanzienlijk te verminderen. Echter, in muizenstudies 
vertoonde Cy5-111In-DTPA-Tyr3-octreotaat een goede opname in de tumoren in deze mui-
zen. De resultaten hebben aangetoond dat Cy5-111In-DTPA-Tyr3-octreotaat een veelbelov-
ende verbinding is voor klinische beeldgeleide resectie van neuroendocriene tumoren met 
gecombineerde nucleaire en optische visualisatie van tumorweefsel. In Hoofdstuk 2.2 bes-
chrijven we de eﬀecten van speciﬁeke activiteit en behandelingsschema’s op de therapeutische 
eﬀecten van 177Lu-DOTA-Tyr3-octreotaat in muizen. Voor een eﬀectieve tumorbehandeling 
moet een hoge stralingsdosis aan de tumor worden gegeven, terwijl gezonde organen juist 
een niet-toxische dosis krijgen om bijwerkingen te voorkomen. Verhoging van de opname in 
tumor versus die in gezonde organen zal daarom de therapeutische opties van deze therapie 
verbeteren. Verhoging van de speciﬁeke activiteit van het toegediende peptide verbeterde de 
stralingsdosis op de tumor en in het algemeen resulteerde dit ook in hogere tumor- / nor-
male orgaanopname in vergelijking met toepassingen met lage speciﬁeke activiteit. Fraction-
ering van de dosis kan ook een rol spelen in de verbetering van de therapeutische eﬀecten, 
aangezien dosisfractionering geen vermindering veroorzaakte in de antitumorrespons, maar 
wel kan zorgen voor minder bijwerkingen in normale organen. 
Hoofdstuk 3 beschrijft het in vivo gedrag in muizen van twee verschillende nanostructuren 
ontwikkeld voor opname van radioactiviteit in tumoren: Pluronic P94 blokcopolymeer en een 
supramoleculaire structuur gebaseerd op Polystyreen-poly (ethyleenoxide) (PS-b-PEO). In 
Hoofdstuk 3.1 beschrijven we de eﬀecten van verschillende toedieningsroutes (intravenous 
(IV) of intratumoraal (IT)) van radioactief gelabelde Pluronic P94 op tumoropname, retentie 
en biodistributie in vivo in een muis tumormodel. Pluronic P94 zijn triblokcopolymeren die 
in tumorcellen in kweekbakjes opname vertoonden en in muizen gunstige bloedcirculatieti-
jden lieten zien, wat deze tracer potentieel geschikt maakt voor tumor imaging. IV-injec-
tie van radioactief gelabelde tracer resulteerde echter in heel beperkte tumoropname, terwijl 
IT-toediening daarentegen de radioactiviteit-opname in tumorweefsel aanzienlijk verbeterde 
en daarmee de opties voor tumortherapie. Er was ook minimale opname in normale organen 
(na IT-toediening), in combinatie met de uitstekende retentietijd in de tumor bleek Pluronic 
P94 copolymeer daarom veelbelovend voor verder onderzoek. In Hoofdstuk 3.2 rapport-
eren we over een nieuwe en eenvoudige methode voor radioactieve labeling van PS-b-PEO 
supramoleculaire aggregaten voor nucleaire beeldvorming. Deze diblokcopolymeren kunnen 
aggregeren tot stabiele supramoleculaire structuren. Tijdens het aggregatieproces kunnen ze 
verschillende stoﬀen opnemen, waaronder radionucliden, met het voordeel dat chemische 
modiﬁcatie van het tracermolecuul (door bijvoorbeeld covalente binding van een chelator) 
niet nodig is. De in vivo-evaluatie van de aggregaten via nucleaire beeldvorming vertoonde 
een gunstige verblijftijd in het bloed in muizen. Ook werd er geen acute toxiciteit gevonden 
en was er relatief lage accumulatie in de lever. Deze observaties laten de potentie van PS-b-
PEO-structuren voor de afgifte van beeldvormings- en / of therapeutische radionucliden aan 
tumoren zien. Naast het gemak van radiolabeling kunnen PS-b-PEO supramoleculaire struc-
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turen eenvoudig worden aangepast qua grootte. De grootte van nanopartikels wordt namelijk 
beschouwd als een van de belangrijkste factoren die de biodistributie beïnvloeden, inclusief de 
eﬃciëntie van tumorafgifte. Weinig is echter bekend van de eﬀecten van verschillende toege-
diende doses bij in vivo toepassing in bijvoorbeeld muizen; hoge doses zouden de  opname 
in verschillende weefsels kunnen verzadigen. De studie in Hoofdstuk 3.3 is de eerste in vivo 
biodistributie en tumoropname studie met PS-b-PEO supramoleculaire aggregaten van twee 
verschillende groottes, deze zijn toegepast in twee verschillende doses in een muismodel in 
vivo. Onze resultaten duiden erop dat PS-b-PEO aggregaten een speciﬁeke grootte-en-dosis 
afhankelijke biodistributie vertonen met een tendens richting een betere verhouding in tu-
mor/normale weefsel verdeling bij lagere doseringen en/of kleinere partikels. 
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